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ABSTRACT 
The introduction of chirality into C=C double bonds is of special interest in organic synthesis. In 
particular, the catalytic asymmetric dihydroxylation (AD) of alkenes has attracted considerable 
attention due to the facile transformation of the chiral diol products into valuable derivatives. By 
chemical means, the metal-catalyzed AD of olefins provides both stereo- and regiospecific cis-diol 
moieties. Next to their toxicity, however, these metal catalysts can also lead to byproduct formation as 
a result of oxidative fission.  
In nature, Rieske non-heme iron oxygenases (ROs) represent promising biocatalysts for this reaction 
since they are the only enzymes known to catalyze the stereoselective formation of vicinal cis-diols in 
one step. ROs are key enzymes in the degradation of aromatic hydrocarbons and can target a wide 
variety of different arenes. Despite their broad substrate scope, limited data is available for the 
conversion of unnatural substrates by this class of enzymes. To explore their potential for alkene 
oxidation, three ROs were tested for the oxyfunctionalization of a set of structurally diverse olefins 
including linear and cyclic arene-substituted alkenes, cycloalkenes as well as several terpenes. 
Naphthalene- (NDO), benzene- (BDO) and cumene dioxygenases (CDO) from different Pseudomonas 
strains where selected as they are amongst the RO enzymes that have already been reported to 
catalyze the oxidation of a small number of olefins. The majority of compounds from the selected 
substrate panel could be converted by NDO, BDO or CDO and products were either isolated and 
identified by NMR analysis or using the authentic standards. Dependent on the substrate, allylic 
monohydroxylation was found in addition to the corresponding diol products, a reaction which is 
chemically still most reliably achieved by the use of SeO2 in stoichiometric amounts.  
However, having been evolved for the dihydroxylation of aromatic compounds, wild type ROs 
displayed low conversions (< 50%) and modest stereoselectivities (≤ 80% ee/de) for several of the 
tested olefins. To overcome these limitations, changes in the active site topology of RO catalysts were 
introduced. A single targeted point mutation that was identified based on sequence and structural 
comparisons with other members of the RO family proved to be sufficient to generate BDO and CDO 
variants displaying remarkable changes in regio- and stereoselectivity for various substrates. In 
particular biotransformations with CDO M232A gave excellent stereoselectivities (≥ 95% ee/de) and 
good activities (> 90%) also for linear alkenes, which have been reported to be challenging substrates 
for RO-catalyzed oxyfunctionalizations.  
Site-saturation mutagenesis at position 232 in CDO revealed a correlation between the steric demand 
of the amino acid side chain and its influence on regio- and/ or stereoselectivities for styrene and 
indene. While the wild type enzyme almost exclusively catalyzed the dihydroxylation of the aromatic 
ring, the regioselectivity was shifted with decreasing side chain size to the terminal vinyl group of 
styrene, yielding up to 96% of the alkene-1,2-diol. For cis-1,2-indandiol formation, 
enantiocomplementary enzymes could be generated, a fact further highlighting the importance of 
position 232 for the engineering of ROs. Moreover, site-saturation mutagenesis of additional residues 
in the substrate binding pocket of CDO (F278, I288, I336 and F378) identified further positions having 
an influence on selectivity and product formation for alkene oxidation. 
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To proof the applicability of ROs for organic synthesis, semi-preparative scale biotransformations 
(70 mg) of selected substrates were performed with CDO M232A. Without further optimization of the 
reaction set-up, products were successfully isolated in > 30% yield. In addition, up-scaling of 
(R)-limonene hydroxylation to 4 L in a bioreactor with growing cells gave final isolated product titers of 
0.4 g L-1 even though substrate volatility and product toxicity diminished the yield.  
In conclusion, these examples demonstrated that a single point mutation was sufficient to transform 
CDO wild type into an efficient catalyst, furthermore constituting the first example of the rational 
engineering of CDO and BDO enzymes for the oxyfunctionalization of a broad range of alkenes. 
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ZUSAMMENFASSUNG 
Die Einführung von Chiralität in C=C Doppelbindungen ist von besonderem Interesse in der 
organischen Synthese. Insbesondere die katalytische asymmetrische Dihydroxylierung (AD) von 
Alkenen hat aufgrund der einfachen Umwandlung der chiralen Diol-Produkte in wertvolle 
Verbindungen beträchtliche Aufmerksamkeit auf sich gezogen. In der Chemie liefert die Metall-
katalysierte AD von Olefinen sowohl regio- als auch stereospezifisch cis-Diolverbindungen. Neben 
ihrer Toxizität können diese Metallkatalysatoren durch oxidative Spaltung jedoch auch zur Bildung von 
Nebenprodukten führen.  
In der Natur stellen Rieske Nicht-Häm Eisen Oxygenasen (ROs) vielversprechende Biokatalysatoren 
für diese Reaktion dar, da sie die einzigen bekannten Enzyme sind, die die stereoselektive Bildung 
von cis-Diolen in nur einem Schritt ermöglichen. ROs sind Schlüsselenzyme beim Abbau von 
Aromaten und akzeptieren eine große Vielzahl von verschiedenen Verbindungen. Trotz ihres breiten 
Substratspektrums stehen nur begrenzte Informationen über die Oxidation von nicht natürlichen 
Substraten mit dieser Enzymklasse zur Verfügung. Um ihr Potential für die Umsetzung von Alkenen zu 
erforschen, wurden drei ROs für die Oxyfunktionalisierung eines Sets an strukturell unterschiedlichen 
Olefinen getestet, das sowohl lineare und zyklische Aryl-substituierte Alkene, Cycloalkene als auch 
verschiedene Terpene umfasste. Naphthalen- (NDO), Benzen- (BDO) und Cumoldioxygenasen (CDO) 
aus verschiedenen Pseudomonas Stämmen wurden ausgewählt, da sie zu den RO Enzymen 
gehören, mit denen bereits die Oxidation einiger weniger Olefine gezeigt werden konnte. Die 
Mehrheit der getesteten Verbindungen aus dem Substratpanel konnte von NDO, BDO oder CDO 
umgesetzt werden und die gebildeten Produkte wurden entweder isoliert und mittels NMR 
Spektroskopie charakterisiert oder anhand eines Standards identifiziert. Abhängig vom Substrat wurde 
neben den entsprechenden Diol-Produkten auch die allylische Monohydroxylierung beobachtet, eine 
Reaktion, die chemisch immer noch am verlässlichsten mit stöchiometrischen Mengen an SeO2 
durchgeführt wird.  
Da die Wildtyp ROs von Natur aus die Dihydroxylierung aromatischer Verbindungen katalysieren, 
zeigten sie jedoch nur geringe Umsätze (< 50%) und moderaten Stereoselektivitäten (≤ 80% ee/de) 
für mehrere der untersuchten Alkene. Um diese Einschränkungen zu überwinden, wurden 
Veränderungen in der Struktur des aktiven Zentrums der ROs eingeführt. Eine einzelne gerichtete 
Punktmutation, die anhand von Sequenz- und Strukturvergleichen mit anderen Mitgliedern der RO 
Familie identifiziert wurde, reichte aus, um CDO und BDO Varianten mit erheblichen Veränderungen 
in der Regio- und Stereoselektivität für verschiedene Substrate zu generieren. Insbesondere in 
Biotransformationen mit der CDO Mutante M232A konnten exzellente Stereoselektivitäten 
(≥ 95% ee/de) und gute Aktivitäten (> 90%) auch für lineare Alkene erzielt werden, die als schwierige 
Substrate für die RO-katalysierte Oxyfunktionalisierung beschrieben worden sind.  
Ortsgerichtete Sättigungsmutagenese an Position 232 in CDO zeigte einen Zusammenhang zwischen 
dem räumlichen Anspruch der Aminosäureseitenkette und ihrem Einfluss auf die Regio- und/ oder 
Stereoselektivität für zwei Substrate, Styrol und Inden. Während das Wildtyp Enzym fast 
ausschließlich die Dihydroxylierung des aromatischen Rings katalysierte, wurde die Regioselektivität 
mit abnehmender Größe der Seitenkette zur terminalen Vinylgruppe von Styrol verschoben und bis zu 
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96% des Alken-1,2-diols gebildet. Für die Bildung von cis-1,2-Indandiol konnten 
enantiokomplementäre Enzyme generiert werden, was die Bedeutung von Position 232 für das 
Engineering von ROs weiter verdeutlicht. Darüber hinaus wurden durch ortsgerichtete 
Sättigungsmutagenese von zusätzlichen Aminosäuren in der Substratbindetasche von CDO 
(F278, I288, I336 und F378) weitere Positionen identifiziert, die einen Einfluss auf die Selektivität und 
Produktbildung bei der Oxidation von Alkenen haben. 
Um die Anwendbarkeit von ROs in der organischen Synthese zu zeigen, wurden Biotransformationen 
in einem semi-präperativen Maßstab (70 mg) mit ausgewählten Substraten und CDO M232A als 
Biokatalysator durchgeführt. Ohne weitere Optimierung des Reaktions-Setups konnten die 
entsprechenden Produkte mit > 30% Ausbeute erfolgreich isoliert werden. Zusätzlich wurde die 
Hydroxylierung von (R)-Limonen mit wachsenden Zellen in einem Bioreaktor auf 4 L hochskaliert, 
wobei die isolierte Produktausbeute von 0.4 g L-1 durch die Flüchtigkeit des Substrats sowie die 
Produkttoxizität verringert wurde.  
Schlussfolgernd zeigen diese Beispiele, dass eine einzelne Punktmutation ausreichend ist, um CDO 
Wildtyp in einen effizienten Biokatalysator zu verwandeln und stellen des Weiteren das erste Beispiel 
für das rationale Engineering von CDO und BDO Enzymen für die Oxyfunktionalisierung eines breiten 
Spektrums an Alkenen dar. 
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1. INTRODUCTION 
1.1. Vicinal diols - Building blocks in the chemical and pharmaceutical industry 
The introduction of chirality into C=C bonds is of special interest in organic synthesis.1 In particular, the 
stereo- and regioselective oxidative functionalization of olefins which is one of the most challenging 
reactions in organic chemistry has attracted considerable attention.2–4 Amongst the various products 
that can be generated, vicinal diols are important building blocks for the pharmaceutical and chemical 
industry.5 Due to their facile transformation into various other functional groups, optically active diols 
represent one of the most sought after molecules in the area of asymmetric synthesis.6 
Frequently, vicinal diols are used as synthons for the preparation of a variety of chiral compounds by 
converting one of the two hydroxyl groups into a leaving group that can be displaced by a 
nucleophile.7 The preparation of 1,2-amino alcohols, diamines, diphosphines, sulfonates, halohydrin 
esters and epoxides has been reported.6,7 Amongst the most important synthons for asymmetric 
synthesis are electrophilic building blocks including chiral epoxides and cyclic sulfates as well as 
halohydrins and glyceraldehyde derivatives. Their electrophilic nature facilitates bond-forming 
transformations and hence, these compounds are widely applied in the synthesis of natural products 
and biologically active molecules.7 Examples for the preparation of pharmaceuticals containing 1,2-diol 
building blocks include the application of chiral cinnamate diols for the synthesis of diltiazem, an anti-
angina drug, and Taxol side chains which was reported by Choudary and coworkers (Scheme 1).8 In 
addition, a potential route to Crixivan® (Indinavir), a HIV protease inhibitor, involves cis-(1S,2R)-
indandiol as synthon for the key intermediate cis-aminoindanol (Scheme 1).9 Furthermore, enantiopure 
diols are frequently employed as chiral ligands and auxiliaries in asymmetric reactions.7 Especially 
hydrobenzoin and its derivatives play important roles in organic synthesis (Scheme 1). Next to its 
application in asymmetric Michael reactions or cyclopropanations, hydrobenzoin can be further 
transformed into stilbenediamine which is employed for the preparation of chiral mediators for 
asymmetric Diels-Alder, aldol and allylmetalation reactions.7 
Besides their major importance in organic synthesis, vicinal diols are also represented in the industrial 
production of bulk and fine chemicals.10 Simple diols like propylene glycol and ethylene glycol are 
applied as polyester monomers or anti-freeze agents and produced on a multi ton scale per year while 
1,2-hexanediol or 2,3-butanediol are important starting materials for the fine chemical industry.11 
 
 
Scheme 1: Biologically active compounds containing diol moieties as building blocks (Crixivan, Taxol, Diltiazem), 
diols used as chiral ligands (hydrobenzoin) or industrially important diols like propylene and ethylene glycol. 
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1.2. Synthesis of vicinal cis-diols 
With respect to their important role in organic synthesis, diverse methodologies have been developed 
to gain access to vicinal diols, focusing on selective catalysts that accept a broad range of substrates.3 
For the preparation of trans- and cis-1,2-diols, both chemical and enzymatic routes have been 
described in literature to obtain the oxidation product in an optically pure form. Herein, the synthesis of 
vicinal trans-diols employs selective reduction, aldol condensation or hydrolysis, either by chemical 
methods (reduction of aliphatic α-hydroxy ketones with Zn(BH4)2, L-proline-catalyzed aldol 
condensation or hydrolysis of epoxides)12–14 or biocatalytic means (epoxide hydrolases (EHs), 
aldolases and alcohol dehydrogenases (ADHs)).3,15,16 In contrast, the chemical synthesis of cis-diols is 
generally heavy metal-catalyzed5 and the direct addition of hydroxyl groups to olefins for the selective 
formation of vicinal cis-diols is an important reaction in asymmetric synthesis.17 While metal oxide-
based methodologies are well established,7 also biocatalytic systems for the selective generation of 
vicinal cis-diols are available which mainly include oxidoreductases and lyases.18–21  
 
1.2.1. Chemical catalysts: Metal-catalyzed asymmetric dihydroxylation (AD) 
For direct cis-diol formation by chemical methods, heavy metal oxides are the most commonly 
employed catalysts in organic synthesis (Scheme 2).5,11 The majority of published results within recent 
years are based on osmium tetroxide (OsO4),4 however, also examples for the use of other metal 
oxides exist which include ruthenium, manganese or iron-oxo catalysts.5 For metal-free systems 
(e.g. Prévost-Woodward-mediated dihydroxylation) or dihydroxylations based on molybdenum, 
palladium, cerium or technetium, the reader is referred to literature as the detailed reviewing of these 
methods would be beyond the scope of this thesis.5 
 
 
Scheme 2: Metal-catalyzed dihydroxylation of alkenes. M = Os, Ru or Mn; L = ligand, adapted from Strassner.22 
 
1.2.1.1. Osmium-catalyzed AD (Sharpless AD) 
One of the most widely applied techniques for the synthesis of vicinal cis-diols is the osmium(VIII)-
catalyzed AD of alkenes developed by Sharpless and coworkers that has found numerous 
applications in organic chemistry.4 The Sharpless AD was the first chemical reaction to form vicinal 
cis-diols with high enantioselectivity and still plays a key role in organic synthesis due to its high 
tolerance towards functional groups, good yields, and excellent stereospecificities.5 
In the process, the dihydroxylation of an olefin substrate is catalyzed by OsO4 in the presence of a 
chiral cinchona alkaloid ligand (quinine or quinidine) and a stoichiometric secondary oxidant like 
potassium ferricyanide (K3Fe(CN)6) in combination with potassium carbonate (K2CO3) or 
N-methylmorpholine oxide (NMO) for catalyst regeneration (Scheme 3).7 During the reaction, 
coordination of the cinchona alkaloid to the osmium catalyst promotes the formation of a chiral 
complex with the amine ligand assumed to provide an enzyme-like binding pocket. This complex can 
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distinguish between the prochiral faces of an alkene substrate, leading to the stereoselective formation 
of vicinal cis-diols.23  
Even though more than 400 different alkaloids have been tested for the AD of alkenes, the cinchona 
alkaloid derivatives developed by Sharpless et al. still represent the most effective approach under 
catalytic conditions.3 Using these alkaloid derivatives, Sharpless and coworkers have designed a 
chiral ligand system consisting of the naturally derived dihydroquinine (DHQ) or dihydroquinidine 
(DHQD) units linked by a spacer (Scheme 4A).23 In combination with DHQ and DHQD, the nature of 
these linkers can significantly influence the stereoselectivity of the AD.4 Only three different classes of 
cinchona-based ligands proved to be sufficient for the dihydroxylation of a broad range of olefins. The 
most general ligands include phthalazines (PHAL) and pyrimidines (PYR) as linkers which afford high 
stereoselectivities for five of the six olefin classes (mono-, trans-di-, gem-di-, tri- and tetra-substituted 
olefins, Table 1).7 For the dihydroxylation of cis-olefins, special indoline ligands (IND) are required. 
However, even when IND linkers are employed, stereoselectivities for cis-di-substituted alkenes are 
only low to moderate with ee values < 90%.24  
 
 
Scheme 3: The asymmetric dihydroxylation (AD) of olefins developed by Sharpless and coworkers. The reaction 
is catalyzed by osmium tetroxide (OsO4) in the presence of a chiral cinchona alkaloid ligand (quinine or quinidine) 
and a stoichiometric secondary reoxidant (K3Fe(CN)6/K2CO3 or NMO). 
Table 1: Preferred ligands for the AD of the different olefin classes I-VI with obtained stereoselectivities modified 
after Sharpless et al..7 
Olefin class 
I 
mono 
II 
gem-di 
III 
cis-di 
IV 
trans-di 
V 
tri 
VI 
tetra 
 
 
   
   
Best ligand PYR/ PHAL PHAL IND PHAL PHAL PYR/ PHAL 
ee [%] 30-97 70-97 20-80 90-99.8 90-99 20-97 
 
Using DHQ- and DHQD-derived ligands, both enantiomers of a diol are accessible during the 
hydroxylation reaction.3 Even though being diastereomers,7 the two cinchona alkaloids behave like 
enantiomers since mainly the nature of the substituent at C-9 of the alkaloid backbone is crucial for 
enantio-differentiation in cis-dihydroxylation (Scheme 4A).23 The enantioselectivity in the AD reaction 
can be predicted dependent on the alkaloid ligand. With DHQD derivatives, the olefin will be attacked 
from the top face (β-face) whereas DHQ-based ligands promote attack from the bottom face (α-face, 
Scheme 4B). However, this prediction does not apply for all alkenes and it can be ambiguous which 
group of the olefin is the large substituent (RL) and which the medium (RM) one to orient the 
substrate.25 
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Scheme 4: (A) Commonly used linkers PHAL, PYR and IND in combination with DHQD or DHQ (Alk*). PHAL can 
be used for most alkene classes while PYR is best for mono- and tetra-substituted olefins. IND is applied for 
cis-di-substituted alkenes.7,25 (B) Mnemonic device for the prediction of enantioselectivity. The olefin is oriented 
so that the large, medium and small substituents match best with the RL, RM and RS positions. RL: large, RM: 
medium, RS: small substituent. NW: north west, NE: north east, SW: south west, SE: south east quadrant.25 
Since its development by Sharpless and coworkers, the osmium-catalyzed AD has been extensively 
optimized, not only in terms of ligand design but also regarding reaction conditions.3 The reaction is 
based on the ligand acceleration effect7 and experimental as well as theoretical work indicate that it 
presumably proceeds through a concerted [3+2]-like pathway which involves an osmium glycolate as 
intermediate.26 The use of K3Fe(CN)6 as oxidant in a two-phase system substantially improved 
enantioselectivities compared to NMO for osmium(VI) regeneration.27 Under homogenous conditions 
as used for the process employing NMO, the reoxidant has constant access to all catalytic 
intermediates and the osmate(VI) monoglycolate ester undergoes reoxidation and can react with a 
second olefin, resulting in the formation of osmium(VI) bisglycolate. This complex can dihydroxylate 
the substrate albeit with low enantioselectivity as the chiral alkaloid ligand is not present (secondary 
cycle, Scheme 5).4,28 With K3Fe(CN)6 applied in biphasic reaction conditions, this secondary cycle was 
nearly completely avoided, increasing the enantioselectivity of the reaction.29 Furthermore, under 
biphasic reaction conditions, the rate-limiting hydrolysis step of the osmium(VI) glycolate ester can be 
accelerated significantly by methanesulfonamide (MeSO2NH2). Thus, addition of MeSO2NH2 allows 
oxidation of sterically hindered alkenes including tetra-substituted olefins as well as reaction 
temperatures of 0°C instead of room temperature, having also beneficial effects on selectivities.29,30  
 
 
Scheme 5: Primary and secondary catalytic cycle under homogenous conditions using NMO as reoxidant.7 
A B 
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The commercial availability of K2OsO2(OH)4 as non-volatile osmium source premixed with 
K3Fe(CN)6/K2CO3 and the chiral ligand as AD-mix α ((DHQ)2PHAL) or AD-mix β ((DHQD)2PHAL) 
makes the reaction easily to be performed. Both AD-mixes can be employed for the dihydroxylation of 
mono-, trans-di-, gem-di- and tri-substituted olefins which are standard substrates for Sharpless AD 
and require very similar reaction conditions.7 However, due to its electrophilic nature, OsO4 reacts only 
slowly with electron-deficient alkenes and hence, their stereoselective cis-dihydroxylation remains a 
major challenge.7,31 
 
1.2.1.2. Osmium-free systems for the direct cis-dihydroxylation of olefins 
Because of its efficiency, high functional group tolerance and excellent stereoselectivities, Sharpless 
AD is still the method of choice for the formation of enantiopure cis-diols and its importance was 
demonstrated with receiving the Nobel Prize 2001 in Chemistry.32 However, regarding the high costs, 
volatility and toxicity of OsO4 that prevent a successful application on an industrial scale,33 alternative 
oxidants were tested to circumvent the use of osmium. 
Two alternative systems that have been applied for the cis-dihydroxylation of olefins include 
permanganate (MnO4-) and ruthenium tetroxide (RuO4). Due to their lower toxicity, these oxidants 
provide a promising approach for the replacement of OsO4.17,34 Yet, efficient asymmetric ruthenium 
and manganese catalysts for dihydroxylation have not been reported to date as reactions are often not 
very selective and difficult to control. The high oxidative potential of both metal oxides impedes the 
termination of the oxidation reaction at the diol stage and overoxidation as well as formation of fission 
products are common side reactions.17,33 Thus, in particular RuO4 is more commonly employed for 
oxidative cleavage and in ketohydroxylations than for the formation of vicinal cis-diols.5,17,33 
Similar to Sharpless AD, engineering of the process conditions led to improvements in the 
dihydroxylation efficiency for both oxidants. For RuO4, high catalyst loadings (7 mol%) which offset the 
lower price of ruthenium compared to osmium could be avoided under acidic conditions using H2SO4 
or CeCl3 to accelerate the reaction.35,36 In the latter system, glycol cleavage is reduced compared to 
the Brønsted acid-accelerated method and hence, the reaction time can be increased, allowing the 
conversion of a wider scope of olefins in good to excellent yields.36 Yet, despite these improvements, 
the RuO4-catalyzed dihydroxylation is still not as general applicable for a broad range of alkenes as 
Sharpless AD.17 Using MnO4- as oxidant which reacts with alcohols, alkenes, aldehydes, saturated 
C-H bonds as well as other functional groups,34 the reaction conditions have to be controlled carefully 
to avoid extensive side-product formation and the reaction pathway is influenced by solvent, pH and 
substrate. The best conditions for cis-dihydroxylation are provided in alkaline media while formation of 
α-hydroxy ketones is catalyzed under neutral or slightly basic conditions. However, reactions are 
always accompanied by C-C bond cleavage which predominates under acidic conditions.34 As the use 
of MnO4- in stoichiometric amounts leads to significant manganese dioxide (MnO2) by-product 
formation,37 different methods for catalytic manganese dihydroxylations have been developed to avoid 
problems caused by MnO2 removal.38,39 
To date, only a limited number of AD reactions catalyzed by RuO4 or MnO4- have been reported in 
literature. For RuO4, these were all based on the chiral auxiliary approach with moderate to good 
overall yields and good to excellent enantio- or diastereoselectivities.40,41 Furthermore, the two 
INTRODUCTION 
20 
methods currently described for the AD using manganese resulted in moderate to good 
stereoselectivities.42,43 
Besides RuO4 and MnO4-, the increasing interest in the use of iron complexes for catalysis due to their 
abundance in nature as well as their lack of toxicity has prompted the development and design of non-
heme iron catalysts for olefin cis-dihydroxylation.11,44 First examples of bio-inspired non-heme iron 
catalysts have been reported by Que and coworkers using tetradentate nitrogen-donor ligands with 
topologies that allow two cis-oriented coordination sites to be available for peroxide binding and 
activation which is used as oxidant. These iron complexes catalyzed olefin cis-dihydroxylation and 
epoxidation although yields and turnovers were generally low.45 To achieve higher ratios of 
diol:epoxide, the group of Que successfully modulated the complexes to obtain a ligand environment 
that more closely mimics the environment of the mononuclear iron center in Rieske non-heme iron 
oxygenase (RO) enzymes.46 Currently, there are only two examples known in literature for the AD with 
iron complexes using hydrogen peroxide (H2O2) as reoxidant which gave moderate to excellent 
enantioselectivities (> 97% ee). 47,48 Yet, despite these promising results for the iron-catalyzed 
cis-dihydroxylation of olefins within the last years, the synthetic utility of bio-mimetic iron complexes 
has not been proven so far. Their application in organic synthesis has been hampered by the iron-
mediated decomposition of H2O2 which obstructs its efficient use as oxidant. The generation of highly 
reactive free hydroxyl radicals induces the degradation of ligand, substrate and product, usually 
requiring a high ratio of substrate to H2O2.11 
 
1.2.2. Biocatalytic access to cis-1,2-diols 
The development of sustainable, efficient and selective catalysts is one of the major goals in organic 
synthesis.49,50 Metal-based reagents for the asymmetric cis-dihydroxylation of C=C double bonds are 
well established but the low sustainability of heavy metal oxides with regard to atom economy, toxicity, 
side-product formation and catalyst stoichiometry has prompted the search for alternative strategies.51 
In this context, biocatalytic routes for the selective formation of vicinal cis-diols have generated great 
interest due to the intrinsic high regio-, stereo- and chemoselectivity of many enzymatic reactions that 
are catalyzed under mild conditions.52  
As an alternative to chemical means, several enzymatic routes to cis-1,2-diols have been explored. 
Herein, the use of EHs represent an exception as these enzymes usually catalyze epoxide hydrolysis 
to yield vicinal diols in anti-configuration.53 Formation of cis-diols is rare and restricted to meso-
epoxides. The first example has been described by Bellucci et al., reporting the biocatalytic synthesis 
of (R,R)-(+)-1,2-diphenyl-1,2-ethanediol by microsomal EH from rabbit liver which catalyzes the ring 
opening of cis-stilbene oxide with high stereoselectivity.54 In addition, Zhao and coworkers identified 
several microbial EHs which provide cis-1,2-diols from different aryl meso-epoxide substrates with 
good to excellent stereoselectivities (up to 99% ee) for the (R,R)-enantiomer (Scheme 6).55 
 
 
Scheme 6: Epoxide hydrolase (EH)-catalyzed formation of vicinal cis-diols by hydrolysis of aryl meso-epoxides. 
R = C6H5, 2-Cl-C6H5, 2-F-C6H5, 3-Cl-C8H5, 4-Cl-C8H5, 2-pyridyl, 3-pyridyl or 4-pyridyl.55 
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Apart from EHs, the main routes to vicinal cis-diols include the reduction of α-diketones and α-hydroxy 
ketones by ADHs, aldolase-catalyzed reactions and cis-dihydroxylation of C=C double bonds by 
ROs.18–21 Amongst these biocatalysts, ADHs have been extensively studied during the last decade by 
both academia and industry. Due to their high stereoselectivities and availability, these enzymes 
represent the method of choice for the synthesis of chiral alcohols.56 Yet, ADHs can also be applied for 
the formation of cis-1,2-diols starting from α-diketones or α-hydroxy ketones and examples include 
ADHs from Rhodococcus ruber DSM44541, Lactobacillus brevis and Ralstonia sp. as well as diacetyl 
reductase from Bacillus stearothermophilus and glycerol dehydrogenase from Enterobacter aerogenes 
or Cellulomonas sp..16,57–60 Due to its excellent stereoselectivity for the reduction of various α-hydroxy 
ketones, Jakoblinnert and Rother applied ADH from Ralstonia sp. (RADH) in the two-step synthesis of 
1-phenylpropane-1,2-diol (Scheme 7).18 Starting from cheap aldehydes, diol formation was 
accomplished with excellent selectivities (> 99% ee/de) and high product concentrations (space-time 
yields up to 327 g L-1 d-1). In a first step, the thiamine diphosphate (ThDP)-dependent benzaldehyde 
lyase (BAL) from Pseudomonas fluorescens catalyzed the carboligation of benzaldehyde and 
acetaldehyde yielding (2R)-2-hydroxy-1-phenylpropan-1-one ((2R)-HPP). (2R)-HPP was subsequently 
reduced by RADH giving (1R,2R)-1-phenylpropane-1,2-diol ((1R,2R)-PPD) as product. Employing this 
two-step approach, also the opposite enantiomer of PPD would be accessible by combining different 
ThDP-dependent enzymes and ADHs possessing Prelog or anti-Prelog specificities.18,52 
 
 
Scheme 7: Enzymatic two-step cascade for the synthesis of the vicinal cis-diol (1R,2R)-1-phenylpropane-1,2-diol 
((1R,2R)-PPD).18 BAL: benzaldehyde lyase, RADH: ADH from Ralstonia sp.. 
Besides ADHs, aldolases can be employed in the formation of 1,2-diol units. Dependent on the type of 
enzyme, cis-diols are generated during the aldolase-catalyzed carboligation of two molecules. 
Dihydroxyacetone phosphate (DHAP)-dependent aldolases catalyze the C-C bond formation at 
1,2-diol junctions that link a DHAP unit with a large variety of aldehyde acceptors. During the reaction, 
α,β-disubstituted carbonyl derivatives are generated, containing two novel vicinal chiral centers at the 
new C-C bond.19 Their stereochemistry can be directed by using different stereocomplementary 
DHAP-dependent aldolases for the reaction.15 DHAP-dependent aldolases typically yield 
carbohydrates or carbohydrate-derived materials according to their substrates but can also be applied 
in the generation of cis-diol synthons for non-carbohydrate natural products. The DHAP-dependent 
aldolase D-fructose 1,6-bisphosphate aldolase (FruA) can catalyze the carboligation of DHAP and 
5-oxohexanal or propanal, yielding enantiopure vicinal cis-diol structures which represent potential 
intermediates in the synthesis of (+)-exo-brevicomin, a beetle pheromone (Scheme 8).19 However, 
even though aldolases can generally tolerate a broad scope of aldehydes as acceptors, the donor 
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compound is often invariable and hence, only a limited structural diversity is accessible for 
cis-1,2-diols.61 Furthermore, the reversibility of the catalyzed aldol reaction is an additional drawback.16 
 
 
Scheme 8: D-Fructose 1,6-bisphosphate aldolase (FruA)-catalyzed generation of different precursors for the 
chemoenzymatic synthesis of (+)-exo-brevicomin, adapted from Fessner.19 
One of the most promising biocatalytic approaches for the selective formation of vicinal cis-diols is 
provided by ROs. In contrast to EHs, ADHs and aldolases which catalyze the formation of both trans- 
and cis-diols, 53–55,58,61 these oxygenases stereoselectively introduce two hydroxyl groups in one 
enzymatic step solely in a cis-directed fashion.62,63 Among the vast number of hydroxylating enzymes, 
as far as known, only ROs possess this unique ability, making them highly interesting biocatalysts for 
organic synthesis.64 By the incorporation of both atoms from O2 into the aromatic ring, ROs, also 
called aromatic-ring-hydroxylating dioxygenases, initiate bacterial pathways for the degradation of a 
wide range of xenobiotic compounds.65 Their presence in arene-degrading soil bacteria was first 
established in the late 1960s by Gibson and coworkers when ROs were found in strains capable of 
growing on toluene, naphthalene or benzene as sole source of carbon.66,67 The resonance energy 
stabilizing the aromatic ring structure can be overcome by the RO-catalyzed oxyfunctionalization, 
leading to the formation of a cis-dihydrodiol intermediate as a common first step which is further 
degraded by ring fission and subsequent breakdown into the intermediates of the tricarboxylic acid 
cycle (Scheme 9).68–71 Like other enzymes involved in metabolic or detoxification pathways, ROs have 
a broad substrate scope and show a high stereospecificity for aromatic compounds.72  
 
 
Scheme 9: Microbial degradation of aromatic compounds. In the first step, dihydroxylation of the aromatic 
nucleus is catalyzed by Rieske non-heme iron oxygenases (ROs).  
Besides arene dihydroxylation, also a few examples are known for the RO-catalyzed 
oxyfunctionalization of aliphatic compounds.9,73–75 Due to their substrate promiscuity, ROs were 
selected as biocatalysts for this project as they might provide a potential alternative to the heavy 
metal-catalyzed AD of alkenes. 
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1.3. Rieske non-heme iron oxygenases (ROs) 
ROs are soluble multicomponent systems that harness the reductive power of NAD(P)H for oxygen 
activation. The cofactor-derived electrons are transferred via a reductase and, dependent on the 
enzyme, a ferredoxin to the terminal oxygenase component containing the active site (Scheme 10).76 
As ROs belong to the class of non-heme iron dependent enzymes, O2 activation takes place at a 
mononuclear iron(II) center.77 The divalent iron in the active site is coordinated by the so-called 
2-His-1-carboxylate facial triad, a common structural motif consisting of two conserved histidines and a 
carboxylic acid (aspartate or glutamate). The motif provides a platform to anchor the iron while 
maintaining three cis-oriented sites available on the iron octahedron to coordinate other endogenous 
or exogenous ligands such as O2, substrate or cofactors.51,78 Besides ROs, several members of the 
non-heme iron dependent enzyme superfamily employ the 2-His-1-carboxylate facial triad for iron 
coordination including α-ketoglutarate-dependent dioxygenases, extradiol cleaving catechol 
dioxygenases, pterin-dependent hydroxylases and other oxidases like isopenicillin N synthase.79 
Although their active sites are based on unrelated protein folds and catalyze a wide range of different 
reactions, these enzymes share the ability to couple O2 reduction with substrate oxyfunctionalization.80 
In addition to the non-heme iron center, the RO oxygenase component contains a second cofactor, 
the so-called Rieske [2Fe-2S] iron sulfur cluster that is involved in the electron transfer to the catalytic 
non-heme iron. In contrast to plant-type [2Fe-2S] centers being coordinated by four cysteine residues, 
the Rieske cluster is complexed by two conserved histidines and two conserved cysteines, resulting in 
significantly different spectroscopic properties and a more positive midpoint reduction potential.76,81 
 
 
 
Scheme 10: Example of an RO electron transfer chain from NAD(P)H via a reductase and (dependent on the RO 
system) a ferredoxin to the terminal oxygenase component, modified after Parales and Resnick.82 
To date, more than 100 ROs have been identified and completely sequenced.82 Due to their versatility, 
ROs are considered as the non-heme analogue of cytochrome P450 monooxygenases and next to 
their relaxed substrate specificity, these enzymes can catalyze various oxidation reactions.20,82–84 
 
1.3.1. Classification of RO systems 
For the classification of ROs, different systems have been proposed which are either based on the 
nature of the electron transport components, the oxygenase sequence homology or a combination of 
both.64,71,85–88 The historical system proposed by Batie et al. in 1991 classified ROs according to their 
electron transfer components and the nature of their redox centers into three main classes (Table 2).85 
Class I enzymes comprise two components, a flavin and [2Fe-2S] cluster containing reductase as well 
as an oxygenase. Class II and class III dioxygenases are both three component systems employing a 
ferredoxin for electron transfer between the reductase and oxygenase component. In class II, the 
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flavin and [2Fe-2S] redox centers are on separate proteins, whereas the reductase of class III contains 
both a flavin and a [2Fe-2S] cluster but also requires an additional [2Fe-2S] center on the ferredoxin 
for electron transfer to the terminal oxygenase. Further subdivision of class I and II into group A and B 
is based on the type of flavin (FMN or FAD, class I) in the reductase and the coordination of the 
[2Fe-2S] center in the ferredoxin (class II, Figure 1). In class IA, the reductase contains an N-terminal 
FMN whereas in class IB, a FAD is present as cofactor. Class IIA has a plant-type ferredoxin 
component while in class IIB, a Rieske-type iron-sulfur cluster is present in the ferredoxin (Figure 1).76 
 
Table 2: Classification of different RO systems according to their components, adapted from Maison et al..76 
System Class Reductase Ferredoxin Oxygenase Example 
2-component 
IA FMN, [2Fe-2S] - [2Fe-2S], Fe Phthalate dioxygenase 
IB FAD, [2Fe-2S] - [2Fe-2S], Fe Benzoate dioxygenase 
3-component 
IIA FAD [2Fe-2S] [2Fe-2S], Fe Pyrazon dioxygenase 
IIB FAD [2Fe-2S] [2Fe-2S], Fe 
Benzene dioxygenase 
Toluene dioxygenase 
III FAD, [2Fe-2S] [2Fe-2S] [2Fe-2S], Fe Naphthalene dioxygenase 
 
 
Figure 1: Classification of ROs by their components (green: oxygenase, red: reductase, orange: ferredoxin). 
Class I: two-component dioxygenases, flavin and iron-sulfur cluster are combined in the same protein, Class IA: 
FMN, Class IB: FAD. Class II: three-component dioxygenases, electron-transport chain with a flavoprotein and a 
separate ferredoxin, Class IIA: plant-type ferredoxin, Class IIB: Rieske-type iron-sulfur cluster in the ferredoxin. 
Class III: three-component dioxygenases, electron-transfer chain with iron-sulfur flavoprotein and ferredoxin. 
Since its publication, the Batie classification scheme has been broadly applied. However, as this 
system is solely based on the electron transfer components, it is lacking any information about the 
terminal oxygenase catalyzing the dihydroxylation reaction.64 Due to difficulties to integrate many 
newly identified oxygenases into the three classes, several other classification systems have been 
suggested that also include the oxygenase components. 64,71,86–88 
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In 1996, the group of Werlen proposed a classification scheme based on amino acid sequence 
comparisons of oxygenase α-subunits, identifying four dioxygenase families (naphthalene, 
toluene/benzene, biphenyl and benzoate/toluate families).86 The clustering of dioxygenases into 
families correlates in general with the native substrates oxidized by the corresponding members. In 
addition to the former mentioned families, the phthalate family was identified by Gibson and Parales 
which is a large and diverse group of enzymes including both mono- and dioxygenases that oxidize 
aromatic acids.64 However, there are also several oxygenases that do not cluster with any of these 
families and thus, in updated classification systems as proposed by Kweon or Chakraborty et al., 
oxygenase sequence information as well as its functional properties were included.71,87 
 
1.3.2. Substrate scope and reaction spectrum 
ROs catalyze the asymmetric cis-dihydroxylation of C=C double bonds with high stereo- and 
regioselectivity. Their broad substrate spectrum comprises more than 300 substrates including 
monocyclic aromatic compounds, polycyclic and heterocyclic arenes, substituted aromatics, 
halogenated arenes as well as aromatic acids and has been investigated in detail for several 
enzymes.89 Toluene dioxygenases (TDOs) from Pseudomonas putida (P. putida) F1 and P. putida 
UV4a catalyze the oxidation of more than 100 compounds and also NDO from Pseudomonas sp. NCIB 
9816-4 has been reported to accept over 75 different substrates.82 Furthermore, these versatile 
enzymes can catalyze various oxidation reactions including monohydroxylations, sulfoxidations, 
dealkylations, desaturations, oxidative cyclizations and epoxidations (Scheme 11).20,82–84 
 
 
Scheme 11: Diverse reactions catalyzed by ROs including cis-dihydroxylation, allylic/ benzylic 
monohydroxylation, desaturation, O- and N-dealkylation, sulfoxidation, epoxidation and oxidative cyclization. 
                                                     
a P. putida UV4 is a mutant of P. putida NCIMB 11767 lacking cis-dihydrodiol dehydrogenase activity.222 
INTRODUCTION 
26 
Although there has been much work on the dihydroxylation of aromatic compounds, little has been 
reported on the conversion of unnatural substrates by ROs. To date, NDO, TDO, benzene (BDO) and 
cumene dioxygenase (CDO) enzymes from different Pseudomonas strains have been shown to 
catalyze the dihydroxylation of a small number of olefins (Table 3). Most of these studies were 
performed with benzocycloalkene or analogous substrates.20 One of the first reported alkene 
dihydroxylation reactions was the TDO-catalyzed oxidation of indene I yielding the corresponding cis-
diol (1S,2R)-Ia (Table 3) next to the allylic alcohol.90,91 NDO from Pseudomonas sp. NCIB 9816-4 
catalyzes the same reaction but favors the opposite enantiomer (1R,2S)-Ia.92 With TDO and NDO, an 
opposite stereochemistry was also found for the corresponding cis-diols of 1,2-dihydronaphthalene II 
and benzocyclohept-1-ene III ((1S,2R)- and (1R,2S)-IIa as well as (3S,4R)- and (3R,4S)-IIIa, 
Table 3),93 making both enzymes enantiocomplementary biocatalysts.94 TDO has been shown in 
addition to be able to dihydroxylate several heterocyclic alkenes (including substrates IV-VI) with high 
enantioselectivity to the corresponding cis-diols IVa-VIa.95 Oxidation of heteromonocyclic alkenes was 
also reported for NDO and the dihydroxylation of the conjugated diene N-methyl-2-pyridone XVIII 
yielded the cis-diol products XVIIIa and XVIIIb.96 
The dioxygenase-catalyzed formation of vicinal cis-diols from different conjugated monoalkenes and 
polyenes could be shown by Boyd and coworkers. Thereby, the asymmetric dihydroxylation of mono-
substituted, gem-di-substituted, cis-di-substituted and tri-substituted olefins but not of trans-di-and 
tetra-substituted alkene bonds was reported.75 In general, the preference for dihydroxylation of the 
conjugated alkene or arene group was dependent on the dioxygenase and alkene type. Several 
substituted styrene substrates XII-XVII were converted by TDO from P. putida UV4 in general to the 
corresponding arene-cis-1,2-dihydrodiols while the alkene-1,2-diols XIIa-XVIIa were formed to a lesser 
extent. In contrast, NDO from P. putida NCIMB 8859 which is unable to promote the dihydroxylation of 
most mono-substituted benzenes, could catalyze diol formation of XII-XVII without arene 
cis-dihydroxylation, yielding the alkene-1,2-diols.75 Additionally, several non-aromatic conjugated cyclic 
dienes (C6-C8, IX-XI) and trienes (C7-C8, VII-VIII) of different ring sizes have been reported to undergo 
stereoselective cis-dihydroxylation catalyzed by TDO and NDO (Table 3).75,97 
Beside the dihydroxylation of cyclic alkenes, the formation of cis-diols from acyclic olefins has been 
reported. However, acyclic alkenes are generally poor substrates for the RO-catalyzed 
dihydroxylation75 and therefore, only few examples known. In 2000, Boyd and coworkers reported the 
biotransformation of isoprene XIX and related dienes (C4 and C5, XX-XXII) to the vicinal cis-diols 
XIXa,b-XXIIa,b by P. putida ML2, a wild-type source of BDO.74 Based on obtained product yields, 
cis-dihydroxylation seemed to occur in the sequence mono-substituted alkene > cis-di-substituted 
alkene > gem-di-substituted alkene > trans-di-substituted alkene. The yields of diols were relatively 
low (< 10%) and whereas the stereoselectivity is excellent for most cyclic substrates, it dropped for the 
open chain derivates to max. 74% ee.74 Furthermore, CDO and TDO have been shown to convert 
different halogenated and nonhalogenated acyclic alkenes XXIII-XXXII into the corresponding 
cis-diols.73,98 For both dioxygenases, only olefins lacking chlorine substituents on double bond carbon 
atoms were dihydroxylated, while in the presence of chlorine atoms, monohydroxylation occurred.73,98 
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Table 3: Dioxygenase-catalyzed cis-dihydroxylation of cyclic and acyclic alkenes.20,74,75,91,93,95,97 
Monohydroxylated products or products resulting from the dihydroxylation of arene moieties are not shown. 
Enzyme (strain) Substrate/ Product ee [%] Yield [%] 
TDO[a] 
(P. putida UV4) 
 
Ia: 20 
IIa-VIa: > 98 
10-47 
NDO[a] 
(Pseudomonas sp. NCIB 
9816-4) 
 
Ia: 72-80[c] 
IIa-IIIa: > 98 
50-65 
NDO 
(P. putida  
NCIMB 8859) 
 
TDO 
(P. putida UV4)  
VIIa-XIa: ≥ 98 
4-24NDO/ 
4-29TDO 
NDO[a] 
(P. putida  
NCIMB 8859) 
 
TDO[b] 
(P. putida UV4) 
 
XII: 80NDO/88TDO 
XIII: 56NDO/42TDO 
XIV: 66NDO/48TDO 
XV: 46NDO/-TDO 
XVI: 82NDO/-TDO 
XVII: 62NDO/62TDO 
12-60NDO/ 
3-22TDO 
NDO 
(Pseudomonas sp. NCIB 
9816-4) 
 
n.d. 55 
BDO 
(P. putida ML2) 
 
XIXa/XIXb: 16/44 
XXa/XXb: 38/33 
XXIa/XXIb: 74/70 
XXIIa: 25 
< 10 
TDO[a] 
(P. putida UV4) 
 
n.d. n.d. 
CDO[a] 
(P. fluorescens IP01) 
 
n.d. n.d. 
[a] Next to cis-dihydroxylation of the C=C double bond, also monohydroxylation in allylic position was observed. 
[b] TDO also catalyzed the dihydroxylation of the aromatic ring forming arene-1,2-dihydrodiols. [c] ee Values vary 
dependent on the bacterial strain employed. n.d.: not determined 
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1.3.3. Structure and catalytic mechanism of ROs 
In the RO multicomponent system, the terminal oxygenase subunit catalyzes substrate 
oxyfunctionalization. Dependent on the RO enzyme, the oxygenase either comprises two separate 
proteins, a large catalytic subunit (α) and a small subunit (β) in hetero-multimeric form (αnβn), or lacks 
the β-subunit and exists in homo-multimeric form (αn).63,71 The α-subunit contains the largely 
hydrophobic active site whereas the β-subunit is assumed to have a structural function. However, in 
distinct RO systems, the β-subunit was proposed to have an influence on substrate specificity.99 For 
ROs being devoid of a β-subunit, loops on the α-subunits might enhance their stability and remove the 
need for a stabilizing small oxygenase subunit.63 
The oxygenase α-subunit contains two metal centers, a Rieske-type [2Fe-2S] cluster that mediates 
electron transfer to the mononuclear iron in the active site where O2 binding and activation is thought 
to take place.100 The active site iron is highly accessible with a large part of its surface available for the 
binding of both oxygen atoms.101 All RO oxygenase structures determined to date possess either an α3 
or α3β3 quaternary structure (Figure 2A). In this complex, electron transfer proceeds between the 
Rieske cluster (blue) and the iron center (green) of adjacent subunits via a bridging aspartate (black, 
Figure 2B) due to the smaller distance compared to intramolecular transfer.63 
b 
 
Figure 2: (A) Quaternary structure of NDO oxygenase α-subunits from Pseudomonas sp. NCIB 9816-4 
(PDB code: 1NDO)102 forming a trimer (single α-subunits shown in green, blue and grey with the non-heme iron 
center shown as orange spheres and the Rieske cluster as orange-yellow spheres). (B) Electron transfer from the 
Rieske center (blue) to the catalytic mononuclear iron (green) of the adjacent subunit proceeds via a conserved 
aspartate residue (black), adapted from Barry and Challis.62 
NDO from Pseudomonas sp. NCIB 9816-4 was the first RO for which the crystal structure has been 
solved and its active site geometry is characteristic for ROs. In NDO, the non-heme iron in the 
hydrophobic active site is coordinated by two histidines (H208 and H213) and a bidentate aspartate 
(D362) which constitute the 2-His-1-carboxylate facial triad.102 Additionally, one or two water 
molecules are found to be bound in the resting state when no substrate is present (Scheme 12).103 
The Rieske center is coordinated by two cysteine residues (C81 and C101) and two histidines 
(H83 and H104) which are located in the highly conserved motif CXHX17CX2H.76,102 In the α3β3 
hexamer, the Rieske cluster of one α-subunit is closer to the catalytic iron of the adjacent subunit 
(~12 Å) than to the Rieske cluster within the same subunit (~44 Å).103 The neighboring non-heme iron 
A B 
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and [2Fe-2S] centers are thought to be coupled by D205 that is within hydrogen-bonding distance of 
the metal-coordinating amino acids and bridges H104 (coordinating the Rieske center) to H208 of the 
mononuclear iron in the active site. D205 is most likely the main electron transfer pathway from the 
Rieske cluster to the iron and replacement of this residue (NDO variant D205A) completely abolished 
activity.104 
In contrast to cytochrome P450 monooxygenases, far less is known about the catalytic mechanism of 
ROs to date.62 Due to difficulties in obtaining spectroscopic information of the mononuclear non-heme 
iron in the presence of the Rieske cluster, the mononuclear ferrous site is more challenging to access 
spectroscopically.103 For dihydroxylation reactions, two possible mechanisms have been suggested for 
NDO which both are initiated by binding of naphthalene to the active site (Scheme 12).62 Substrate 
binding converts the iron coordination geometry from a distorted octahedral geometry to a five-
coordinate square pyramid due to the elimination of the water ligand (I, Scheme 12). The geometric 
and electronic structures of the catalytic site in the presence of the substrate are significantly affected 
by the redox state of the Rieske center. Reduction of the Rieske cluster transforms the square 
pyramidal geometry into a mixture of trigonal bipyramidal and square pyramidal sites, priming the 
catalytic iron for the activation of molecular oxygen. These protein dynamics regulate the reactivity 
toward O2 during the catalytic cycle with both substrate binding and reduction of the [2Fe-2S] center 
being required for O2 activation. The structural changes prevent oxygen activation in the absence of 
bound substrate and hence the formation of reactive oxygen species which might lead to enzyme 
inactivation.103,105 The crystal structure of NDO from Pseudomonas sp. NCIB 9816-4 co-crystallized 
with O2 (PDB code: 1O7N) shows side-on binding of oxygen to the catalytic non-heme iron center.101 
Coordination of O2 to the iron complex in a side-on fashion is a unique feature of these enzymes and 
allows each oxygen atom to attack adjacent carbons from the same face of the substrate, leading to 
cis-diol formation. Other RO crystal structures show that oxygen and substrate bind in a similar 
manner with the atoms closest to the Fe-O2 complex being oxidized. Thereby, interactions between 
the substrate and residues constituting the active site are assumed to orient the substrate in the 
enzyme binding pocket.63  
After O2 binding, subsequent electron transfer from the Rieske cluster to the non-heme iron center 
results in a ferric peroxide complex which is transferred by subsequent protonation and loss of the 
water ligand into a bidentate hydroperoxide complex (Fe(III)-OOH; II, Scheme 12).62 The formation of 
a (hydro)peroxo species as pathway intermediate is supported by the uncoupling of O2 reduction and 
dihydroxylation.100 Upon exposure to certain substrate analogues (e.g. benzene for NDO), uncoupled 
NADH and substrate oxidation generates H2O2 in stoichiometric amounts, suggesting that “poor” 
substrates lead to a longer lifetime for an iron-peroxo species which finally decays into H2O2.21 The 
intermediates of the next step have not been completely solved yet and it is still unknown whether a 
high-valent Fe(V) or Fe(IV) oxo intermediate is formed. In case O-O bond cleavage precedes 
substrate oxidation, a Fe(V)=O(OH) complex is the proposed intermediate (IIIa, Scheme 12) which 
subsequently reacts with the substrate (IVa, Scheme 12). When O-O bond cleavage and substrate 
oxidation are coupled, a Fe(IV)=O complex is formed in combination with a substrate radical 
intermediate (IIIb, Scheme 12) that reacts further (IVb, Scheme 12). Regeneration of the enzyme 
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resting state affords transfer of a second electron from the [2Fe-2S] cluster to the iron and protonation 
of the intermediate which results in the release of the oxyfunctionalized product (V, Scheme 12).62 
 
 
Scheme 12: Proposed mechanism for the RO-catalyzed dihydroxylation, adapted from Barry and Challis.62 
As mentioned in the previous section, ROs are able to catalyze both dihydroxylation and 
monohydroxylation reactions. For the introduction of a single hydroxyl group, Chakrabarty and 
coworkers proposed a mechanism involving radical intermediates (Scheme 13).106 By using 
cyclopropane-containing substrates like norcarane and bicyclohexane as probes, formation of radical 
or cationic intermediates could be distinguished as either rearranged or ring expanded products are 
obtained. Results for conversion of norcarane and bicyclohexane using NDO as biocatalyst support a 
radical rebound mechanism for which the radical lifetime can be estimated by the ratio of unarranged 
to rearranged products. As already proposed for dihydroxylation reactions, the mechanism of 
monohydroxylation might include a high-valent Fe(V)-oxo-hydroxo intermediate (Scheme 13) and 
results for the oxidation of cyclopropane-containing substrate probes indicate the formation of a Fe(V) 
species prior to the insertion reaction.106 
 
 
Scheme 13: Proposed mechanism for the monohydroxylation of norcarane by NDO.106 
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1.3.4. Applications of ROs 
To date, the stereoselective cis-dihydroxylation of aromatic compounds has been the basis for most 
applications using RO enzymes. As no chemical single-stage alternative with similar broad substrate 
specificity and excellent stereoselectivity is available, a strong interest in ROs as biocatalysts has 
been developed.51 Due to their unique ability to generate arene cis-dihydrodiols, ROs are used for the 
preparation of lead structures found in natural products, polyfunctionalized metabolites and 
pharmaceutical intermediates.82 Arene-1,2-dihydrodiols are versatile chiral building blocks that can be 
further functionalized in various ways (Scheme 14),107 e.g. by replacing the hydroxyls with other 
functional groups or using the two chiral centers to direct stereo-controlled Diels-Alder reactions at or 
Michael addition reactions to the cyclohexadiene double bonds.21 
 
 
Scheme 14: Functionalization of arene cis-dihydrodiols by cycloaddition, cross-coupling reactions, Claisen 
rearrangement, epoxidation, aziridination or ozonolysis, adapted from Schrittwieser and Resch.107 
Within the last decades, there has been an enormous increase in the application of RO enzymes in 
organic synthesis.3,108 In particular the research group of Hudlicky has focused on the application of 
enzymatically derived arene cis-dihydrodiol units as chiral building blocks in synthetic organic 
chemistry. Starting from cyclohexadiene-1,2-diols as intermediates, various compounds including 
inositols, conduritols and cyclitols,108 strawberry furanone,109 prostaglandin E2α,110 morphine111 and 
pancratistatin111 were synthesized in different chemoenzymatic approaches. To overcome the problem 
that the highly stereoselective RO-catalyzed dihydroxylation only provides access to one enantiomer, 
Hudlicky and coworkers employed the TDO-mediated oxidation of para-dihalobenzenes with a iodine 
substituent that results in the opposite configuration of the products compared to the unsubstituted 
compounds, followed by removal of the iodine atom.112 
To date, several industrial applications of RO-catalyzed cis-dihydroxylations have been described. In 
1983, the Imperial Chemical Industries group reported a biotechnological route to polyphenylene with 
meso-cis-cyclohexanedienediol as intermediate.113 Another application is the RO-catalyzed formation 
of the blue dye indigo.114 The biotechnological production of indigo starts from glucose with 
metabolically engineered Escherichia coli (E. coli) strains expressing NDO.21 In the process, NDO 
catalyzes the dihydroxylation of indole formed in the tryptophan biosynthetic pathway and the resulting 
cis-diol undergoes spontaneous dehydration and dimerization to indigo. Furthermore, Merck applied 
ROs for the biocatalytic production of cis-aminoindan-2-ol, a key intermediate in the synthesis of the 
HIV inhibitor Crixivan®. The process relies on the biotransformation of indene to cis-1,2-indandiol and 
TDO forms the desired (1S,2R)-enantiomer which can be used as synthon for the preparation of 
(1S,2R)-amino-indan-2-ol. However, the process is hampered due to by-product formation (1-indenol) 
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and low stereoselectivities that can be overcome by the presence of a dihydrodiol dehydrogenase in 
P. putida (ee > 98%). As alternative strategy, a Rhodoccocus strain harboring a suitable RO system 
was employed for the formation of cis-1,2-indandiol with good stereoselectivities.9 
Next to the generation of chiral building blocks, ROs are applied as a platform for bioremediation. Due 
to its broad substrate scope regarding aromatic compounds, biphenyl dioxygenase (BphDO) has been 
extensively studied for the biodegradation of arenes with an emphasis on polychlorinated biphenyls 
(PCBs) which are serious environmental pollutants.63 Next to PCBs, carcinogenic chloroethenes like 
trichloroethylene (TCE) found in soil and groundwater115 have been shown to be transformed by TDO 
into formate and glyoxylate.82 
 
1.4. Protein engineering – Different strategies for the tailoring of ROs 
Even though the application of enzymes in organic synthesis offers many advantages due to their 
intrinsic high chemo-, regio- and stereoselectivity,52 potential biocatalytic routes might not always be 
efficient enough compared to chemical synthesis.116,117 Protein engineering allows improving the 
performance of enzymes as catalysts in synthetic organic chemistry and biotechnology. Two main 
strategies, rational design and directed evolution can be employed to alter enzyme properties for the 
desired application (Figure 3).118 Both strategies or a combination thereof (semi-rational design) have 
been described for the engineering of ROs to alter their substrate scope, activity or selectivity.119 The 
best studied examples include NDO, TDO and BphDO which have been subjected to various 
engineering methods in order to identify residues controlling selectivity and activity.82 
 
 
Figure 3: Protein engineering approaches including directed evolution, rational design and semi-rational design, 
adapted from Steiner and Schwab.120 
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1.4.1. Rational enzyme design 
In rational enzyme design, site-specific mutagenesis is applied to introduce amino acid changes in 
order to alter or induce desired properties.121 To be able to predict the most promising sites for 
mutagenesis in the protein sequence, detailed knowledge about structural and mechanistic features is 
required and often combined with in silico modeling.116 Yet, the required structural and mechanistic 
data are available for only a small number of proteins. Furthermore, one of the most significant 
limitation in the general application of rational design is the complexity of the structure-function 
relationship in enzymes and predicting the effect of mutations on protein features proved to be 
difficult.119,122  
Despite these limitations, rational design was successfully applied for the mutagenesis of different 
ROs, mainly targeting residues located in the substrate binding pocket. For many biocatalysts, the 
majority of mutations that beneficially affect enzyme properties like enantioselectivity or substrate 
specificity are rather located in or near the active site and might include amino acid residues that are 
involved in substrate binding.123 Several residues in the active site of NDO were identified by site-
directed mutagenesis resulting in altered selectivity and product formation compared to the wild type 
enzyme.124–126 In particular, position F352 in NDO from Pseudomonas sp. strain NCIB 9816-4 plays a 
major role in controlling both the regio- and stereoselectivity towards biphenyl and phenanthrene, 
offering the possibility to engineer dioxygenases by the introduction of a single point mutation.124 The 
corresponding position, F366 in tetrachlorobenzene dioxygenase from Ralstonia sp. PS12 was also 
shown to influence the regioselectivity of the enzyme. By remodeling of the active site using site-
directed mutagenesis, variant F366L displayed significant changes in regioselectivity for 2-, 3-chloro-, 
2,4-, 2,5- and 2,6-dichlorotoluene.127 Furthermore, an alteration in regiospecificity of BphDO from 
Pseudomonas pseudoalcaligenes KF707 for biphenyl-related compounds could be achieved by active 
site engineering.128 Variants F227V, I335F, T376N, F377L and F377A showed altered 
regioselectivities for dihydroxylation of various PCBs compared to the wild type enzyme. In addition, 
the change in four amino acids (positions 335, 336, 338 and 341) by site-directed mutagenesis of 
BphDO from Pseudomonas sp. LB400 enhanced its capacity to degrade PCBs by extending the 
substrate range of BphDO.129  
Yet, rational site-directed approaches are restricted due to the limited sequence space that can be 
explored at a time. In contrast, directed evolution of enzymes offers the possibility to randomly 
introduce mutations to cover a large sequence space. Using the random approach, also mutations far 
from the active site that influence distinct enzyme properties like activity or thermostability can be 
identified.123 
 
1.4.2. Directed evolution 
In directed evolution, random changes are introduced into a gene of interest, altering the amino acid 
sequence of an enzyme in an iterative manner until the desired properties are obtained.117 It is the 
most widely applied approach for protein engineering as new functional properties can be evolved in 
enzymes without prior knowledge about the structure or function of the target protein.122,130 Directed 
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evolution is based on two iterative steps which involve repeating cycles of mutagenesis for diversity 
generation and screening or selection for the identification of improved variants.131 
In directed evolution experiments, molecular diversity is created either by in vitro gene recombination 
methods or by random mutagenesis.131 During recombination, a set of related sequences is randomly 
combined whereas non-recombining methods only target a single protein sequence.116 Among the 
most often used mutagenesis methods in directed evolution are error-prone PCR (epPCR), saturation 
mutagenesis and shuffling approaches.121 Often, a combination of both random mutagenesis and 
recombination is applied as deleterious mutations introduced by methods like epPCR can be crossed 
out by shuffling and only beneficial mutations are preserved.132 By directed evolution, a large 
sequence space can be covered, generating a huge number of mutants that must be screened. 
Hence, a reliable high-throughput screening (HTS) or selection assay is needed to identify functionally 
improved variants under relevant conditions. The development of a suitable HTS assay is one of the 
major limitations of directed evolution and the success of random mutagenesis experiments often 
depends on the availability of screening or selection methods.122,131  
Directed evolution of ROs has helped to identify residues that effect enzyme function.63 A widely 
applied method for the introduction of mutations into ROs was the use of in vitro gene recombination 
methods like DNA shuffling, staggered extension process (StEP) or random priming 
recombination.21,133,134 These methods mimic nature by random recombination of selected genes in 
vitro and thus offer an attractive approach as RO enzymes can be grouped into families similar in size 
and amino acid sequence.64 Herein, enzymes belonging to the same family have evolved from a 
common ancestor to acquire new catalytic functions through recombination, duplication, multiple point 
mutations, deletion or integration, resulting in diverse but highly related sequences135 and studies of 
hybrid ROs have shown altered selectivities and product formations.63 Using recombination methods, 
one extensively studied example in directed evolution experiments is BphDO that has been evolved 
for bioremediation applications by extending its substrate scope. For BphDOs from different aromatics 
degrading strains, variations in the PCB congener selectivity patterns and activities were found.135 
BphDOs from Pseudomonas pseudoalcaligenes strain KF707 and Pseudomonas cepacia LB400 differ 
in their substrate range despite their nearly identical amino acid sequence of the oxygenase 
α-subunits which vary in only 20 amino acid residues (96.4% identity). By construction of chimeric 
BphDOs from both strains, a small number of amino acid residues at the C-terminus was identified 
that are involved in substrate specificity and regioselectivity, being responsible for PCB recognition. 
Using three restriction sites common to the α-subunits of BphDO oxygenases from both strains, a 
KF707 variant with an expanded range of biodegradable PCB congeners could be generated.136 
Based on these results, DNA shuffling of bphA1 genes encoding for the BphDO α-subunits from 
Pseudomonas pseudoalcaligenes KF707 and Pseudomonas cepacia LB400 was used to recombine 
as many differences in both enzymes as possible.135 Several evolved BphDO variants could be 
identified based on the formation of yellow colored meta-cleavage products, showing enhanced 
degradation capacity for PCB and related biphenyl compounds. In addition, novel degradation 
capacity for smaller aromatic substrates like benzene and toluene was detected which are only poorly 
attacked by wild type BphDOs.135  
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Yet, in these DNA shuffling experiments by Kumamaru and coworkers, no chimeric enzymes were 
found that combine the ability of both parental clones to dihydroxylate double ortho- and 
para-substituted PCBs. Whereas strain LB400 preferentially dihydroxylates ortho-substituted PCBs, 
para-substituted PCBs are oxidized by Pseudomonas pseudoalcaligenes KF707. Applying DNA 
shuffling and StEP to recombine BphDO α-subunits, Brühlman and Chen identified several variants 
that equally degraded both PCB substitution patterns and also showed enhanced dihydroxylation 
activity for several tetra- and pentachlorinated PCBs being hardly degraded by wild type BphDOs.133 
Interestingly, both Kumamaru et al. and Brühlman and Chen identified variants T335A and F336I 
during their mutagenesis studies, indicating a crucial effect of these positions on selectivity.133,135 
Besides the various recombinative approaches for RO engineering, also examples for the use of non-
recombinative evolutionary methods exist. Random mutagenesis was applied to increase the activity 
of aniline dioxygenase for aniline derivatives. In order to enhance the bioremediation of aromatic 
amines, the mutant V205A was used as template for one round of saturation mutagenesis on the 
active site residues followed by a round of epPCR. Even though variant V205A exhibited an extended 
substrate specificity for 2-isopropylaniline compared to the wild type enzyme, replacement of valine by 
alanine at position 205 decreased the activity for aniline (8.4 x) and 2,4-dimethylaniline (28 x). 
Applying random mutagenesis, aniline dioxygenase activity was improved, yielding several mutants 
with increased dihydroxylation capacity.137 Likewise, in order to extend the substrate scope of TDO 
towards 4-picoline, a combination of epPCR and saturation mutagenesis was applied and screening of 
mutant libraries was accomplished using Gibbs’ reagent (2,6-dichloroquinone-4-chloroimide)138 which 
strongly reacts with ortho- and meta-substituted phenolic compounds to form colored products.139 
 
1.4.3. Semi-rational design: Combining directed evolution and rational design 
As mentioned in the previous sections, both rational enzyme design and directed evolution have 
distinct limitations. Whereas rational design is restricted due to the insufficient knowledge on protein-
structure relationships, the availability of fast and reliable HTS methods for screening of large library 
sizes can be limiting in directed evolution experiments.116 In addition, even in huge protein libraries, 
only a fraction of the possible protein variants is represented and biases resulting from the degeneracy 
of the genetic code further restrict diversity.140 Taking these problems into account, the focus has 
moved onto new strategies for the design of smaller libraries with high quality that eliminate the need 
for suitable HTS assays. For library design, a combination of rational design and directed evolution 
approaches is applied to overcome the limitations of each method and combine the advantages of 
both strategies to create small focused mutant libraries.116,118 
In semi-rational design, the choice of positions to mutate remains rational in most cases and the 
reduced library size results from the focus on specific amino acid residues that are targeted on the 
basis of prior structural or functional knowledge. Sequence-based enzyme engineering uses multiple 
sequence alignments and phylogenetic analyses to determine amino acid conservation and 
evolutionary relationships among groups of homologous proteins.141 Furthermore, structural analysis 
can facilitate the mutation of enzymes in a more targeted manner and due to the growing number of 
structures and advances in homology modeling, structure-based enzyme redesign allows the effective 
location of key residues.141 The resulting focused mutant libraries are more likely to yield positive 
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results as multiple mutations can be introduced at positions where they might be most effective e.g. in 
or near the active site when targeting enzyme properties like enantioselectivity, substrate specificity or 
new catalytic activities.122,123  
Site-directed saturation mutagenesis was applied to improve the activity and selectivity of 
nitrobenzene dioxygenase from Comamonas sp. for the selective oxidation of aromatic sulfides. 
Targeting different residues in the active site generated dioxygenase variants with opposite 
enantioselectivities and increased activities on substrates like thioanisole, Cl- or Br-thioanisole and p-
tolyl compared to the wild type enzyme.142 Furthermore, the BphDO-catalyzed dihydroxylation of 7-
hydroxyflavone and 5,7-dihydroxyflavone was successfully enhanced by site-saturation mutagenesis 
at positions 324 and 325 of the best BphDO variants obtained from family shuffling of the oxygenase 
α-subunits from Pseudomonas pseudoalcaligenes strain KF707 and Pseudomonas putida strain 
KF715.143  
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1.5. Aim of the work 
Due to the increasingly stringent environmental constraints and with regard to atom efficiency, novel 
catalytic methodologies for organic synthesis are in great demand by the pharmaceutical and chemical 
industries.144 Being part of the project “Chemistry for the 21th century” (CHEM21) with the aim to 
establish sustainable alternatives to existing chemical methods, this PhD project has focused on a 
biocatalytic access to cis-1,2-diols. Employing enzymatic routes for alkene cis-dihydroxylation would 
reduce the need for toxic heavy metal catalyst which can lead to byproduct formation due to over-
oxidation and ring fission.5 In order to provide efficient biocatalysts for the formation of vicinal cis-diols, 
the following objectives were targeted:  
 Identification of suitable biocatalysts for the asymmetric dihydroxylation of alkenes 
 Tailoring these enzymes for the oxyfunctionalization of a selected panel of olefins 
 Characterization of biocatalysts and comparison with chemical means 
 Proof of the applicability of designed biocatalysts for organic synthesis 
In a first step, the identification and selection of enzymes suitable for the oxyfunctionalization of olefins 
should be performed. As ROs have been described to be the only enzymes capable of inserting both 
atoms of O2 in one enzymatic step to stereoselectively catalyze the formation of vicinal cis-diols,63 this 
enzyme class was further investigated. Being naturally involved in the dihydroxylation of aromatic 
compounds,65 RO enzymes had to be selected that show an extended substrate specificity towards 
unnatural alkene substrates. These enzymes were to be characterized regarding their substrate scope 
and selectivities using a panel of structurally different alkenes to give a first overview of the olefins that 
can be targeted employing ROs. To evaluate biocatalytic olefin oxidation against heavy metal 
catalyzed methods like Sharpless AD, the panel of compounds should also include alkenes difficult to 
target with OsO4 as catalyst. 
In the second step, wild type enzymes were to be optimized by protein engineering for the selective 
oxyfunctionalization of the alkene substrates. Rational and semi-rational design should be applied as 
mutagenesis strategies to create a small focused mutant library. Within this mutant library, amino acid 
residues crucial for selectivity and substrate specificity of ROs should be identified. Generated variants 
were to be characterized and compared to both wild type enzymes and chemical methods for olefin 
dihydroxylation. 
In the third step, the applicability of RO-catalyzed olefin oxidation in organic synthesis should be 
demonstrated by performing semi-preparative biotransformations in mg scale.  
 
 
Scheme 15: Natural reaction of ROs and the dihydroxylation of alkenes addressed in this work. 
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2. EXPERIMENTAL SECTION 
2.1. Materials 
Except not noted otherwise, chemicals, solvents and buffer components were obtained from Sigma-
Aldrich and Fluka (Steinheim, Germany), Carl Roth GmbH (Karlsruhe, Germany), Acros Organics 
(Geel, Belgium), VWR (Darmstadt, Germany), Alfa Aesar (Karlsruhe, Gemany) and Serva (Heidelberg, 
Germany). Restriction enzymes as well as the T4 DNA ligase were purchased from Thermo Scientific 
(Schwerte, Germany), Pfu polymerase from GeneOn (Ludwigshafen, Germany) and enzymes for 
Gibson Assembly from NEB (Frankfurt am Main, Germany). Kits for PCR product purification, gel 
extraction of DNA and plasmid minipreparations were obtained from Zymo Research (Freiburg, 
Germany). DNA markers for agarose gel electrophoresis as well as protein markers for SDS-PAGE 
were obtained from peqlab (peqlab Biotechnology GmbH, Erlangen, Germany) or Fermentas (Thermo 
Fisher Scientific Germany, Braunschweig). peqGREEN for DNA staining in agarose gel 
electrophoresis was purchased from peqlab (peqlab Biotechnology GmbH, Erlangen, Germany). DNA 
sequencing was performed by GATC Biotech (Konstanz, Germany) and all primers were synthesized 
by metabion International AG (Martinsried, Germany).  
 
2.2. Plasmids, strains and storage of E. coli cultures 
The plasmid pDTG141 carrying the nah genes encoding for NDO oxygenase α- (nahAc) and 
β- (nahAd) subunits, ferredoxin (nahAb) and reductase (nahAa) from Pseudomonas sp. strain NCIB 
9816-4 was obtained from Rebecca Parales.145 The plasmid pJRM501 containing the genes for BDO 
oxygenase α- (bedC1) and β- (bedC2) subunits, ferredoxin (bedB) and reductase (bedA) from 
P. putida ML2 was provided by David Leak.146 The plasmid pIP107D harboring the genes for CDO 
oxygenase α- (cumA1) and β- (cumA2) subunits, ferredoxin (cumA3) and reductase (cumA4) from 
Pseudomonas fluorescens IP01 was obtained from Hideaki Nojiri.147 
 
               
Figure 4: The plasmids pJRM501 (left) and pDTG141 (right) encoding the RO genes for BDO and NDO. 
pJRM501 is based on the pKK223-3 vector containing an ampicillin resistance gene (AmpR) and BDO genes are 
under the control of the IPTG-inducible tac promotor (tacP).148 pDTG141 is based on the pT7-5 vector harboring 
an ampicillin resistance gene (AmpR) and NDO genes are under the control of the T7 promotor (T7P).92  
  EXPERIMENTAL SECTION 
39 
 
Figure 5: Plasmid pIP107D encoding the RO genes for CDO. pIP107D is based on the pUC118 vector containing 
an ampicillin resistance (AmpR) and genes are under the control of the IPTG-inducible lac promotor (lacP).147 
For cloning, E. coli XL1-Blue was employed, a strain deficient in endonuclease (endA) and 
recombination (recA). The cleavage of cloned DNA by the EcoK endonuclease system is prevented by 
the hsdR mutation (Table 4). For expression of RO genes, E. coli strains JM109 (CDO and BDO) and 
JM109 (DE3) (NDO) were used. E. coli JM109 (DE3) carries a chromosomal copy of the T7 RNA 
polymerase gene under the control of the lacUV5 promotor (Table 4). 
 
Table 4: Different E. coli strains used for cloning and expression of RO genes. 
Strain Genotype 
E. coli XL1-Blue 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac 
[F´ proAB lacIqZ∆M15 Tn10 (Tetr)] 
E. coli JM109 
endA1 recA1 gyrA96 thi hsdR17 (rk– mk+) relA1 supE44 
Δ(lac-proAB) [F´ traD36 proAB laqIqZΔM15] 
E. coli JM109 (DE3) 
endA1 recA1 gyrA96 thi hsdR17 (rk– mk+) relA1 supE44 λ–
Δ(lac-proAB) [F´ traD36 proAB lacIqZΔM15] lDE3 
 
For long term storage of E. coli strains at -80°C, glycerol stocks were prepared by the addition of 
sterile glycerol to E. coli overnight cultures grown in lysogeny broth (LB) medium to a final 
concentration of 15% (v/v). 
 
2.3. Methods 
2.3.1. Restriction enzyme-based gene cloning - Reconstruction of plasmid pIP107D 
The plasmid pIP107D that was obtained from Hideaki Nojiri lacked part of the reductase gene cumA4. 
Thus, the reductase was restored using plasmid pIP103 (provided by Hideaki Nojiri) as template for 
PCR which harbored the corresponding cis-dihydrodiol dehydrogenase and the extradiol dioxygenase 
next to the RO components.147 By touchdown PCR,149 an EcoRI restriction site was appended after 
the stop codon of cumA4 using the primers given in Table 5. The plasmid pIP107D as well as the PCR 
product were digested with SalI and EcoRI restriction enzymes according to the manufacturer’s 
instructions. Digested DNA was purified with the Zymoclean™ Gel DNA Recovery Kit (plasmid DNA) 
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or with the DNA Clean & Concentrator-5™ kit (PCR product) and ligated in a ratio of 3:1 
(PCR product:plasmid DNA) with T4 DNA ligase over night at room temperature according to the 
manufacturer’s instructions. After heat inactivation of the T4 DNA ligase, 2.5 µl of the ligation mixture 
were transformed in 50 µl chemically competent E. coli XL1-Blue cells and plated on LB agar (1.5%) 
supplemented with 100 µg mL-1 ampicillin. Colonies were picked and grown over night for 
minipreparations. The correct sequence was confirmed by DNA sequencing (primers in Table S24). 
 
Table 5: Primers used to amplify the cumA4 gene and append an EcoRI restriction site (underlined) after the stop 
codon. fwd: forward primer, rev: reverse primer. 
Primer name Sequence 
pIP107D 4_fwd 5’-GCC AATCTCCTCGGGACTTTGC-3’ 
pIP107D cumA4 EcoRI_rev 5’-CATAATGAATTCTCACTCGCATCGCTCAGCTTTAG-3’ 
 
2.3.2. Site-directed mutagenesis 
Site-directed mutagenesis of CDO (CDO M232A) and NDO (NDO A206I and NDO A206M) was 
performed according to the Stratagene QuikChange™ protocol150 using the primers given in Table 6. 
To introduce mutation M220A in BDO, one step isothermal Gibson assembly151 was applied as 
QuikChange™ PCR did not give the desired results. Plasmid pJRM501 carrying the bed genes was 
digested with EcoRI and vector DNA gel purified with the Zymoclean™ Gel DNA Recovery Kit. To 
create overlapping parts with the digested plasmid, BDO genes were amplified using standard PCR 
protocols with the given primers (BDO M220A_fwd and GA BDO M220A_rev/ BDO M220A_rev and 
GA BDO M220A_fwd, Table 6) and the PCR reactions were digested for 1 h at 37°C with DpnI to 
remove the template DNA. After Gibson assembly151 of the plasmid DNA and the PCR product, 2.5 µl 
of the reaction mixture were transformed in 50 µl chemically competent E. coli XL1-Blue cells and 
plated on LB agar (1.5%) supplemented with 100 µg mL-1 ampicillin. The correct DNA assembly and 
the insertion of point mutations was confirmed by DNA sequencing (primers given in Table S24) after 
minipreparation of plasmids from overnight cultures of grown colonies. 
 
Table 6: Primers used for site-directed mutagenesis of BDO, NDO and CDO and the generation of overlapping 
PCR products for Gibson assembly of BDO. Nucleotides to insert point mutations are underlined. fwd: forward 
primer, rev: reverse primer. 
Primer name Sequence 
BDO M220A_fwd 5’-GTTTTGTAGTGACGCGTACCATGCCGGGAC-3’ 
BDO M220A_rev 5’-GTCCCGGCATGGTACGCGTCACTACAAAAC-3’ 
GA BDO M220A_fwd 5’-CGACATCATAACGGTTCTGGC-3’ 
GA BDO M220A_rev 5’-GAGTTCGGCATGGGGTCAG-3’ 
CDO M232A_fwd 5’-CTGTAGCGATGCGTACCATGCGGGAAC-3’ 
CDO M232A_rev 5’-GTTCCCGCATGGTACGCATCGCTACAG-3’ 
NDO A206I_fwd 5’-CTTTGTGGGAGATATCTACCACGTGGGTTG-3’ 
NDO A206I_rev 5’-CAACCCACGTGGTAGATATCTCCCACAAAG-3’ 
NDO A206M_fwd 5’-CTTTGTGGGAGATATGTACCACGTGGGTTG-3’ 
NDO A206M_rev 5’-CAACCCACGTGGTACATATCTCCCACAAAG-3’ 
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2.3.3. Site-saturation mutagenesis and indole screening assay 
For site-saturation mutagenesis of CDO at positions F278, I288, I336 and F378, primers with DBC or 
BBT degenerated codons were used encoding for 8 (DBC: F, C, I, T, S, V, A, G) and 9 (BBT: F, S, C, 
L, P, R, V, A, G) mainly small amino acids. For mutagenesis at position M232, the NDT degenerated 
codon was used to introduce a balanced mix of 12 polar and nonpolar, aliphatic and aromatic as well 
as negatively and positively charged amino acids (F, L, I, V, Y, H, N, D, C, S, R and G).140 DBC, BBT 
and NDT libraries were prepared using the primers with the degenerated codons given in Table 7. For 
BBT and DBC mutant libraries, overlapping DNA fragments containing the introduced mutations 
(forward primers for introduction of point mutations and pIP107D cumA3_rev/ reverse primers for 
introduction of point mutations and pIP107D PP_fwd) were generated using standard PCR protocols. 
The PCR reactions were digested for 1 h at 37°C with DpnI to remove the template DNA. Plasmid 
pIP107D was digested with HindIII and SalI and DNA gel purified with the Zymoclean™ Gel DNA 
Recovery Kit. PCR products and digested vector DNA were assembled using one step isothermal 
DNA assembly after Gibson et al.151 to generate the circular vector containing the mutation. For the 
NDT mutant library, the QuikChange™ mutagenesis method according to the Stratagene protocol150 
was applied and one step isothermal Gibson assembly151 was performed to seal nicks. Chemically 
competent E. coli JM109 cells were transformed with 2.5 µl of the Gibson assembly mixtures and 
selected on LB agar containing 100 µg mL-1 ampicillin. For a coverage of ≥ 95%, at least 25 (BBT and 
DBC libraries) and 65 (NDT library) colonies, respectively, were screenedb and a balanced library was 
confirmed by sequencing the resuspended clones of the whole plate (example shown in Figure 6). 
DNA sequencing confirmed the correct DNA assembly and insertion of point mutations (primers given 
in Table S24). 
 
Table 7: Primers applied for the site-saturation mutagenesis of CDO at positions M232, F278, I288, I336 and 
F378. Degenerated codons are underlined. fwd: forward primer, rev: reverse primer. 
Primer name Sequence 
CDO M232NDT_fwd 5’-CTGTAGCGATNDTTACCATGCGGGAAC-3’ 
CDO M232NDT_rev 5’-GTTCCCGCATGGTAAHNATCGCTACAG-3’ 
CDO F278DBC_fwd 5’-CATGGGACCGGCTGGDBCAATGACGATTTCGC-3’ 
CDO F278DBC_rev 5’-GCGAAATCGTCATTGVHCCAGCCGGTCCCATG-3’ 
CDO I288BBT_fwd 5’-CACTTCTGCAAGCCBBTATGGGTCCTAAGGTTG-3’ 
CDO I288BBT_rev 5’-CAACCTTAGGACCCATAVVGGCTTGCAGAAGTG-3’ 
CDO I336BBT_fwd 5’-CATTTCTTCCTGGCBBTAATACAGTCCGTAC-3’ 
CDO I336BBT_rev 5’-GTA CGG ACT GTATTAVVGCCAGGAAGA AATG-3’ 
CDO F378DBC_fwd 5’-GAAAAACATCTTCACCDBCAATCAAGG GGGAACC-3’ 
CDO F378DBC_rev 5’-GGTTCCCCCTTGATTGVHGGTGAAGATGTTTTTC-3’ 
pIP107D PP_fwd 5’-CTGGAAAGCGGGCAGTG-3’ 
pIP107D cumA3_rev 5’-GGTCAAGCCTTTTTCAGAGTTTC-3’ 
                                                     
b The number of colonies that have to be screened for 95% coverage was calculated by CASTER.223 
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Figure 6: Randomization efficiency of each nucleotide (black: G, blue: C, red: T, green: A) for the NDT mutant 
library at positions encoding M232 in CDO (black box). N = A, G, T or C; D = A, G or T. 
For screening of DBC and BBT mutant libraries, a colorimetric solid phase assay based on indigo 
formation was applied. E. coli JM109 cells transformed with the mutant libraries were grown over night 
at 37°C on LB agar plates supplemented with 100 µg mL-1 ampicillin. After colony formation, dried 
Whatman filter papers soaked in a 10% solution of indole in acetone were placed into petri dish covers 
and incubated at room temperature until a blue color formation was observed.145  
 
2.3.4. Preparation of chemically competent E. coli cells and transformation of E. coli 
The preparation of chemically competent E. coli cells was performed according to the rubidium 
chloride (RbCl) method as described in literature.152 
Heat-shock transformation of chemically competent E. coli cells was performed at 42°C for 45 s after 
incubating the cells mixed with the plasmid DNA for 30 min on ice. The heat-shock treatment was 
followed by cooling on ice for 2 min and cells were subsequently incubated for 1 h at 37°C and 
180 rpm in SOC medium (5 g L-1 yeast extract, 20 g L-1 tryptone, 0.584 g L-1 NaCl, 0.186 g L-1 KCl, 
20 mM MgSO4 and 20 mM glucose). After incubation, E. coli cells were plated on LB agar (1.5%) 
supplemented with 100 µg mL-1 ampicillin. 
 
2.3.5. Heterologous expression of RO wild type enzymes and variants 
Expression of NDO and BDO was carried out as described previously.145,153 E. coli JM109 cells 
harbouring the plasmid pIP107D were grown at 37°C and 180 rpm in LB medium (10 g L-1 tryptone, 
5 g L-1 yeast extract and 5 g L-1 NaCl) containing 50 μg mL−1 ampicillin. At an OD600 of 0.5-0.7, the 
culture was supplemented with 0.2 mM IPTG to induce expression of CDO. Cells were harvested after 
cultivation for 2 h at 30°C and 180 rpm by centrifugation (9,000 x g, 20 min, 4°C). For expression of 
RO variants, conditions described for the wild type enzymes were applied. To avoid loss of activity, 
whole cell biocatalysts were immediately used for in vivo biotransformations. As expression levels of 
ROs were low and overexpressed protein bands hardly visible in SDS-PAGE, expression of active 
enzyme was routinely controlled by the conversion of indole to form the blue dye indigo. 
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2.3.6. In vivo biotransformations with wild type and mutant enzymes 
Reaction mixtures in in vivo biotransformations contained 0.2 g cells mL-1 (cww) in 100 mM potassium 
phosphate buffer pH 7.2, 20 mM glucose for in situ cofactor regeneration, 50 µg mL-1 ampicillin and 
10 mM substrate in a total volume of 1 mL. Due to the volatility of several of the tested substrates, 
reactions were performed in gas tight screwed capped glass vials (V = 20 mL). Biotransformations 
were incubated at 30°C and 180 rpm for 24 h. Negative controls were performed with E. coli JM109 
cells carrying the empty vector. 
For GC analysis, cells were centrifuged and 500 µL supernatant was transferred in an Eppendorf tube 
and supplemented with NaCl and 1-decanol as internal standard, followed by three times extraction 
with 250 µL ethyl acetate.  
Preparative biotransformations for product characterization were performed in 1 L flasks with 
0.25 g cells mL-1 (cww) and 70 mg substrate in a total volume of 55 mL, applying the same reaction 
set-up as described above. After cell lysis by ultrasonication and addition of NaCl, the reaction mixture 
was extracted four times with 50 mL ethyl acetate. The combined organic fractions were concentrated 
in vacuo and subjected to flash column chromatography. 
 
2.3.7. Up-scaling of (R)-limonene hydroxylation to 4 L 
For up-scaling of (R)-limonene hydroxylation in a bioreactor, the protocol described by Yildirim et al. 
for the biotransformation of benzonitrile in a 2 L reactor with E. coli JM101 expressing chlorobenzene 
dioxygenase was adapted for CDO M232A.154 Biotransformations with E. coli JM109 expressing the 
CDO variant M232A were performed in a Labfors stirred tank reactor (Infors AG, Bottmingen, 
Switzerland) with a total volume of 4 L terrific broth (TB) media (12 g L-1 tryptone, 24 g L-1 yeast 
extract, 4 g L-1 glycerol mixed 10:1 with 0.17 M KH2PO4 and 0.72 M K2HPO4) supplemented with 
50 µg mL-1 ampicillin. The temperature was kept at 30°C and the pH was adjusted to 7.2 using 
25% NH4OH and 10% H3PO4. The reactor was aerated with 2 vvm and stirred at 1000 rpm. After 
inoculation with an OD600 of 0.05, cells were supplemented with 7 g L-1 (NH4)2HPO4 as additional 
N-source and grown overnight (~12 h). The resulting culture with a cell dry weight (cdw) of about 
7-8 g L-1 was supplemented with 15 ml trace element solution US* (4.87 g L-1 FeSO4·7 H2O, 
4.12 g L-1 CaCl2·H2O, 1.50 g L-1 MnCl2·4 H2O, 1.50 g L-1 MnCl2·4 H2O, 1.05 g L-1 ZnSO4, 
0.30 g L-1 H3BO3, 0.25 g L-1 Na2MoO4·2 H2O, 0.15 g L-1 CuCl2·2 H2O and 0.15 g L-1 CuCl2·2 H2O)155 
and 16 mg thiamine. Subsequently, fed batch fermentation was started with a constant feed of 15 g h-1 
using 50% glycerol and 1% MgSO4. After 1 h, protein expression was induced by the addition of 
0.2 mM IPTG. After 2 h, (R)-limonene was added to start the biotransformation. Due to the reported 
antimicrobial effect of (R)-limonene,156 the substrate was added repeatedly in aliquots to a final 
concentration of 5 mM. At different time points, samples were taken from the biotransformation to 
monitor substrate depletion and product formation by GC-FID analysis and measure acetate levels by 
HPLC analysis. 
To determine the isolated product yields, the fermentation broth was extracted four times with ethyl 
acetate after addition of NaCl and the combined organic fractions were concentrated in vacuo and 
subjected to flash column chromatography. 
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2.3.8. Microbial toxicity of (1R,5S)-carveol on E. coli JM109 
To determine a toxic effect of the biotransformation product (1R,5S)-carveol on growing E. coli JM109 
cells, cultures were exposed to varying amounts of (1R,5S)-carveol (0 mM, 1 mM, 5 mM and 10 mM). 
E. coli JM109 cells carrying the plasmid encoding CDO M232A were inoculated in TB medium 
supplemented with 50 µg mL-1 ampicillin to a start OD600 of 0.05. After addition of carveol to the 
medium, cultures were grown at 30°C and 180 rpm. Cell growth was monitored by measuring the 
OD600 and compared to growth of E. coli JM109 (pIP107D M232A) without carveol. 
 
2.3.9. GC, HPLC and NMR analytics  
Nuclear magnetic resonance (NMR) spectroscopy 
1H and 13C nuclear magnetic resonance (NMR) spectra were recorded on a Bruker Avance 500 
spectrometer operating at 500.15 MHz and 125.76 MHz, respectively. All spectra were recorded at 
room temperature in CDCl3. Chemical shifts (δ) are expressed in parts per million (ppm) relative to 
tetramethylsilane (TMS, δ = 0 ppm). For the 1H NMR spectra, data are reported as follows: chemical 
shift, integration, multiplicity (s = singulet, d = doublet, t = triplet, q = quartet, m = multiplet, br s = 
broad singulet, br t: broad triplet) and coupling constant (Hz). Assignments of chemical shifts were 
performed by heteronuclear single quantum coherence (HSQC) and heteronuclear multiple bond 
correlation (HMBC) analyses. 
 
Gas chromatography (GC) analytics 
GC-MS analyses were performed on a Shimadzu GCMS-QP2010 system equipped with an AOC-5000 
auto injector. For product identification, GC-MS analyses were performed on a ZB-5 capillary column 
(Phenomenex, 15 m x 0.25 mm x 0.25 µm) or a DB-5 capillary column (Hewlett Packard, 
30 m × 0.25 mm × 0.25 µm) using He as carrier gas (linear velocity 30 cm s-1) and split injection with 
an injector temperature of 250°C. Mass spectra were determined by EI ionization with 70 eV, an ion 
source temperature of 200°C and an interface temperature of 250°C. Mass detection was performed 
in scan mode from 40 m/z to 450 m/z. 
The temperature program was as following:  
2 min at 50°C, 10°C min-1 to 280°C, hold for 2 min, 40°C min-1 to 310°C and hold for 2 min 
GC-FID analyses were performed on a Shimadzu GC-2010 system equipped with an AOC-20i auto 
injector. For quantification of product formation by GC-FID, a DB-5 capillary column (Hewlett Packard, 
30 m × 0.25 mm × 0.25 µm) was used with H2 as carrier gas (linear velocity 30 cm s-1). The injector 
temperature was 250°C and compounds were detected via flame ionization detector (FID) at 330°C. 
For monitoring of the product formation and substrate depletion during the up-scaling of (R)-limonene 
hydroxylation in a bioreactor, a Zebron™ ZB-FFAP capillary column (Phenomenex, 30 m x 0.25 mm x 
0.25 µm) was used with H2 as carrier gas (linear velocity 30 cm s-1). The injector temperature was 
250°C and compounds were detected via FID at 270°C. 
The temperature programs for the analyses of the different compounds are described in Table 8.  
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Table 8: GC-FID temperature programs for analysis of biotransformations with substrates 1-(R)-7 performed on a 
DB-5 or a ZB-FFAP capillary column. 
Compound Column Temperature program 
styrene 1 DB-5 
3 min at 120°C, 10°C min-1 to 140°C, 10°C min-1 to 178°C, 75°C min-1 to 
310°C and hold for 4 min 
vinylcyclohexane 2 DB-5 
3 min at 120°C, 10°C min-1 to 140°C, 10°C min-1 to 178°C, 75°C min-1 to 
310°C and hold for 4 min 
cyclohexene 3 DB-5 
3 min at 70°C, 4°C min-1 to 85°C, 10°C min-1 to 190°C, 75°C min-1 to 310°C 
and hold for 4 min 
indene 4 DB-5 
3 min at 120°C, 10°C min-1 to 140°C, 10°C min-1 to 178°C, 75°C min-1 to 
310°C and hold for 4 min 
myrcene 5 DB-5 
3 min at 120°C, 10°C min-1 to 145°C, 5°C min-1 to 178°C, 75°C min-1 to 
310°C and hold for 4 min 
(+)-α-pinene 6 DB-5 
3 min at 120°C, 10°C min-1 to 140°C, 10°C min-1 to 178°C, 75°C min-1 to 
310°C and hold for 4 min 
(R)-limonene (R)-7 
DB-5 
3 min at 120°C, 10°C min-1 to 140°C, 10°C min-1 to 178°C, 75°C min-1 to 
310°C and hold for 4 min 
ZB-FFAP[a] 
3 min at 70°C, 10°C min-1 to 100°C, 10°C min-1 to 150°C, 40°C min-1 to 
230°C and hold for 4 min 
[a] Analysis of (R)-limonene (R)-7 and its biotransformation products was performed without derivatization on the 
ZB-FFAP capillary column. 
For quantification of product formation by GC-FID, standard curves of the respective products were 
used with 1-decanol as internal standard. Standard curves were prepared in Eppendorf tubes as 
dilutions in 100 mM KPi pH 7.2. The respective products were prepared as 1 M dimethyl sulfoxide 
(DMSO) stocks and diluted to 20 mM in 100 mM KPi for the preparation of a concentration range from 
0.1 mM–10 mM or 12 mM. Extraction with ethyl acetate and further work up was performed as 
described for whole cell biotransformations.  
For GC-FID analyses on the DB-5 capillary column, sample derivatization was performed with an 
excess of acetic anhydride and pyridine (50 µl sample was mixed with 40 µl of each pyridine and 
acetic anhydride), except for biotransformation products of (+)-α-pinene 6 that were quantified without 
derivatization. To ensure complete derivatization, samples were incubated for 1 h at 70°C except for 
biotransformation reactions of styrene 1. Due to decomposition of the underivatized 
arene-1,2-dihydrodiol 1b at high temperatures, samples were incubated for 2 h at room temperature.  
Due to polymerization of 3-vinylcyclohexa-3,5-diene-1,2-diol 1b when concentrated in vacuo, 
synthesis and purification of the arene-1,2-dihydrodiol to use it as standard could not be performed. 
Furthermore, during synthesis of 1-indenol 4a, explosive hydroperoxide intermediates 
(indene-1-peroxide) are formed157 and hence, relative response factor (RF) values were used to 
determine concentrations for cyclohexa-3,5-diene-1,2-diol 1b and 1-indenol 4a in reference to a 
standard (1-phenyl-1,2-ethanediol 1a and 1-indanol, respectively). RF values were calculated from the 
effective carbon numbers (ECN) of the respective compounds (ECNx) in relation to the ECN of the 
standard (ECNSTD) using equation (1).158,159 
 =  


 (1) 
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The concentrations of the analytes were determined by external calibration using standards and 
normalized with the calculated RF values (Table 9). Due to identical ECN values for 3,10-dihydro 
myrcene 5b, 2-methyl-6-methyleneoct-7-ene-2,3-diol 5c and 1,2-dihydro myrcene 5d after 
derivatization, quantification of 2-methyl-6-methyleneoct-7-ene-2,3-diol 5c and 1,2-dihydro myrcene 
5d was performed using 3,10-dihydro myrcene 5b as standard. Likewise, the acetylated forms of 
(Z)-2-methyl-6-methyleneocta-2,7-dien-1-ol 5a and 2-methyl-6-methylene-octa-1,7-dien-3-ol resulting 
from dehydration of 2-methyl-6-methyleneoct-7-ene-2,3-diol 5c, had identical ECN values and thus, 
quantification of 2-methyl-6-methylene-octa-1,7-dien-3-ol and (Z)-2-methyl-6-methyleneocta-2,7-dien-
1-ol 5a was performed using (E)-2-methyl-6-methyleneocta-2,7-dien-1-ol as standard. 
 
Table 9: Calculated ECN and RF values for quantification of product formation in GC-FID analysis. 
Compound ECN RF 
1a[a] 9.5 
0.968 
1b[a] 9.2 
4a[a] 9.65 
0.990 
1-indanol[a] 9.75 
5a[a] 10.45 
1 
2-methyl-6-methylene-octa-1,7-dien-3-ol[a] 10.45 
5b[a] 11.3 
1 
5c[a] 11.3 
5d[a] 11.3 
1 
5c[a] 11.3 
7a[a] 10.55 
1 
7b[a] 10.55 
[a] ECN and RF values were calculated for the acetylated compounds. 
Dependent on the compound, chiral GC-FID analysis was performed either on a Supelco β-Dex 225 
column (Sigma-Aldrich, 30 m × 0.25 mm × 0.25 µm), on a Supelco β-Dex 110 column (Sigma-Aldrich, 
30 m × 0.25 mm × 0.25 µm), on a Hydrodex-β-6TBDM column (Macherey-Nagel, 25 m x 0.25 mm) or 
on a CP-Chirasil-Dex CB column (Agilent, 25 m × 0.25 mm × 0.25 µm) with H2 as carrier gas 
(linear velocity 30 cm s-1). The injector temperature was 230°C and compounds were detected via 
flame ionization detector (FID) at 250°C. The temperature programs were as described in Table 10. 
Chiral analyses were performed with underivatized samples. 
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Table 10: Temperature programs and columns used for chiral GC-FID analysis of products 1a-4a, 4b, 5b-5c, 6a 
and 7b. 
Compound Column Temperature program 
1-phenyl-1,2-ethanediol 1a Hydrodex-β-6TBDM 
2 min at 90°C, 2°C min-1 to 120°C, 1°C min-1 to 150°C, 
40°C min-1 to 230°C and hold for 3 min 
1-cyclohexylethane-1,2-diol 2a CP-Chirasil-Dex CB 
1 min at 40°C, 10°C min-1 to 130°C, hold for 1 min, 
0.5°C min-1 to 190°C and hold for 1 min  
2-cyclohexen-1-ol 3a Supelco β-Dex 225 
2 min at 70°C, 2°C min-1 to 95°C, 1°C min-1 to 115°C, 
5°C min-1 to 150°C, 40°C min-1 to 210°C and hold for 
2 min 
1-indenol 4a Supelco β-Dex 225  
2 min at 90°C, 2°C min-1 to 120°C, 1°C min-1 to 150°C, 
40°C min-1 to 210°C and hold for 2 min 
3,10-dihydro myrcene 5b 
Supelco β-Dex 110 
1 min at 40°C, 10°C min-1 to 115°C, hold for 60 min, 
0.5°C min-1 to 130°C 1,2-dihydro myrcene 5d 
2-methyl-6-methyleneoct-7-
ene-2,3-diol 5c 
Supelco β-Dex 110 1 min at 40°C, 2.5°C min-1 to 190°C and hold for 1 min 
pinanediol 6a CP-Chirasil-Dex CB 1 min at 40°C, 2.5°C min-1 to 190°C and hold for 1 min 
carveol 7b CP-Chirasil-Dex CB 1 min at 40°C, 2.5°C min-1 to 190°C and hold for 1 min 
 
High-performance liquid chromatography (HPLC) analytics 
HPLC analysis was performed on an Agilent 1200 series system equipped with a G1315D diode array 
detector (DAD), a G1362A refractive index detector (RID), a G1322A degasser, a G1311A quaternary 
pump, a G1316A temperature controlled column compartment and a G1329A autosampler unit.  
Chiral stationary-phase HPLC analysis of 1-phenyl-1,2-ethanediol 1a and 1-indenol 4a was performed 
with a Chiralpak IB column (Daicel Chiral Technologies Europe S.A.S., 5 µm, 150 x 4.6 mm). For 
separation of 1-phenyl-1,2-ethanediol 1a enantiomers, a mobile phase of hexane:isopropanol (93:7) at 
a flow rate of 0.9 mL min-1 and 20°C was used. After injecting 10-20 µl sample, the UV signal was 
monitored at the maximum specific absorbance wavelength (258 nm). Enantiomers of 1-indenol 4a 
were separated with a mobile phase of hexane:isopropanol (90:10) at a flow rate of 1 mL min-1 and 
25°C. After injecting 10-20 µl sample, the UV signal was monitored at the maximum specific 
absorbance wavelength (266 nm). 
For chiral stationary-phase HPLC analysis of cis-1,2-indandiol 4b, a Reprosil-AM column (Dr. Maisch, 
5 µm, 4.6 mm x 250 mm) was used. Separation of enantiomers was performed with a mobile phase of 
hexane:isopropanol (92:8) at a flow rate of 1 mL min-1 and 25°C. 10 µl sample were injected and the 
UV signal was monitored at 220 nm.  
All chiral analyses were performed with underivatized samples. 
For quantification of acetate levels during fed-batch fermentation, samples were centrifuged and the 
supernatant was filtered (0.45 µm). Samples were measured on an Aminex HPX-87H Ion Exclusion 
Column (BIO-RAD, USA, 300 mm x 78 mm) at 60°C with a mobile phase of 5 mM sulfuric acid and a 
flow rate of 0.5 mL min-1. 10 µl sample were injected and signals were monitored on a RID at 35°C 
and a DAD at 210 nm. Acetate concentrations were determined by external calibration using acetate 
standard curves (0.25 mM-40 mM) that were prepared in the same manner as the samples. 
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2.3.10. Chemical synthesis of product standards 
In chemical synthesis, all non-aqueous reactions were run under an inert nitrogen atmosphere by 
using standard techniques for manipulating air-sensitive compounds and all glassware was flame 
dried prior to use. 
Flash column chromatography was performed with 0.040-0.063 mm mesh silica. Analytical thin-layer 
chromatography (TLC) was performed on silica plates (Macherey-Nagel) and TLC analysis was 
visualized using anisaldehyde staining solution (50 mL glacial acetic acid, 0.5 mL p-anisaldehyde and 
1 mL sulfuric acid 95-97%). 
 
Synthesis of (S)- and (R)-1-cyclohexylethane-1,2-diol (2a) 
 
 
 
1.4 g AD-mix α and β, respectively, was dissolved in a mix of tert-butanol and water (1:1, 5 mL each) 
at room temperature. After cooling the solution to 4°C, 1 mmol vinylcyclohexane was added and the 
suspension was stirred over night. 0.5 g Sodium metabisulfite was added slowly to the reaction 
mixture, followed by 20 mL of water and the suspension was stirred for 30 min at room temperature. 
Extraction was performed 3 x with ethyl acetate and the organic phases were combined, dried over 
anhydrous sodium sulfate and concentrated in vacuo. The product was purified by flash column 
chromatography (step gradient cyclohexane/EtOAc 1:2 and cyclohexane/EtOAc 1:3). 
 
(S)-1-cyclohexylethane-1,2-diol ((S)-2a, AD-mix α) 
Colorless solid (90% yield); 1H NMR δ (CDCl3, 500 MHz), 0.98-1.09 (2 H, m), 1.10-1.29 (3 H, m), 
1.36-1.44 (1 H, m), 1.60-1.70 (2 H, m), 1.70-1.80 (2 H, m), 1.87 (1 H, d, J = 12.51 Hz), 2.71 (2 H, br s), 
3.40-3.46 (1 H, m), 3.49-3.55 (1 H, m), 3.69 (1 H, dd, J1 = 11.05 Hz, J2 = 2.83 Hz); 13C NMR δ (CDCl3, 
500 MHz), 25.99, 26.07, 26.38, 28.66, 28.95, 40.70, 64.80, 76.52. MS (GC, EI): m/z (%) = 
127 (0.05, M+ – H2O), 113 (34), 95 (100), 67 (21), 55 (19), 41 (17) 
 
(R)-1-cyclohexylethane-1,2-diol ((R)-2a, AD-mix β) 
Colorless solid (86% yield); 1H NMR δ (CDCl3, 500 MHz), 0.98-1.09 (2 H, m), 1.10-1.30 (3 H, m), 
1.35-1.45 (1 H, m), 1.60-1.70 (2 H, m), 1.70-1.80 (2 H, m), 1.87 (1 H, d, J = 12.53 Hz), 2.61 (2 H, br s), 
3.40-3.47 (1 H, m), 3.48-3.55 (1 H, m), 3.70 (1 H, d, J = 10.64 Hz); 13C NMR δ (CDCl3, 500 MHz), 
25.99, 26.07, 26.37, 28.66, 28.95, 40.70, 64.80, 76.51. MS (GC, EI): m/z (%) = 127 (0.06, M+ – H2O), 
113 (33), 95 (100), 67 (24), 55 (20), 41 (20) 
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Synthesis of (R)-(+)-2-cyclohexenol ((R)-(+)-3a) 
 
 
 
Synthesis of (R)-(+)-2-cyclohexenol was performed according to Wynberg et al.160 yielding an 
enantiomeric excess of 13% as determined by chiral GC-FID analysis. To 0.56 g (15 mmol) LiAlH4 in 
100 mL dry diethyl ether, 4.75 g (15 mmol) quinine was added and the suspension was refluxed for 
15 min. After cooling to 0°C, 1.28 g (13 mmol) cyclohexenone dissolved in 3.3 mL diethyl ether were 
added and the mixture was stirred for 1 h at 0°C. After addition of 2 mL water and 10% H2SO4, the 
reaction was extracted 3 x with 50 mL ethyl acetate and the combined organic phases were dried over 
anhydrous sodium sulfate and concentrated in vacuo. The product was purified by flash column 
chromatography (cyclohexane/EtOAc 3:1). 
 
Colorless oil (2% yield); 1H NMR δ (CDCl3, 500 MHz), 1.51-1.66 (3 H, m), 1.68-1.79 (1 H, m), 
1.83-1.91 (1 H, m), 1.92-2.01 (2 H, m), 4.20 (1 H, s), 5.73-5.78 (1 H, m), 5.81-5.86 (1 H, m); 
13C NMR δ (CDCl3, 500 MHz), 18.93, 25.06, 32.01, 65.51, 129.85, 130.60. MS (GC, EI): m/z (%) = 
99 (2, M+), 98 (28, M), 97 (28), 83 (50), 79 (28), 77 (16), 70 (100), 69 (46), 55 (46), 43 (24) 
 
 
Synthesis of (1R,2S)-cis-1,2-indandiol (4b) 
 
 
 
1.4 g AD-mix β was dissolved in a mix of tert-butanol and water (1:1, 5 mL each) at room temperature 
and 95 mg methanesulfonamide was added to accelerate the reaction. After cooling the solution to 
4°C, 1 mmol indene was added and the reaction mixture stirred over night. 0.5 g Sodium metabisulfite 
and 20 mL water were added. After warming to room temperature, the reaction mixture was stirred for 
30 min and extracted three times with ethyl acetate. The organic phases were combined, dried over 
anhydrous sodium sulfate and concentrated in vacuo. The product was purified by flash column 
chromatography (cyclohexane/EtOAc 1:1). 
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White solid (69% yield); 1H NMR δ (CDCl3, 500 MHz), 2.90 (1 H, dd, J1 = 16.31 Hz, J2 = 3.49 Hz), 
2.94-3.01 (1 H, m), 3.06 (1 H, dd, J1 = 16.31 Hz, J2 = 5.66 Hz), 3.09-3.15 (1 H, m), 4.34-4.44 (1 H, m), 
4.87-4.95 (1H, m), 7.19-7.28 (3H, m), 7.37-7.41 (1H, m); 13C NMR δ (CDCl3, 500 MHz), 38.51, 73.43, 
75.95, 125.05, 125.33, 127.14, 128.77, 140.15, 141.94. MS (GC, EI): m/z (%) = 151 (3, M+), 
150 (29, M), 119 (13), 107 (64), 104 (100), 103 (44), 91 (34), 79 (26), 77 (41), 65 (15), 63 (9), 51 (18) 
 
 
Synthesis of (E)-2-methyl-6-methyleneocta-2,7-dien-1-ol ((E)-5a) 
 
 
 
Synthesis of (E)-2-methyl-6-methyleneocta-2,7-dien-1-ol was performed according to Granger et al..161 
To a solution of 7 g (0.05 mol) myrcene in 50 mL pure EtOH, 3 g (0.025 mol) SeO2 were added and 
the reaction mixture was refluxed for 1 h. After 3 x extraction with 50 mL diethyl ether, organic phases 
were combined, dried over anhydrous sodium sulfate and concentrated in vacuo. The product was 
purified by flash column chromatography (cyclohexane/EtOAc 5:1). 
 
Yellow oil (14% yield); 1H NMR δ (CDCl3, 500 MHz), 1.67 (3 H, s), 2.26 (4 H, br s), 4.00 (2 H, s), 
5.01 (2 H, d, J = 14.10 Hz), 5.07 (1 H, d, J = 10.59 Hz), 5.24 (1 H, d, J = 17.61 Hz), 5.41-5.47 (1 H, m), 
6.38 (1 H, dd, J1 = 17.58 Hz, J2 = 10.86 Hz); 13C NMR δ (CDCl3, 500 MHz), 13.70, 26.20, 31.02, 68.86, 
113.18, 115.88, 125.66, 135.15, 138.87, 145.81. MS (GC, EI): m/z (%) = 152 (0.16, M), 134 (20), 
121 (12), 119 (29), 105 (16), 93 (94), 91 (40), 80 (10), 79 (48), 77 (24), 67 (25), 55 (18), 43 (100) 
 
 
Synthesis of 2-methyl-6-methyleneoct-7-ene-2,3-diol (5c) 
 
 
 
1.4 g AD-mix α or β was dissolved in a mix of tert-butanol and water (1:1, 5 mL each) at room 
temperature and 95 mg methanesulfonamide was added to accelerate the reaction. After cooling the 
solution to 4°C, 1 mmol myrcene was added and the reaction mixture stirred over night. 0.5 g Sodium 
metabisulfite and 20 mL water were added. After warming to room temperature, the reaction mixture 
was stirred for 30 min and extracted three times with ethyl acetate. The organic phases were 
combined, dried over anhydrous sodium sulfate and concentrated in vacuo. The product was purified 
by flash column chromatography (step gradient cyclohexane/EtOAc 1:1 and cyclohexane/EtOAc 1:2). 
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(R)-2-methyl-6-methyleneoct-7-ene-2,3-diol ((R)-5c, AD-mix β) 
Colorless oil (36% yield); 1H NMR δ (CDCl3, 500 MHz), 1.16 (3 H, s), 1.21 (3 H, s), 1.46-1.55 (1 H, m), 
1.63-1.72 (1 H, m), 2.12 (1 H, br s), 2.23-2.32 (1 H, m), 2.40 (1 H, br s), 2.50-2.59 (1 H, m), 3.40 (1 H, 
dd, J1 = 10.58 Hz, J2 = 1.59 Hz), 5.02-5.06 (2 H, m), 5.08 (1 H, d, J = 10.87 Hz), 5.27 (1 H, d, 
J = 17.66 Hz), 6.38 (1 H, dd, J1 = 17.63 Hz, J2 = 10.81 Hz); 13C NMR δ (CDCl3, 500 MHz), 23.20, 
26.51, 28.49, 30.15, 73.14, 78.21, 113.58, 116.04, 138.66, 146.10. MS (GC, EI): m/z (%) = 
152 (2, M – H2O), 137 (2), 125 (1), 119 (1), 109 (3), 102 (1), 94 (8), 81 (10), 79 (14), 71 (25), 68 (27), 
67 (17), 59 (100) 
 
 
Synthesis of 1,2- and 3,10-dihydro myrcene (5d and 5b) 
 
 
 
Synthesis of 1,2- and 3,10-dihydro myrcene was performed according to Fauchet et al..162 After stirring 
a solution of 2.61 g (16.5 mmol) potassium permanganate and 5.32 g (16.5 mmol) 
benzyltributylammonium chloride in 500 mL dichloromethane for 3 h, the solution was cooled to -5°C 
and 5 g (36 mmol) of myrcene were added under stirring for 1 h. The reaction mixture was treated with 
sodium hydroxide (NaOH; 5 g in 80 mL H2O), NaHSO3 (5 g in 80 mL H2O) and H2SO4 (10 g in 
100 ml H2O) and extracted with 3 x 100 mL diethyl ether. After washing with H2O, the combined 
organic phases were dried over anhydrous sodium sulfate and concentrated in vacuo. The product 
was purified by flash column chromatography (gradient cyclohexene/EtOAc 2:1, cyclohexene/EtOAc 
1:1, cyclohexene/EtOAc 1:2). 
 
1,2-dihydro myrcene (5d) 
Slightly yellow oil (4% yield); 1H NMR δ (CDCl3, 500 MHz), 1.61 (3 H, s), 1.69 (3 H, s), 1.95-2.20 (4 H, 
m), 2.93 (2 H, br s), 3.53 (1 H, dd, J1 = 11.34 Hz, J2 = 7.54 Hz), 3.69 (1 H, dd, J1 = 11.32 Hz, 
J2 = 3.23 Hz), 4.19 (1 H, br dd, J1 = 7.27 Hz, J2 = 2.96 Hz), 4.98 (1 H, s), 5.11 (1H, br t), 5.14 (1H, s); 
13C NMR δ (CDCl3, 500 MHz), 17.74, 25.67, 26.55, 32.56, 65.64, 75.13, 110.82, 123.66, 132.16, 
148.21. MS (GC, EI): m/z (%) = 171 (0.1, M+), 170 (0.6, M), 152 (2), 139 (8), 119 (10), 109 (20), 
101 (18), 95 (12), 85 (11), 81 (11), 69 (100), 67 (17), 55 (17) 
 
3,10-dihydro myrcene (5b) 
Slightly yellow oil (5% yield); 1H NMR δ (CDCl3, 500 MHz), 1.47-1.54 (1 H, m), 1.60 (3 H, s), 
1.61-1.66 (1 H, m), 1.68 (3 H, s), 1.95-2.04 (1 H, m), 2.04-2.13 (1 H, m), 2.57 (2 H, br s), 3.46-3.52 
(2 H, m), 5.11 (1 H, br t), 5.26 (1 H, dd, J1 = 10.81 Hz, J2 = 1.22 Hz), 5.35 (1 H, dd, J1 = 17.55 Hz, 
J2 = 1.27 Hz), 5.81 (1 H, dd, J1 = 10.82 Hz, J2 = 17.21 Hz); 13C NMR δ (CDCl3, 500 MHz), 17.72, 22.00, 
25.69, 36.76, 68.84, 76.30, 115.28, 124.15, 132.23, 140.64. MS (GC, EI): m/z (%) = 170 (0.1, M), 
152 (3), 139 (12), 121 (30), 119 (9), 109 (4), 93 (18), 83 (22), 79 (14), 69 (100), 55 (46)  
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Synthesis of (1S,2S,3R,5S)-(+)-pinanediol (6a) with OsO4 
 
 
 
Synthesis of (1S,2S,3R,5S)-(+)-pinanediol with OsO4 was performed according to Erdik et al..163 To a 
solution of 4.9 g (0.041 mol) NMO and 15.5 g (0.11 mol) hexamethylenetetramine in 85 mL 
tert-butanol and 15 mL H2O, 5.6 g (0.04 mol) (+)-α-pinene and 0.14 g (0.55 mmol) OsO4 were added 
under nitrogen atmosphere. The reaction mixture was heated to 70°C for 10 h and after cooling, 100 
mL of a 10% aqueous sodium bisulfite solution was added. The reaction mixture was stirred until the 
dark brown color of the aqueous phase changed to yellow and the aqueous phase was extracted 3 x 
with 100 mL diethyl ether. The organic phases were combined, dried over anhydrous sodium sulfate 
and concentrated in vacuo. The product was purified by flash column chromatography 
(cyclohexane/EtOAc 1:2). 
 
Colorless oil that started to solidify after some time (92% yield); 1H NMR δ (CDCl3, 500 MHz), 
0.93 (3 H, s), 1.27 (3 H, s), 1.31 (3 H, s), 1.37 (1 H, d, J = 10.39 Hz), 1.61-1.67 (1 H, m), 1.89-1.94 
(1 H, m), 2.01 (1 H, t, J = 5.8 Hz), 2.17-2.23 (1 H, m), 2.41-2.49 (1 H, m), 2.80 (1 H, br s), 3.12 (1 H, d, 
J = 6.58 Hz), 3.99 (1 H, ddd, J1 = 9.36 Hz, J2 = 6.58 Hz, J3 = 5.23 Hz); 13C NMR δ (CDCl3, 500 MHz), 
24.13, 27.82, 28.04, 29.59, 38.11, 38.94, 40.50, 53.95, 69.16, 73.81. MS (GC, EI): m/z (%) = 137 (2), 
126 (16), 111 (27), 99 (46), 93 (16), 83 (17), 81 (20), 71 (36), 55 (35), 43 (100) 
 
 
Synthesis of (+)-mentha-1.8-dien-10-ol (7a) 
 
 
 
 
Synthesis of (+)-mentha-1.8-dien-10-ol was performed according to Thomas and Bucher.164 11 g of 
(R)-limonene were warmed to 50°C and a hot solution of SeO2 (4.4 g dissolved in 7 mL of EtOH) were 
added dropwise within 30 min. The reaction mixture was stirred for 2 h at 95-96°C and after cooling, 
the precipitated selenium was removed by filtration, washed with diethyl ether and EtOH. The 
combined organic phases were dried over anhydrous sodium sulfate and concentrated in vacuo. The 
product was purified by flash column chromatography (1. column: DCM/cyclohexene/EtOAc 20:4:0.5, 
2. column: cyclohexene/EtOAc 10:1). 
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Yellow oil (2% yield); 1H NMR δ (CDCl3, 500 MHz), 1.43-1.56 (2 H, m), 1.65 (3 H, s), 1.78-2.23 
(6 H, m), 4.14 (2 H, d, J = 5.95 Hz), 4.91 (1 H, s), 5.04-5.07 (1 H, m), 5.40 (1 H, br s); 13C NMR δ 
(CDCl3, 500 MHz), 23.45, 28.18, 30.53, 31.34, 36.89, 65.19, 107.83, 120.43, 133.83, 153.65. 
MS (GC, EI): m/z (%) = 153 (1, M+), 152 (14, M), 134 (56), 119 (93), 106 (99), 105 (42), 93 (71), 
91 (89), 79 (93), 67 (100), 55 (56) 
 
 
Synthesis of (1R,5R)-carveol (7b) 
 
 
 
Synthesis of (1R,5R)-carveol starting from (R)-(-)-carvone was performed according to Dhulut et al..165 
2 g (13.3 mmol) (R)-(-)-carvone in 10 mL diethyl ether were slowly added to 6.7 mL (6.7 mmol) of a 
1 M solution of LiAlH4 at -78°C. After 30 min, 450 µl (25 mmol) H2O, 450 µl (25 mmol) NaOH and 
additional 450 µl (25 mmol) H2O were successively added and the reaction mixture was stirred until a 
white precipitate appeared. The reaction mixture was dried over anhydrous sodium sulfate and 
concentrated in vacuo. The product was purified by flash column chromatography 
(cyclohexene/EtOAc 8:2). 
 
Colorless oil (39% yield); 1H NMR δ (CDCl3, 500 MHz), 1.51 (2 H, td, J1 = 12.10 Hz, J2 = 9.52), 
1.74 (3 H, br s), 1.76 (3 H, br s), 1.90-2.33 (4 H, m), 4.19 (1 H, br s), 4.73 (2 H, s), 5.50 (1 H, br s); 
13C NMR δ (CDCl3, 500 MHz), 18.99, 20.66, 31.02, 37.99, 40.42, 70.91, 109.16, 123.90, 136.13, 
149.00. MS (GC, EI): m/z (%) = 153 (0.2, M+), 152 (1, M), 134 (54), 119 (32), 109 (62), 91 (39), 
84 (100), 69 (51), 55 (70)  
 
 
Synthesis of (1S,5S)-carveol (7b) 
 
 
 
Synthesis of (1S,5S)-carveol starting from (S)-(+)-carvone was performed according to 
Bermejo et al..166 2 g (13.3 mmol) (S)-(+)-carvone in 10 mL diethyl ether were slowly added to 6.7 mL 
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(6.7 mmol) of a 1 M solution of LiAlH4 at -78°C. After 1.5 h, 450 µl (25 mmol) H2O, 450 µl (25 mmol) 
NaOH and additional 450 µl (25 mmol) H2O were successively added and the reaction mixture was 
stirred until a white precipitate appeared. The reaction mixture was dried over anhydrous sodium 
sulfate and concentrated in vacuo. The product was purified by flash column chromatography 
(cyclohexene/EtOAc 8:2). 
 
Colorless oil (40% yield); 1H NMR δ (CDCl3, 500 MHz), 1.51 (1 H, td, J1 = 12.22, J2 = 9.53), 1.60 (1 H, 
br s), 1.74 (3 H, s), 1.76 (3 H, br s), 1.90-2.32 (4 H, m), 4.19 (1 H, br s), 4.73 (2 H, s), 5.50 (1 H, br s); 
13C NMR δ (CDCl3, 500 MHz), 19.00, 20.66, 31.03, 37.99, 40.44, 70.91, 109.16, 123.88, 136.15, 
149.00. MS (GC, EI): m/z (%) = 153 (0.1, M+), 152 (1, M), 134 (39), 119 (29), 109 (54), 91 (48), 
84 (82), 69 (47), 55 (73)  
 
 
2.3.11. Identification of biotransformation products by NMR and GC-MS analysis 
Preparative large scale biotransformations for product isolation were performed only with the RO 
enzyme showing the best conversion rates. In case the amount of formed product was too low to be 
isolated, product identification was performed using an authentic standard in combination with GC-MS 
analysis.  
 
Biotransformation of styrene (1) to 1-phenyl-1,2-ethanediol (1a) and 
3-vinylcyclohexa-3,5-diene-1,2-diol (1b) 
 
 
 
1-phenyl-1,2-ethanediol (1a) 
RO-catalyzed biotransformations 
MS (GC, EI) m/z (%) = 139 (0.9, M+), 138 (10, M), 107 (100), 79 (66), 77 (40), 51 (10) 
Standard Fluka  
MS (GC, EI) m/z (%) = 139 (0.9, M+), 138 (10, M), 107 (100), 79 (82), 77 (51), 51 (12) 
 
3-vinylcyclohexa-3,5-diene-1,2-diol (1b) 
MS (GC, EI) m/z (%) = 139 (1, M+), 138 (11, M), 120 (44), 109 (13), 92 (40), 91 (100), 81 (23), 79 (27), 
77 (27), 65 (22), 53 (18) 
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Biotransformation of vinylcyclohexane (2) to 1-cyclohexylethane-1,2-diol (2a) with 
CDO M232A 
 
 
 
The product was purified by flash column chromatography (cyclohexane/EtOAc 1:3). 
 
1H NMR δ (CDCl3, 500 MHz), 0.97-1.08 (2 H, m), 1.09-1.29 (3 H, m), 1.34-1.44 (1 H, m), 1.65 (2 H, t, 
J = 13.16 Hz), 1.69-1.79 (2 H, m), 1.87 (1 H, d, J = 12.62 Hz), 3.38-3.44 (1 H, m), 3.47-3.52 (1 H, m), 
3.54 (1 H, br s), 3.67 (1 H, dd, J1 = 11.20 Hz, J2 = 2.50 Hz); 13C NMR δ (CDCl3, 500 MHz), 26.03, 
26.11, 26.40, 28.70, 29.01, 40.71, 64.75, 76.53. MS (GC, EI): m/z (%) = 127 (0.05, M+ – H2O), 
113 (34), 95 (100), 67 (21), 55 (19), 41 (17) 
 
 
Biotransformation of cyclohexene (3) to 2-cyclohexenol (3a) and 
cis-1,2-cyclohexanediol (3b)  
 
 
 
 
2-cyclohexenol (3a)  
RO-catalyzed biotransformations 
MS (GC, EI) m/z (%) = 99 (2, M+), 98 (31, M), 97 (34), 83 (51), 79 (20), 70 (100), 69 (32), 55 (38), 
41 (36) 
Standard Fluka  
MS (GC, EI) m/z (%) = 99 (2, M+), 98 (30, M), 97 (34), 83 (52), 79 (31), 70 (100), 69 (31), 55 (37), 
41 (33) 
 
cis-1,2-cyclohexanediol (3b)  
RO-catalyzed biotransformations 
MS (GC, EI) m/z (%) = 116 (8, M), 98 (34), 83 (33), 70 (100), 69 (22), 57 (61), 42 (31), 41 (37) 
Standard Sigma-Aldrich  
MS (GC, EI) m/z (%) = 117 (0.6, M+), 116 (8, M), 98 (35), 83 (34), 70 (100), 69 (21), 57 (61), 42 (31), 
41 (36) 
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Biotransformation of indene (4) to 1-indenol (4a) and cis-1,2-indandiol (4b) with CDO 
 
 
 
The product was purified by flash column chromatography (step gradient cyclohexane/DCM/EtOAc 
4:4:0.5 and cyclohexane/EtOAc 1:2). 
 
1-indenol (4a) 
Slightly yellow oil; 1H NMR δ (CDCl3, 500 MHz), 1.71 (1 H, br s), 5.17 (1 H, s), 6.40 (1 H, dd, 
J1 = 5.96 Hz, J2 = 1.88 Hz), 6.73 (1 H, d, J = 5.63 Hz), 7.18-7.29 (3 H, m), 7.51 (1 H, d, J = 7.15 Hz); 
13C NMR δ (CDCl3, 500 MHz), 77.59, 121.42, 123.42, 126.13, 128.51, 132.72, 137.70, 142.32, 145.45. 
MS (GC, EI): m/z (%) = 133 (9, M+), 132 (100, M), 131 (87), 115 (15), 103 (42), 89 (5), 77 (28), 63 (8), 
51 (18) 
 
cis-1,2-indandiol (4b) 
White solid; 1H NMR δ (CDCl3, 500 MHz), 2.86 (1 H, dd, J1 = 16.31 Hz, J2 = 3.45 Hz), 3.01 (1 H, dd, 
J1 = 16.31 Hz, J2 = 5.74 Hz), 3.30 (1 H, br s), 3.45 (1 H, br s), 4.27-4.37 (1 H, m), 4.80-4.89 (1 H, m), 
7.17-7.27 (3 H, m), 7.34-7.38 (1 H, m); 13C NMR δ (CDCl3, 500 MHz), 38.40, 73.41, 75.93, 125.05, 
125.28, 127.08, 128.71, 140.16, 141.94. MS (GC, EI): m/z (%) = 151 (3, M+), 150 (28, M), 119 (14), 
107 (62), 104 (100), 103 (44), 91 (35), 79 (27), 77 (42), 65 (16), 63 (9), 51 (19) 
 
 
Biotransformation of myrcene (5) to (Z)-2-methyl-6-methyleneocta-2,7-dien-1-ol 
((Z)-5a), 3,10-dihydro myrcene (5b), 2-methyl-6-methyleneoct-7-ene-2,3-diol (5c) and 
1,2-dihydro myrcene (5d) with CDO M232A 
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The products were purified by flash column chromatography (step gradient cyclohexane/DCM/EtOAc 
4:4:0.5 and cyclohexane/EtOAc 1:1). 
 
(Z)-2-methyl-6-methyleneocta-2,7-dien-1-ol ((Z)-5a) 
Yellow oil; 1H NMR δ (CDCl3, 500 MHz), 1.73 (3 H, s), 2.18 (4 H, d, J = 3.38 Hz), 4.03 (2 H, s), 
4.89-4.98 (2 H, m), 5.00 (1 H, d, J = 10.68 Hz), 5.17 (1 H, d, J = 17.57 Hz), 5.22-5.30 (1 H, m), 
6.30 (1 H, dd, J1 = 17.67 Hz, J2 = 10.86 Hz); 13C NMR δ (CDCl3, 500 MHz), 20.25, 25.16, 30.58, 60.51, 
112.37, 115.11, 126.84, 133.87, 137.65, 144.63. MS (GC, EI): m/z (%) = 152 (0.17, M), 134 (18), 
121 (10), 119 (34), 105 (18), 93 (89), 91 (45), 84 (21), 79 (51), 77 (25), 67 (28), 55 (22), 43 (100) 
 
3,10-dihydro myrcene (5b) 
MS (GC, EI): m/z (%) = 152 (3, M – H2O), 139 (12), 121 (32), 119 (10), 109 (4), 93 (19), 83 (24), 
79 (16), 69 (100), 55 (47) 
 
2-methyl-6-methyleneoct-7-ene-2,3-diol (5c) 
Colorless oil; 1H NMR δ (CDCl3, 500 MHz), 1.16 (3 H, s), 1.21 (3 H, s), 1.47-1.56 (1 H, m), 
1.64-1.72 (1 H, m), 1.93 (1 H, br s), 2.23 (1 H, br s), 2.25-2.33 (1 H, m), 2.50-2.58 (1H, m), 3.40 (1 H, 
dd, J1 = 10.54 Hz, J2 = 1.58 Hz), 5.02-5.06 (2 H, m), 5.09 (1 H, d, J = 10.77 Hz), 5.27 (1 H, d, 
J = 17.47 Hz), 6.38 (1 H, dd, J1 = 17.66 Hz, J2 = 10.83 Hz); 13C NMR δ (CDCl3, 500 MHz), 23.21, 
26.53, 28.49, 30.16, 73.12, 78.23, 113.59, 116.06, 138.65, 146.11. MS (GC, EI): 
m/z (%) = 152 (2, M – H2O), 137 (2), 125 (1), 119 (1), 109 (3), 102 (1), 94 (9), 81 (11), 79 (15), 71 (25), 
68 (27), 67 (17), 59 (100) 
 
1,2-dihydro myrcene (5d) 
MS (GC, EI): m/z (%) = 152 (4, M – H2O), 139 (7), 119 (12), 109 (19), 101 (16), 95 (12), 85 (12), 
81 (14), 69 (100), 67 (19), 55 (23)  
 
 
Dehydration of 2-methyl-6-methyleneoct-7-ene-2,3-diol (5c) to 2-methyl-6-methylene-
octa-1,7-dien-3-ol 
 
During RO-catalyzed biotransformations of myrcene (5), the alcohol 2-methyl-6-methylene-octa-1,7-
dien-3-ol was detected that most likely results from the dehydration of the diol product 2-methyl-6-
methyleneoct-7-ene-2,3-diol (5c). 
 
 
 
The product was purified by flash column chromatography (step gradient cyclohexane/DCM/EtOAc 
4:4:0.5 and cyclohexane/EtOAc 1:1). 
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Slightly yellow oil; 1H NMR δ (CDCl3, 500 MHz), 1.62 (1 H, br s), 1.74 (3 H, s), 1.69-1.81 (2 H, m), 
2.19-2.27 (1 H, m), 2.28-2.38 (1 H, m), 4.11 (1 H, t, J = 6.43 Hz), 4.85-4.87 (1 H, m), 4.97 (1 H, s), 
5.03 (2 H, br s), 5.06 (1 H, d, J = 10.91 Hz), 5.25 (1 H, d, J = 17.72 Hz), 6.38 (1 H, dd, J1 = 10,63 Hz, 
J2 = 17.63 Hz); 13C NMR δ (CDCl3, 500 MHz), 17.65, 27.32, 33.37, 75.62, 111.14, 113.40, 115.87, 
138.76, 146.02, 147.44. MS (GC, EI): m/z (%) = 152 (0.39, M), 137 (13), 134 (8), 123 (20), 119 (23), 
109 (24), 105 (23), 96 (19), 93 (27), 91 (30), 84 (37), 81 (23), 79 (49), 71 (58), 69 (72), 67 (77), 
55 (32), 53 (35), 43 (93), 41 (100) 
 
During the CDO M232A-catalyzed biotransformation of 5, a potential byproduct (*) might be formed in 
addition to the above described products which could not be identified due to low amounts formed 
(estimated < 5%). 
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Figure 7: GC-FID chromatogram of the CDO M232A-catalyzed biotransformation of myrcene 5 after 
derivatization. (*): potential byproduct. 
 
 
Biotransformation of (+)-α-pinene (6) to pinanediol (6a) with CDO M232A 
 
 
 
The product was purified by flash column chromatography (step gradient cyclohexane/EtOAc 1:1 and 
cyclohexane/EtOAc 1:2). 
 
1H NMR δ (CDCl3, 500 MHz), 0.94 (3 H, s), 1.27 (3 H, s), 1.31 (3 H, s), 1.37 (1 H, d, J = 10.39 Hz), 
1.61-1.67 (1 H, m), 1.89-1.94 (1 H, m), 2.01 (1 H, t, J = 5.8 Hz), 2.17-2.23 (1 H, m), 2.42-2.49 (1 H, m), 
2.77 (1 H, br s), 3.09 (1 H, br s), 3.99 (1 H, dd, J1 = 9.36 Hz, J2 = 5.20 Hz); 13C NMR δ (CDCl3, 
500 MHz), 24.13, 27.82, 28.03, 29.56, 38.10, 38.95, 40.50, 53.96, 69.19, 73.86. MS (GC, EI): 
m/z (%) = 137 (2), 126 (15), 111 (26), 99 (42), 93 (16), 83 (17), 81 (20), 71 (34), 55 (35), 43 (100) 
* 
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During the CDO M232A-catalyzed biotransformation of 6, a potential byproduct (*) might be formed in 
addition to the above described product which could not be identified due to low amounts formed 
(estimated < 5%). 
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Figure 8: GC-FID chromatogram of the CDO M232A-catalyzed biotransformation of (+)-α-pinene 6. (*): potential 
byproduct. 
 
 
Biotransformation of (R)-limonene ((R)-7) to (+)-mentha-1.8-dien-10-ol (7a) and 
carveol (7b) with CDO M232A 
 
 
 
 
(+)-mentha-1.8-dien-10-ol (7a) 
MS (GC, EI): m/z (%) = 152 (9, M), 134 (49), 119 (89), 106 (91), 105 (38), 93 (66), 91 (89), 79 (87), 
67 (100), 55 (69) 
 
Carveol was purified by flash column chromatography (step gradient cyclohexane/EtOAc 8:1 and 
cyclohexane/EtOAc 6:1). 
 
 
* 
OH
OH
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carveol (7b) 
1H NMR δ (CDCl3, 500 MHz), 1.61 (2 H, dt, J1 = 13.30, J2 = 3.99), 1.75 (3 H, s), 1.80 (3 H, br s), 
1.82-1.90 (1 H, m), 1.91-1.97 (1 H, m), 2.10-2.19 (1 H, m), 2.28-2.37 (1 H, m), 4.03 (1 H, s), 
4.74 (2 H, d, J = 10.18 Hz), 5.59 (1 H, br s); 13C NMR δ (CDCl3, 500 MHz), 20.86, 20.93, 30.99, 35.23, 
36.73, 68.57, 109.04, 125.40, 134.30, 149.19. MS (GC, EI): m/z (%) = 153 (1, M+), 152 (9, M), 
137 (10), 119 (13), 109 (100), 91 (19), 84 (53), 69 (23), 55 (28)  
 
During the CDO M232A-catalyzed biotransformation of (R)-7, potential byproducts (*) might be formed 
in addition to the above described products which could not be identified due to low amounts formed 
(estimated < 5%). 
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Figure 9: GC-FID chromatogram of the CDO M232A-catalyzed biotransformation of (R)-limonene (R)-7 after 
derivatization. (*): potential byproduct. 
 
 
Biotransformation of (S)-limonene ((S)-7) to carveol (7b), isopiperitenol (7c) and 
1-methyl-4-(prop-1-en-2-yl) cyclohex-2-enol (7d) with CDO I288V 
 
 
 
Isopiperitenol was purified by flash column chromatography (step gradient cyclohexane/EtOAc 10:1 
and cyclohexane/EtOAc 8:1). 
* * 
O
O
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isopiperitenol (7c) 
Colorless oil; 1H NMR δ (CDCl3, 500 MHz), 1.55-1.65 (1 H, m), 1.70 (3 H, s), 1.70-1.73 (1 H, m), 
1.73 (3 H, s), 1.82 (1 H, s), 1.89-1.97 (1 H, m), 2.03-2.12 (2 H, m),4.08-4.16 (1 H, m), 4.87 (2 H, d, 
J = 19.36 Hz), 5.45 (1 H, s); 13C NMR δ (CDCl3, 500 MHz), 19.36, 23.07, 26.21, 30.23, 50.95, 68.71, 
112.36, 124.34, 136.75, 146.47. MS (GC, EI): m/z (%) = 152 (2, M), 134 (2), 119 (3), 109 (8), 108 (9), 
91 (6), 84 (100), 83 (46), 81 (10), 77 (6), 69 (14), 56 (20), 53 (8), 43 (5) 
 
1-methyl-4-(prop-1-en-2-yl) cyclohex-2-enol (7d) 
Standard (Sigma-Aldrich) 
MS (GC, EI): m/z (%) = 137 (51), 134 (93), 119 (50), 109 (100), 95 (35), 93 (30), 91 (56), 81 (33), 
79 (74), 77 (35), 69 (24), 67 (35), 55 (23), 43 (81), 41 (37) 
CDO I288V-catalyzed biotransformation 
MS (GC, EI): m/z (%) = 152 (3, M), 137 (56), 134 (94), 119 (44), 109 (100), 95 (36), 93 (29), 91 (44), 
81 (34), 79 (76), 77 (33), 69 (26), 67 (36), 55 (24), 43 (89), 41 (38) 
 
 
2.3.12. Docking 
Docking of styrene 1 and indene 4 into the active sites of CDO wild type and variants was performed 
using AMBER force field-03167 in implementation of AutoDock Vina in Yasara.168 
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3. RESULTS 
3.1. Oxyfunctionalization of alkenes by wild type ROs 
ROs are naturally involved in the degradation of aromatic compounds and a vast array of arenes is 
known to be accepted by these enzymes.65 Despite their broad substrate specificity, the conversion 
of unnatural substrates has only started to receive a growing interest within recent years and limited 
data is available concerning the RO-catalyzed oxidation of olefins when compared to arene 
dihydroxylation. To explore the potential of ROs for the oxyfunctionalization of alkenes, NDO from 
Pseudomonas sp. NCIB 9816-4, BDO from P. putida ML2 and CDO from Pseudomonas 
fluorescens IP01 were examined for their ability to oxidize aliphatic C=C double bonds. The three 
enzymes were selected as they are amongst the ROs that have already been reported to catalyze 
the oxyfunctionalization of several olefins.73,74,92,146,169 Furthermore, the crystal structures of NDO 
(PDB code: 1O7N)101 and CDO (PDB code: 1WQL)170 have been solved, providing information of 
the enzymes’ active sites.101,170 For BDO, no structural data were available, yet, due to its high 
sequence identity of 93% with the α-subunit of TDO from P. putida F1,153 a homology model could 
be generated based on the TDO crystal structure (PDB code: 3EN1).171 
As ROs are cofactor-dependent multicomponent enzymes,76 in vivo biotransformations were 
performed using 0.2 g mL-1 (cww) resting E. coli cells supplemented with glucose for in situ cofactor 
regeneration. In the whole cell system, oxygenase subunits as well as electron transport 
components (reductase and ferredoxin) were simultaneously expressed in one cell, also addressing 
the challenge of low stability reported for purified oxygenase enzymes.172,173 As negative control, 
E. coli harboring the empty vector was employed to exclude product formation catalyzed by 
endogenous enzymes. 
 
3.1.1. Cloning and expression of RO genes 
Plasmids encoding NDO, BDO and CDO genes for the simultaneous expression of all RO 
components in E. coli were obtained from Rebecca Parales, David Leak and Hideaki Nojiri. For 
NDO and BDO, expression was performed as reported in literature145,153 and the presence of 
functional enzymes was confirmed with the natural substrate naphthalene (NDO) as well as with 
ethylbenzene (BDO).153,173 Since two different protocols for the heterologous expression of NDO 
have been described, both literature conditions were tested which differ in the medium, expression 
temperature and time as well as in induction.145,174 Applying the protocol described by Parales and 
coworkers, cells were grown in minimal medium and after 2 h of IPTG-induced protein expression at 
30°C, full conversion with naphthalene as substrate could be achieved in whole cell 
biotransformations.145 In contrast, activities were significantly lower applying the conditions reported 
by Seo et al. with cell growth over night at 37°C to induce protein expression by autoinduction in LB 
medium.174 Due to higher product formations, expression of NDO was hence performed as 
described by the group of Parales. 
For CDO, the plasmid pIP107D containing all RO components according to literature147 lacked 
about 400 bp at the C-terminal end of the reductase cumA4. Thus, the reductase gene was restored 
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using plasmid pIP103 as template for PCR which harbored the corresponding cis-dihydrodiol 
dehydrogenase and the extradiol dioxygenase next to the RO genes.147 By PCR, an EcoRI 
restriction site was appended after the stop codon of cumA4 and the PCR product was used for the 
assembly of plasmid pIP107D by restriction digest (SalI, EcoRI) and ligation. Reconstruction of the 
reductase as well as functional expression of all RO components was confirmed in 
biotransformations with the natural substrate cumene. In contrast to NDO and BDO, the expression 
protocol for CDO was slightly varied from literature conditions.73 Instead of 37°C, the expression 
temperature was lowered to 30°C while higher IPTG concentrations of 200 µM instead of 10 µM 
were used for induction. With the adapted conditions, a stronger blue color formation was observed 
with indole as substrate. 
 
3.1.2. Pre-screening of different olefins 
In order to elucidate the substrate spectrum of RO enzymes, an initial screening of various olefins 
was performed to define a panel of different compounds for the further characterization of NDO, 
BDO and CDO. For alkene selection, special attention was paid to include a variety of structurally 
diverse compounds as well as different alkene types (mono-, gem-di-, cis-di- and tri-substituted 
olefins). The panel of olefins that was examined during the pre-screening process comprised arene-
substituted alkenes like styrene 1 and its derivatives 3-chlorostyrene 13 and α-methylstyrene 14 as 
well as various terpenes including the monoterpenes myrcene 5, (+)-α-pinene 6, (R)- and 
(S)-limonene 7 and the sesquiterpene (+)-valencene 8. In addition, indene 4 and other chromane 
substrates like 1,2-dihydronaphthalene 9, 2,3-benzofuran 10, 1-benzothiophene 11 and indole 12 
were examined as well as the linear and cyclic alkenes vinylcyclohexane 2 and cyclohexene 3, both 
possessing an unconjugated C=C double bond (Scheme 16). 
Of the 14 olefins that were assayed, most compounds were accepted as substrates by BDO, CDO 
or NDO. The only exceptions comprised terpenes 6 and 8 which possess a sterically demanding 
structure when compared to the planar nature of the natural aromatic compounds and no 
conversion was detected with the examined ROs (Table 11). Next to 6 and 8, the three enzymes 
showed differences in their substrate scope for the remaining olefins. In contrast to NDO or CDO, 
BDO possessed only minor activities < 10% for alkenes 2, 5 and 7 while no conversion could be 
detected for compound 13 (Table 11), reducing its substrate scope compared to the other enzymes. 
Yet, also CDO showed low activities with < 10% conversion for alkene 13. 
According to detected masses in GC-MS analysis, monohydroxylated products were obtained next 
to the corresponding diols for alkenes 3, 4, 5, 7 and 14 depending on the RO enzyme. Furthermore, 
for olefin 9, desaturation of the substrate as already described for NDO was also observed with 
BDO and CDO.175 Even though containing different positions for RO-catalyzed oxidations, 
compounds 1, 2 and 7 were converted with good regioselectivities in biotransformations with NDO 
or CDO. For the other alkenes of the panel, multiple products were obtained with the main product 
constituting ≤ 90% of the mixture. As the three ROs differed in their regioselectivities, substrates 1, 
10, 11, 13 and 14 yielded diverse products but even when the same products were formed, ratios 
with NDO, BDO and CDO always varied.  
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Scheme 16: Substrate panel of alkenes examined in initial in vivo biotransformations with BDO, CDO and 
NDO.  
Table 11: Activity of NDO, BDO and CDO towards selected olefins (10 mM) in whole cell biotransformations. 
Olefin 1 2 3 4 5 6 (R)-7[a] 8   9 10 11 12 13  14 
NDO +++ + + +++ + - n.d. - +++ ++ ++ ++ +++ +++ 
BDO +++ (+) ++ +++ (+) - (+) - + + + ++ - ++ 
CDO +++ ++ + +++ ++ - ++ - + +++ +++ + (+) +++ 
+++: Conversion of 70- > 99%, ++: Conversion of 40-70%, +: Conversion of 10-40%, (+): < 10% conversion, 
-: no conversion detected, n.d.: not determined. Conversion was estimated from the GC areas of substrate and 
product. As no derivatization of biotransformation products prior to GC-analysis was performed in the pre-
screening, very low product formations might have been missed due to the higher detection limit of 
underivatized compounds. [a] Conversion was only determined for (R)-7 as the (S)-enantiomer was not 
commercially available in optically pure form containing also (R)-7 (68% ee). With both enantiomers, a 
monohydroxylated product was obtained according to GC-MS analysis and product formation with (S)-7 as 
substrate was observed with CDO. Reactions in the pre-screening were performed as duplicates. 
In order to determine product formations as well as stereo- and regioselectivities of BDO, CDO and 
NDO for different olefins, the original substrate panel of 14 alkenes was reduced in size. With 
regard to the results from the pre-screening, alkenes 1-7 were selected for further investigation. 
Herein, compounds 1, 2 and 7 were chosen due to the good regioselectivities obtained for CDO or 
NDO. While 1 and 2 allowed evaluating the dihydroxylation of conjugated versus unconjugated 
linear alkenes, biotransformations with terpene 7 solely yielded the alcohol product instead of the 
diol. Furthermore, the cyclic alkene 3 was included in the panel since it represents the smallest 
olefin in size of the selected compounds. Of the chromane substrates, alkene 4 was selected for 
further examination as conversions > 70% were obtained for all enzymes, not having been 
described in literature for CDO and BDO. In addition, the alkene-1,2-diol represents a potential 
precursor for Indinavir which is applied as HIV inhibitor.9 With polyene 5, a tri-substituted C=C 
double bond was included while combining three different alkene types in one molecule. Also 
terpene 6 contained a tri-substituted alkene bond but was not accepted by the wild type enzymes. 
Yet, with regard to the second part of this work, the optimization of wild type ROs for olefin 
oxyfunctionalization, biotransformation of 6 was further examined, too.  
Even though limited to seven compounds, this panel of structurally diverse olefins included arene-
substituted, cyclic and linear alkenes comprising mono- (1, 2, 5), gem-di- (5, 7), cis-di- (3, 4) and tri-
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substituted C=C double bonds (5, 6, 7), enabling the evaluation of the RO-catalyzed AD of different 
alkene types against heavy metal catalysts like OsO4. Furthermore, several of the substrates 
allowed oxidation at different positions as they possess either an aromatic ring besides the alkene 
moiety (1 and 4) or include several aliphatic C=C double bonds (5 and 7), hence representing 
interesting substrates to compare ROs for differences in regioselectivity. 
 
3.1.3. Characterization of ROs towards a panel of selected alkene substrates 
Conversions of alkenes 1-7 selected in the pre-screening process were characterized in in vivo 
biotransformations with 10 mM substrate and 0.2 g mL-1 cells expressing BDO, CDO or NDO. For 
identification of biotransformation products, the reaction set-up was either up-scaled in order to 
isolate the compounds of interest and to determine their structure by NMR analysis or products 
were identified by comparison with an authentic standard (Scheme 17). For product identification 
and quantification as well as determination of stereoselectivities, (R)- and (S)-2a, (R)-(+)-3a, 
(1R,2S)-4b, (E)-5a, rac-5b, (R)- and (S)-5c, rac-5d, (1S,2S,3R,5S)-(+)-6a, 7a as well as (1S,5S)- 
and (1R,5R)-7b were synthesized as described in the experimental section.  
 
 
Scheme 17: Selected substrate panel of alkenes for the characterization of in vivo biotransformations with 
BDO, CDO and NDO as well as detected biotransformation products. 
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Table 12: Product formations and distributions for CDO, NDO and BDO with alkenes 1-7 (10 mM). 
 
Olefin Product formation [%][a] Product distribution [%][b] 
 CDO NDO BDO CDO NDO BDO 
1 71 ± 6 > 99 90 ± 7 0.3:99.7 (1a:1b) > 99 (1a) 59:41 (1a:1b) 
2 44 ± 6 20 ± 3 < 1 >95 (2a) > 95 (2a) n.d. 
3[b] 36 ± 4 27 ± 5 59 ± 6 80:20 (3a:3b) 51:49 (3a:3b) 76:24 (3a:3b) 
4[c] 80 ± 7 87 ± 10 > 99 64:36 (4a:4b) 38:62 (4a:4b) 10:90 (4a:4b) 
5 29 ± 6 34 ± 11 5 ± 0.1 
48:18:18:17 
(5a:5b:5c:5d) 
12:41:3:44 
(5a:5b:5c:5d) 
56:14:14:15 
(5a:5b:5c:5d) 
6 - - - - - - 
(R)-7[d] 46 ± 10 n.d. < 1 >95 (7b:7a) n.d. n.d. 
[a] Product formations were determined by GC-FID analysis after 24 h using standard curves of the 
respective products. Standard deviations also include variations in the expression level as triplicates from 
at least two different expression batches were used for the determination of product formations. [b] Product 
distributions were determined by GC-FID. Cyclohexanone formation resulting from isomerization of 3a was 
added to the total amount of 3a. [c] Traces of 1-indanol (1-2%) were detected resulting from the RO-
catalyzed oxidation of indane trace amounts present in 4. [d] Since (S)-7 was only available as mixture of 
both substrate enantiomers (68% ee), product formations were solely determined with (R)-7 being 
commercially available in enantiopure form. -: not detected. n.d.: not determined. 
Table 13: Stereoselectivities for CDO, NDO and BDO. 
Product Stereoselectivity ee or de [%][a] 
CDO NDO BDO 
1a 43 ± 3 (R-1a) 80 ± 1 (R-1a) 8 ± 2 (R-1a) 
2a 91 ± 3 (R-2a) > 98 (R-2a) n.d. 
3a 74 ± 0.5 (R-3a) 65 ± 2 (R-3a) 90 ± 1 (R-3a) 
4a 
4b 
        10 ± 1 (R-4a) 
            38 ± 1 (1S,2R-4b) 
71 ± 4 (S-4a) 
76 ± 1 (1R,2S-4b) 
45 ± 1 (S-4a) 
42 ± 1 (1R,2S-4b) 
5b 
5c 
5d 
78 (n.d., 5b) 
> 95 (R-5c) 
47 (n.d., 5d) 
> 95 (n.d., 5b) 
n.d. 
> 95 (n.d., 5d) 
n.d. 
- 
n.d. 
6a - - - 
(R)-7 > 98 (1R,5S-7b) n.d. n.d. 
(S)-7 95 (1R,5R-7b) n.d. n.d. 
[a] Enantiomeric and diastereomeric excess values were determined by GC-FID or 
HPLC analysis using a chiral stationary phase. For chiral GC and HPLC 
chromatograms see supplementary. To determine standard deviations, triplicates 
from at least two different expression batches were used. -: not detected. n.d.: not 
determined. 
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Of the seven selected model substrates, compound 1 was accepted by each of the three enzymes. 
Depending if oxidation took place at the aromatic ring or the terminal vinyl group of the olefin, the 
AD of 1 yielded either alkene-1,2-diol 1a or arene-1,2-dihydrodiol 1b (Scheme 17). Selective 
dihydroxylation of 1 by NDO exclusively at the terminal vinyl group has been already reported in 
literature.169 In contrast, during CDO- and BDO-catalyzed biotransformations, 1b was formed 
besides 1a. While CDO showed an excellent regioselectivity for the aromatic moiety of the substrate 
(0.3:99.7 1a:1b), a mix of 1a and 1b (59:41) was observed for biotransformations with BDO. All 
enzymes had a preference for the (R)-enantiomer of 1a with NDO giving the best stereoselectivity 
(80% ee). Yielding ee values of only 8% and 43% for (R)-1a, stereoselectivities obtained with BDO 
and CDO were low (Table 13). 
Even though it has been reported in literature that non-conjugated linear alkenes are generally 
found to be poor substrates for cis-dihydroxylation by ROs,75 CDO catalyzed the oxidation of 2 with 
44% product formation and good stereoselectivity (ee = 91% for diol (R)-2a). Compared to CDO, 
biotransformations with NDO gave even better ee values of > 98% for (R)-2a, albeit conversions 
were low (20%, Table 12). For the cyclic alkene 3, the second non-conjugated olefin in this study, 
all examined ROs catalyzed the allylic hydroxylation of the substrate yielding 3a besides diol 3b 
(Scheme 17). Thereby, enzymes displayed varying product distributions with NDO forming the 
highest ratio of diol 3b (49%) whereas alcohol 3a was the main product with CDO and BDO 
(80% and 76%, respectively, Table 12). 
The arene-substituted olefin 4 was converted by NDO, CDO and BDO yielding diol 4b and the 
monohydroxylated product 4a (Scheme 17). No oxyfunctionalization of the aromatic ring was found 
to take place with CDO and BDO as observed for compound 1. Furthermore, BDO, NDO and CDO 
showed only low to moderate stereoselectivities for the conversion of 4. Interestingly, CDO favored 
opposite enantiomers for both 4a and 4b compared to BDO and NDO albeit the obtained 
stereoselectivities were low. CDO-catalyzed biotransformation of 4 gave (R)-4a with an ee value of 
10% whereas BDO and NDO yielded (S)-4a with significantly higher stereoselectivities (45% and 
71% ee, respectively). Also for product 4b, NDO showed the best stereoselectivity with 76% ee for 
the (1R,2S)-enantiomer. Like for alcohol 4a, CDO gave the opposite enantiomer of 4b compared to 
BDO and NDO. With 42% and 38% ee, the stereoselectivities for the diol were however low for 
BDO and CDO. Yet, moderate stereoselectivities are also obtained for the OsO4-catalyzed AD of 4 
as cis-di-substituted alkenes represent challenging substrates for this reaction.176,177 Furthermore, 
the product ratios of 4a and 4b differed between the three enzymes. Forming 90% of diol 4b, BDO 
showed the best regioselectivity. Likewise, NDO-catalyzed biotransformation of 4 gave 62% 4b 
whereas with CDO, alcohol 4a was the main product formed (64%, Table 12). 
Even though applied as flavors and fragrances,178 the oxyfunctionalization of terpenes by RO 
enzymes has rarely been described. Hence, compounds 5, 6 and 7 were tested as substrates for 
the RO-catalyzed oxidation. Biotransformations of the linear polyalkene 5 with NDO, BDO and CDO 
gave a mixture of 5a, 5b, 5c and 5d. In contrast to the SeO2-mediated allylic oxidation of 5 yielding 
the (E)-isomer of 5a,161 (Z)-5a was exclusively formed during biotransformations. For CDO and 
BDO, alcohol (Z)-5a was the main product (48% and 56%, respectively) of the oxidation of 5. With 
NDO, diols 5b and 5c were obtained in a ratio of 41:44 while the reaction proceeded with excellent 
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stereoselectivities > 95% for both products. With CDO, high stereoselectivities > 95% were obtained 
for diol 5c, however, ee values for 5b and 5d were only moderate (78% and 47% ee, respectively). 
Nevertheless, having the ability to target the electron-deficient C=C double bonds of 5 is of special 
interest as in Sharpless AD, osmylation of unsymmetrical polyenes preferentially occurs at the most 
electron-rich double bond7,11 and during OsO4-catalyzed oxidation of 5, diol 5c was formed 
selectively. As diols 5b and 5d had hence to be synthesized with KMnO2 giving a racemic mixture 
of both compounds,162 the absolute configurations in RO-catalyzed biotransformations could not be 
assigned. Yet, both CDO and NDO showed the same stereopreference. Due to the low product 
formations with BDO (5%), stereoselectivities for diols 5b, 5c, and 5d could not be determined. 
For CDO-catalyzed biotransformations of limonene 7, allylic hydroxylation yielded alcohol 7b as 
main product. Depending if the (R)- or the (S)-enantiomer was employed as a substrate, 
(1R,5S)-(+)- or (1R,5R)-(-)-7b was formed with an ee value of > 98% and 95%, respectively. With 
BDO, conversions were < 1% and hence, products were not further characterized (Table 12).  
As already mentioned in the pre-screening, terpene 6 with its sterically demanding structure and 
tri-substituted alkene bond could not be converted by BDO, NDO or CDO. Accordingly, compound 6 
also proved to be a challenging substrate for Sharpless AD under standard conditions requiring 
elevated temperatures ≥ 70°C.163  
 
3.2. Rational design – Optimization of ROs for selective olefin oxyfunctionalization 
From the selected substrate panel, CDO, NDO and BDO converted six of the seven alkenes. Yet, 
unlike described for their natural substrates, enzymes displayed only low conversions (< 50%) and 
modest stereoselectivities (≤ 80% ee) for several of the tested olefins. In particular, the sterically 
demanding terpene 6 proved to be a challenging substrate for the RO-catalyzed 
oxyfunctionalization and no conversion could be detected for NDO, BDO or CDO. High 
stereoselectivities ≥ 90% were only obtained for diols 2a (NDO and CDO), 5c (CDO), 5b and 5d 
(NDO), alcohol 7b (CDO) as well as for the BDO-catalyzed formation of alcohol 3a (Table 12 and 
Table 13). The results are in accordance with literature where it has been shown that the application 
of ROs in organic synthesis is partly restricted by their poor stereoselectivity and activity, especially 
for linear alkenes.74,75 To overcome these limitations, changes in the active site topology of RO 
catalysts were introduced to generate variants with improved characteristics for the selective 
oxyfunctionalization of olefins in order to optimize these enzymes for the conversion of unnatural 
substrates. 
 
3.2.1. Selection of amino acid residues by phylogenetic comparison 
Since the focus of this project has been placed on the selective oxyfunctionalization of aliphatic 
C=C double bonds, the identification of amino acid residues influencing selectivity and activity of 
ROs was one of its key issues. Although closely related (46-78% similarity of the α-subunits 
containing the active site)c, NDO, BDO and CDO displayed a strong bias with respect to substrate 
                                                     
c The sequence similarity was determined by performing pairwise sequence alignments with the European 
Molecular Biology Open Software Suite (EMBOSS) applying the Needleman-Wunsch algorithm.221 
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specificity as well as selectivity. Caused by variations in the active site topology of the three 
enzymes that influence enzyme characteristics, selectivities and activities for the different alkene 
types were strongly dependent on the RO employed.  
In order to identify amino acid residues that are essential for RO selectivity, a structural as well as 
sequence alignment of the active sites of CDO, BDO and NDO was performed (Figure 10 and 
Figure S30). Examining all amino acid residues within 8 Å of the catalytic iron center, only those 
side chains were considered for mutagenesis that differed between ROs in structurally equivalent 
positions. Using this strategy, conserved amino acids which are essential for activity like the 
2-His-1-carboxylate facial triad coordinating the catalytic iron were excluded. Furthermore, amino 
acid side chains pointing away from the active site were not taken into account as these residues 
might most likely not contribute to the orientation of the substrate in the binding pocket.  
 
Table 14: Amino acid residues within 8 Å of the catalytic iron center of NDO, CDO, BDO and TDO.  
Position[a] NDO CDO BDO TDO Position[a] NDO CDO BDO TDO 
201 N Q Q Q 307 L L L L 
202 F F F F 352 F F F F 
205 D D D D 358 W Y F F 
206 A M M M 359 E E E E 
208* H H H H 361 D D D D 
209 V A A A 362* D D D D 
212 T A A S 365 N N N N 
213* H H H H 366 M W W W 
[a] Numbering refers to NDO from Pseudomonas sp. NCIB 9816-4. * Amino acids constituting the 
2-His-1-carboxylate facial triad. Amino acid residues differing between the enzymes are marked in bold. 
Of the 16 amino acids located within 8 Å of the mononuclear iron center, positions 201, 206, 209, 
212, 358 and 366 (numbering refers to NDO) varied between the enzymes (Table 14). Amongst 
these 6 residues, the methionine side chain at position 220 and 232, respectively, in BDO and CDO 
was located closest to the substrate (Figure 10, residues correspond to position 206 in NDO). With 
regard to the reported interactions of methionine with aromatic systems,179,180 residues 232 and 220 
might be involved in the positioning of aryl-substituted substrates like 1 and 4 in the active sites of 
both ROs, representing two of the most striking examples for differing selectivities between the 
three enzymes. Interestingly, the methionine residue pointing into the active site was not only 
present in CDO and BDO, but also at the corresponding position of TDO from P. putida F1 (M220, 
Table 14).181 As these enzymes all catalyzed the dihydroxylation of compound 1 at the aromatic 
ring, this was a further indication for the side chain of methionine playing an important role in the 
orientation of 1 in the substrate binding pocket. 
Mutations at the corresponding position 206 in NDO have been already reported to show an 
significant effect on product formations as well as selectivities for several aromatic compounds.125 
Furthermore, variation of M220 in TDO resulted in an expanded substrate spectrum towards 
1,2,4,5-tetrachlorobenzene,182 suggesting an influence of this position on RO specificity. In contrast, 
only slight alterations in product formation were observed for variations of N201, W358 or M366 in 
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NDO145 while no mutational studies of the remaining variable residues have been published for the 
selected RO enzymes. Considering these data, methionine residues 220 and 232, respectively, in 
BDO and CDO were selected amongst the variable positions and exchanged by the corresponding 
alanine found in NDO. Of the three ROs, NDO not only catalyzed dihydroxylation of 1 exclusively at 
the terminal vinyl group but also gave the best stereoselectivities for most of the tested substrates 
(Table 13). 
 
 
Figure 10: Structural alignment of amino acid residues in a distance of 8 Å around the catalytic active iron 
(orange sphere) from CDO (PDB code: 1WQL, green lines),170 NDO (PDB code: 1O7N, grey lines)101 and BDO 
(blue lines). The alignment was performed using the PyMOL molecular graphics system, version 1.2r1 
Schrödinger, LLC. For BDO, a homology model was created based on the TDO crystal structure (PDB code: 
3EN1)171 using SWISS-MODEL.183 Residues M232 (CDO, green), A206 (NDO, grey) and M220 (BDO, blue) 
chosen for mutagenesis are shown as sticks. The bound substrate (indole) is shown as red sticks. Positions 
refer to numbering in NDO from Pseudomonas sp. NCIB 9816-4. 
3.2.2. Rational design - Characterization of generated RO variants 
After altering their active site topology by site-directed mutagenesis, CDO M232A and BDO M220A 
were characterized with the selected alkene panel. For conversion of 1, both RO variants showed 
indeed a dramatic shift in regioselectivity towards the terminal vinyl group and product formation of 
alkene-1,2-diol 1a was increased to 92% compared to 0.3% and 59% for CDO and BDO wild type 
enzymes (Figure 11A). This change in regioselectivity was accompanied by a significant increase in 
stereospecificity (Figure 11B). For CDO M232A, the ee for (R)-1a improved from 43% to 95% which 
is even better than ee values obtained with NDO (80% ee) and represents one of the highest 
stereoselectivities reported so far for the dihydroxylation of a linear aliphatic substrate by ROs. 
Moreover, the single amino acid substitution of methionine to alanine also enhanced the 
stereoselectivity of BDO M220A for 1a by about 8-fold to 67%. Yet, these changes in the catalytic 
site topology did not cause a dramatic change in activity. For BDO M220A, product formation 
decreased only slightly from 90% for the wild type enzyme to 81% whereas for CDO M232A an 
increase to 97% product formation was observed (Table 16).  
A206 
L307 
F202 
T212 
H213 
N365 
E359 
S360 
H208 
D362 
F352 
W358 
N363 
M366 
V209 
N361 
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Figure 11: (A) Ratios of products 1a (black) and 1b (grey) for the biotransformation of styrene 1 with CDO, 
CDO M232A, BDO, BDO M220A and NDO. (B) ee Values for alkene-1,2-diol 1a with CDO, CDO M232A, 
BDO, BDO M220A and NDO. 
 
 
Figure 12: Docking of styrene 1 (green spheres) in the active site of CDO wild type (left) and CDO M232A 
(right). Methionine at position 232 in the wild type and alanine inserted by site-directed mutagenesis in the 
CDO variant are shown as yellow dots. Surrounding amino acids that constitute the substrate binding pocket 
are shown in grey (surface and sticks). In the crystal structure (PDB code: 1WQL),170 O2 (red spheres) is 
bound to the catalytic non-heme iron (orange spheres, only partly visible, located behind the red spheres). The 
C=C double bond of the substrate is circled in red. The homology model of the CDO variant M232A was 
created with SWISS-MODEL183 based on the CDO crystal structure (PDB code: 1WQL).170 
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Regarding these differences in selectivities of wild type enzymes and variants, docking of 1 into the 
active site of CDO and CDO M232A was performed. Depending on the shape of the chiral binding 
pocket, either the aromatic ring (CDO wild type) or the vinyl group (CDO M232A) of 1 is oriented 
close to the catalytic iron center (Figure 12), supporting the hypothesis of different substrate 
positions in the active sites of wild type and mutant enzymes. 
With respect to the dramatic changes in regio- and stereoselectivity that can be introduced by the 
single point mutation in CDO and BDO, the effect of methionine at the corresponding position A206 
in NDO was investigated for conversion of 1. However, the diminishment of the active site volume 
by the introduction of the bulky methionine side chain caused a significant decrease in activity to 
only 20% product formation (Table 15). In contrast to CDO and BDO, the amino acid exchange did 
not induce an alteration in regioselectivity. Yet, a slight increase in ee for alkene-1,2-diol 1a was 
observed for NDO A206M, suggesting that also in NDO, this position has an influence on selectivity 
for olefin conversion (Table 15). As the introduction of methionine into the substrate binding pocket 
caused a substantial loss of activity, mutant NDO A206I was generated to investigate the effect, a 
residue smaller than methionine but larger than alanine might have on oxidation of 1. Furthermore, 
this variant has already been described in literature to influence enzyme selectivity during arene 
oxidation.125 Whereas the decrease in activity for NDO A206I (80% product formation) was less 
severe than with NDO A206M, this mutation neither showed a significant impact on stereoselectivity 
nor on regioselectivity for substrate 1 (Table 15). 
 
Table 15: Product formations as well as regio- and stereoselectivities for the conversion of 1 (10 mM) with 
NDO wt and NDO variants A206M and A206I. 
RO Product formation [%][a] Regioselectivity [%] Stereoselectivity ee [%][b] 
NDO wt > 99 > 99 (1a) 80 ± 1 (R-1a) 
NDO A206M 20 ± 1 > 99 (1a) 85 ± 1 (R-1a) 
NDO A206I 80 ± 11 > 99 (1a) 81 ± 3 (R-1a) 
[a] Product formations were determined by GC-FID analysis after 24 h using standard curves of the 
respective products. Standard deviations for NDO variants were determined with triplicates of one 
expression batch. [b] Enantiomeric excess values were determined by GC-FID or HPLC analysis using a 
chiral stationary phase. 
Besides alkene 1, substrates 2-7 were re-examined with CDO M232A and BDO M220A variants. 
Compared to the wild type enzymes, mutants displayed not only altered selectivities but also 
changes in product formations for several of the investigated compounds. Especially the use of 
CDO M232A resulted in enhanced stereoselectivities for compounds displaying higher ee values 
with NDO than CDO wild type. For the unconjugated linear olefin 2, CDO M232A showed an 
enhanced conversion and stereoselectivity compared to the wild type enzyme. In biotransformations 
with CDO M232A, the conversion could be increased about 2-fold, resulting in 93% overall product 
formation (Table 16). Of the two possible enantiomers, (R)-2a was formed with an excellent 
stereoselectivity of > 98% ee instead of 91% ee for the wild type enzyme. In contrast, for BDO 
M220A, exchange of methionine by alanine did not have a significant effect on product formation 
and conversion of 2 was still below < 1% as already observed for BDO wild type.  
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Unlike for 1 and 2, the ee values for the oxidation of the second non-conjugated alkene 3 decreased 
in biotransformations with both variants. BDO M220A showed a slight decrease in stereoselectivity 
from 90% to 86% ee whereas for CDO M232A, the ee value dropped from 74% to 28%. Despite this 
drastic change in stereoselectivity, product formation of CDO M232A was not affected (Table 12 
and Table 16). Yet, for BDO M220A, conversion decreased from 59% to 5%. 
 
Table 16: Product formation, distribution and stereoselectivities for CDO M232A and BDO M220A with 
substrates 1-(R)-7 (10 mM). Values determined for the wild type enzymes are shown in Table 12 and Table 13. 
Olefin 
Product formation [%][a] Product distribution [%] Stereoselectivity ee or de [%][b] 
CDO 
M232A 
BDO 
M220A 
CDO 
M232A 
BDO 
M220A 
CDO 
M232A 
BDO 
M220A 
1 97 ± 10 81 ± 10 92:8 (1a:1b) 92:8 (1a:1b) 95 ± 1 (R-1a) 67 ± 2 (R-1a) 
2 93 ± 5 < 1 > 95 (2a) n.d. > 98 (R-2a) n.d. 
3[c] 36 ± 4 5 ± 1 82:18 (3a:3b) 68:32 (3a:3b) 28 ± 1 (R-3a) 86 ± 1 (R-3a) 
4[d] 80 ± 11 82 ± 13 56:44 (4a:4b) 22:78 (4a:4b) 
87 ± 1 (S-4a) 
54 ± 4  
(1R,2S-4b) 
82 ± 1 (S-4a) 
33 ± 1  
(1R,2S-4b) 
5 > 99 37 ± 4 71:3:21:4 
(5a:5b:5c:5d) 
31:39:15:15 
(5a:5b:5c:5d) 
> 95 (n.d. 5b) 
> 95 (R-5c) 
n.d. 
n.d. 
6 33 ± 7 - > 95% (6a) - > 95 
(1S,2S,3R,5S-6a) 
- 
(R)-7 > 99 < 1 95:5 (7b:7a) n.d. > 98 (1R,5S-7b) n.d. 
[a] Product formations were determined by GC-FID analysis after 24 h using standard curves of the respective 
products. Standard deviations also include variations in the expression level as triplicates from at least two 
different expression batches were used for the determination of product formations. [b] Enantiomeric and 
diastereomeric excess values were determined by GC-FID or HPLC analysis using a chiral stationary phase. 
For 6a, diastereomeric excess values were in addition verified by 1H NMR spectroscopy as only one of the two 
possible diastereomers was available as standard. For chiral GC or HPLC chromatograms and NMR spectra 
see supplementary. [c] Cyclohexanone formation resulting from isomerization of 3a was added to the total 
amount of 3a. [d] Traces of 1-indanol (1-2%) were detected resulting from the RO-catalyzed oxidation of indane 
trace amounts present in 4. -: not detected. n.d.: not determined.  
With the arene-substituted alkene 4, the most pronounced change in stereoselectivity could be 
observed for CDO M232A. The single point mutation in the active site of CDO enhanced not only 
the ee value by about 9-fold but also led to a change in the absolute configuration of the product 4a, 
yielding the (S)-enantiomer with 87% ee. Likewise, for diol 4b, the increase in ee from 38% to 54% 
was accompanied by a switch from (1S,2R)-4b to (1R,2S)-4b, turning CDO and CDO M232A into 
enantiocomplementary enzymes for the conversion of 4. An altered stereoselectivity was also 
observed for BDO variant M220A. Yet, whereas the ee for (S)-4a was improved from 45% to 82%, 
the stereoselectivity for the diol 4b decreased to 33% (Table 13 and Table 16).  
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With CDO M232A and BDO M220A, enhanced substrate oxidation up to 7-fold was achieved for the 
linear polyalkene 5. In CDO M232A-catalyzed biotransformations, the stereoselectivity for product 
5b was increased to > 95% while maintaining the excellent stereoselectivity for diol 5c already 
observed for the wild type enzyme (Table 13 and Table 16). Additionally, both variants exhibited 
altered product ratios of (Z)-5a, 5b, 5c and 5d with CDO M232A forming alcohol (Z)-5a as main 
product with 71% (Table 16) . 
Like the wild type enzyme, CDO M232A-catalyzed oxidation of (R)-7 gave alcohol 7b with good 
regioselectivity, yet, conversion could be improved 2-fold from 46% to > 99%. Furthermore, for 
oxidation of (S)-7, the de slightly increased from 95% to > 98%. In contrast, for BDO M220A, the 
alteration of its active site topology did not influence conversion and product formation of 7b was 
still < 1%. 
For terpene 6, the only compound of the panel not converted by the wild type enzymes, the 
increase in the size of the binding pocket of CDO M232A resulted in an extended substrate scope. 
Biotransformations with this variant yielded 33% product formation of diol 6a with an excellent 
stereoselectivity of > 95% de for the (1S,2S,3R,5S)-(+)-diastereomer. However, besides position 
232 (CDO) or 220 (BDO), the surrounding amino acids in the enzymes also seemed to control 
substrate specificity as with BDO M220A, still no conversion of 6 could be detected. Docking 
analysis suggested that oxyfunctionalization of the terpene in BDO M220A was sterically hindered 
as 6 could apparently not enter the active site and residues lining the entrance tunnel or the 
substrate binding pocket might prevent productive binding and therewith catalysis. 
 
3.3. Site-saturation mutagenesis of CDO - Creation of a focused mutant library  
In addition to rational design, site-saturation mutagenesis was applied for CDO to create a focused 
mutant library which was screened for variants displaying improved selectivities or activities for 
alkene oxyfunctionalization. In contrast to site-directed enzyme design, the effect of diverse amino 
acid residues at a distinct position could be examined using site-saturation mutagenesis. Having 
been identified as active site hotspot, methionine at position 232 in CDO was selected to be 
replaced with a balanced mix of 12 structurally different amino acid side chains. Furthermore, four 
additional positions (F278, I288, I336 and F378) located in the substrate binding pocket of CDO 
were assayed for their influence on selectivity and activity, mainly using small amino acid residues 
for mutagenesis to increase the active site volume. 
 
3.3.1. Exploring the influence of various amino acid residues at position 232 
Considering the strong impact of mutation M232A in CDO on selectivity, the effect of additional 
amino acid residues at position 232 was examined by site-saturation mutagenesis using the NDT 
codon degeneracy. NDT encodes for a mix of 12 polar, non-polar, charged, uncharged, aliphatic 
and aromatic amino acids (F, L, I, V, Y, H, N, D, C, S, R and G) which excludes structurally similar 
residues and thus reduces the screening effort compared to the NNK codon degeneracy.140 11 of 
these CDO variants (CDO M232F, L, I, V, Y, H, N, D, C, S and G) were tested for conversion of the 
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arene-substituted alkenes 1 and 4 as changes in regio- and stereoselectivity of CDO M232A were 
most pronounced with these substrates. 
Of the generated mutants, only CDO variants M232Y, D and N lost complete activity towards 
compounds 1 and 4. The other variants of the NDT library proved to be robust for the introduced 
mutations and formation of products 1a and 1b as well as 4a and 4b was detected even though with 
diminished activities compared to CDO wild type and CDO M232A (Table 17). For alkene 1, higher 
product formations were achieved with all variants compared to the conversion of compound 4. With 
substrate 4, best activities were obtained for variants possessing sterically less demanding amino 
acid side chains (CDO M232C, S and G) but even with the most active mutants, product formations 
were still < 20% (Table 17). 
Despite this decrease in conversions, the variants of the NDT mutant library displayed interesting 
changes in selectivities which seemed to be correlated with the steric demand of the amino acid 
residue. For compound 1, the amino acid side chain size at position 232 was shown to directly 
influence both regio- and stereoselectivity. In general, smaller amino acid residues favored the 
formation of alkene-1,2-diol 1a accompanied by enhanced stereoselectivities (Figure 13). As an 
exception, the ratio of 1a increased to 96% for CDO variant M232S, giving a higher regioselectivity 
than CDO M232A (92%) and CDO M232G (95%, Figure S31). Yet, in accordance with the general 
trend, both CDO M232A and CDO M232G showed better stereoselectivities for the alkene-1,2-diol 
(95% and 94% ee for (R)-1a) when compared to CDO M232S (88% ee for (R)-1a, Table 18).  
 
 
 
 
 
 
 
Figure 13: Product distribution (bars) for the RO-catalyzed conversion of styrene 1 yielding alkene-1,2-diol 1a 
(black) and arene-1,2-dihydrodiol 1b (grey) as well as stereoselectivities for 1a (squares). 
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For alkene 4, CDO M232H showed a 3-fold enhancement in ee to 28% (R)-4a whereas a switch in 
stereoselectivity from (R)-4a to (S)-4a was observed for the allylic alcohol with the other CDO 
variants compared to the wild type (Table 18). As demonstrated for 1a, the stereoselectivity for 
(S)-4a generally increased with smaller amino acid residues (Figure 15A). For the diol formation, 
large side chains (F, L, I) gave (1S,2R)-4b with up to 57% ee for CDO M232L while variants 
CDO M232V, C, S, and G yielded the opposite enantiomer (1R,2S)-4b (Figure 15B). Amongst the 
mutants that favored the (1R,2S)-enantiomer of 4b, CDO M232A stilled showed the best 
stereoselectivity with 54% ee, followed by CDO M232S and CDO M232G having slightly lower ee 
values (47% and 46% ee, respectively, Table 18).  
Docking analysis of compound 4 in the active sites of CDO M232L, CDO M232S and CDO M232G, 
the mutants resulting in the highest stereoselectivities for (1S,2R)- or (1R,2S)-4b of the examined 
NDT library variants, indicated different substrate binding modes. While in CDO M232S and 
CDO M232G, the positioning of the substrate to the catalytic iron center was identical, 4 was bound 
in a different orientation in CDO M232L, enabling the attack of dioxygen from the opposite face of 
the substrate (Figure 14). These diverse binding modes caused by the single amino acid exchange 
presumably turned CDO M232L and CDO M232G/ CDO M232S into enantiocomplementary 
biocatalysts, yielding opposite absolute configurations for diol 4b.  
 
               
Figure 14: Docking of indene 4 (green spheres with the C=C double bond shown in dark green) in the active 
site of CDO M232L (left) as well as of CDO M232S and CDO M232G (right, both structures are aligned). 
Amino acid residues at position 232 in the CDO variants are shown in red (CDO M232L and CDO M232S) or 
orange (CDO M232G). Amino acids that constitute the 2-His-1-carboxylate facial triad are shown as grey lines 
and the catalytic iron as orange spheres. Homology models of the three CDO variants were created with 
SWISS-MODEL183 based on the CDO crystal structure (PDB code: 1WQL).170 Structures of CDO M232S and 
CDO M232G with 4 docked into the active site were aligned in the PyMOL molecular graphics system, version 
1.2r1 Schrödinger, LLC and show the same substrate orientation while in CDO M232L, 4 is positioned with its 
opposite face to the catalytic iron. 
In contrast to the stereoselectivities, the effect on mono- versus dihydroxylation for substrate 4 
observed within the NDT mutant library seemed, however, not to be clearly correlated with the 
amino acid side chain size at position 232 (Table 17). Highest ratios of the diol 4b were obtained 
with variants CDO M232H (78%), M232F (72%) and M232G (65%) while mutant CDO M232C gave 
best ratios for the allylic alcohol 4a (52%). 
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Figure 15: (A) ee Values for the formation of 4a with CDO, CDO M232A and variants of the CDO NDT mutant 
library. (B) ee Values for the formation of 4b with CDO, CDO M232A and variants of the CDO NDT mutant 
library. 
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Table 17: Product formations and distributions for CDO variants of the NDT mutant library. 
 
CDO variant 
Product formation [%][a] Product distribution [%][b] 
1[c]  4[c] 1 4 
M232H 32 ± 1 
 
3 ± 0.2 14:86 (1a:1b) 22:78 (4a:4b) 
M232L 29 ± 5 7 ± 2 31:69 (1a:1b) 42:58 (4a:4b) 
M232F 34 ± 3 5 ± 0.4 28:72 (1a:1b) 28:72 (4a:4b) 
M232I 46 ± 7 9 ± 1 36:64 (1a:1b) 50:50 (4a:4b) 
M232V 36 ± 2 4 ± 0.4 54:46 (1a:1b) 46:54 (4a:4b) 
M232C 42 ± 5 15 ± 1 79:21 (1a:1b) 52:48 (4a:4b) 
M232S 32 ± 6 19 ± 1 96:4 (1a:1b) 50:50 (4a:4b) 
M232G 43 ± 6 19 ± 4 95:5 (1a:1b) 35:65 (4a:4b) 
M232Y - - - - 
M232D - - - - 
M232N - - - - 
[a] Product formations were determined by GC-FID analysis after 24 h using standard curves 
of the respective products. Standard deviations also include variations in the expression level 
as duplicates from two different expression batches were used for the determination of 
product formations. [b] Product distributions were determined by GC-FID analysis. [c] Total 
product formation (1a and 1b as well as 4a and 4b). Traces of 1-indanol were detected (1-2%) 
resulting from the RO-catalyzed oxidation of 1-indane present in small amounts in 4. 
-: not detected. n.d.: not determined.  
Table 18: Stereoselectivities for CDO variants of the NDT mutant library. 
CDO variant 
Stereoselectivity ee [%][a] 
1a 4a 4b 
M232H 20 ± 1 (R-1a) 28 ± 2 (R-4a) n.d. 
M232L 47 ± 2 (R-1a) 16 ± 1 (S-4a) 57 ± 1 (1S,2R-4b) 
M232F 36 ± 2 (R-1a) 36 ± 0.3 (S-4a) 9 ± 3 (1S,2R-4b) 
M232I 61 ± 2 (R-1a) 52 ± 0.1 (S-4a) 24 ± 2 (1S,2R-4b) 
M232V 65 ± 1 (R-1a) 81 ± 1 (S-4a) 12 ± 1 (1R,2S-4b) 
M232C 84 ± 3 (R-1a) 80 ± 1 (S-4a) 12 ± 1 (1R,2S-4b) 
M232S 88 ± 3 (R-1a) 86 ± 0.1 (S-4a) 47 ± 1 (1R,2S-4b) 
M232G 94 ± 0.3 (R-1a) 82 ± 0.1 (S-4a) 46 ± 2 (1R,2S-4b) 
M232Y - - - 
M232D - - - 
M232N - - - 
[a] Enantiomeric excess values were determined by HPLC analysis using a 
chiral stationary phase. For chiral HPLC chromatograms see supplementary. 
Standard deviations were determined from triplicates. -: not detected, n.d.: not 
determined. 
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3.3.2. Site-saturation mutagenesis at additional positions in CDO 
In order to identify further residues that influence the selectivity and activity of ROs, site-saturation 
mutagenesis at four different positions (F278, I288, I336 and F378) in the substrate binding pocket 
of CDO was performed. Most of these residues were selected using HotSpot Wizard, a web server 
for the automatic identification of “hot spots” in order to engineer substrate specificity, activity or 
enantioselectivity of enzymes.184 HotSpot Wizard targets amino acids with low conservation levels 
which are located in the active site or lining the access tunnels. Selecting only functional residues in 
highly variable positions represents an effective strategy for altering catalytic properties with the 
reduced risk that the amino acid replacement will compromise the enzymatic function.184 In contrast 
to position M232 having an average conservation level, the other residues located within 8 Å of the 
catalytic iron center (Table 14) were higher conserved amongst ROsd and hence not suggested for 
mutagenesis by the web server. Yet, even though residue F378 was ranked with low mutability, it 
was nevertheless chosen for site-saturation mutagenesis as substitutions at the corresponding 
position F352 have been reported to be a major hotspot affecting selectivity in NDO.124  
In order to select further residues for mutagenesis, the radius around the non-heme iron was 
expanded to 12 Å as within this distance, amino acid residues still have an increased probability to 
result in an altered substrate specificity or stereoselectivity.123 Using HotSpot Wizard, positions 
F278, I288 and I336 were identified as residues with high (F278 and I288) and average mutability 
(I336, Figure 16). In CDO, residues F278 and I288 are part of a loop that ranges from F278 to G290 
and runs parallel to a second loop (L248 to N264), opening a channel to the active site. 
Furthermore, the two loops are also involved in formation of the catalytic pocket, thus representing 
an interesting target for mutations.170  
 
 
Figure 16: Mutability of different functional amino acid residues in CDO as determined by HotSpot Wizard184 
according to their conservation level, ranging from high (red) to low mutability (blue). Amino acids selected for 
mutagenesis as well as residue M232 are labeled. 
                                                     
d The conservation level and therewith the mutability of residues was determined by HotSpot Wizard.184 
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As several alkenes of the selected substrate panel are substituted with sterically demanding methyl 
groups and lack the planar nature of the natural aromatic substrates, a diminishment of the active 
site volume was avoided. Therefore, bulky amino acid side chains like tyrosine, tryptophan, lysine or 
glutamine were excluded from mutagenesis. To cover a broad range of structurally diverse amino 
acids that were equal in size or smaller than the corresponding residues in the wild type enzyme, 
BBT and DBC degenerated codons were chosen for library construction. DBC and BBT encode 8 
and 9 amino acids (DBC: F, C, I, T, S, V, A, G and BBT: F, S, C, L, P, R, V, A, G), respectively, 
resulting in only 25 colonies that have to be screened for a library coverage of 95%.e Herein, the 
BBT codon degeneracy was used for positions encoding isoleucine in the wild type enzyme as DBC 
also contains this amino acid residue. In total, 34 variants were generated by site-saturation 
mutagenesis within the four mutant libraries that were screened in a first step with a colorimetric 
solid phase assay for activity. 
 
 
Figure 17: Amino acid residues targeted for site-saturation mutagenesis in CDO (PDB code: 1WQL)170 using 
the BBT (F, S, C, L, P, R, V, A and G) and DBC (F, C, I, T, S, V, A and G) codon degeneracy (B = C, G or T; 
D = A, G or T). Positions F278, I288, I336 and F378 are shown as yellow sticks, position M232 is shown as red 
sticks. The catalytic non-heme iron center (orange spheres) with bound O2 (red spheres) is coordinated by the 
2-His-1-carboxylate facial triad (shown as grey lines). 
Colorimetric solid phase screening - Indigo assay 
To exclusively select RO mutants for further characterization that have maintained their activity, a 
solid phase screening with indole was performed. This assay has been applied several times in 
literature to chose only colonies that turned blue due to the expression of RO mutants still able to 
oxidize indole and thus form the blue dye indigo (Figure 18).109,124,185 Also for CDO wild type which 
was employed as control to test the functionality of the assay, blue color formation could be 
observed. 
                                                     
e The number of colonies that have to be screened for 95% coverage was calculated by CASTER.223 
M232 
F278DBC 
I336BBT 
I288BBT 
F378DBC 
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Using the solid phase assay, libraries of CDO F278DBC, I288BBT, I336BBT and F378DBC were 
screened for indole oxidation. Interestingly, variants of the focused mutant libraries based on 
positions F278, I288 and I336 showed more pronounced indigo formation than the library of 
CDO F378DBC and about 86-93% of the colonies turned blue during screening. In contrast, the 
F378DBC mutant library contained only a small fraction of colored colonies (10%, Figure 18 and 
Table 19) and the blue clones sent for sequencing all represented wild type CDO (DBC also 
encodes for phenylalanine). Based on observed indigo formation, positions 278, 288 and 336 
seemed to be rather robust for mutations as oxidation activity for indole still could be maintained. In 
contrast, position 378 had a lower tolerance for introduced mutations and variants of this library 
apparently had lost their ability to convert indole. 
Even though the colorimetric solid phase assay allowed the fast screening of a large number of 
colonies, it was not based on the substrate or product of interest and thus, false negative or positive 
results might be obtained due to the structural differences between indole and the targeted alkene 
panel. To examine the suitability of the screening assay for the selection of CDO variants, also 
white colonies were tested in in vivo biotransformations for their activity towards the selected 
alkenes. Of the examined mutants from the focused libraries F378DBC and I288BBT displaying no 
indigo formation, neither variant F378S nor mutant I288P showed any activity for olefins 1, 3, 4, 5, 6 
and 7 what corresponds to the lack of color formation observed in the indole assay. 
 
 
     
Figure 18: Solid phase colorimetric assay based on indigo formation. (A) The majority of colonies (> 80%) 
from mutant libraries based on F278DBC, I288BBT and I336BBT showed blue color formation (DBC library 
based on position F278 is shown representative for the other mutant libraries). (B) Most variants of the mutant 
library based on position F378 did not show activity towards indole. 
Table 19: Screening results from the CDO BBT and DBC mutant libraries with the colorimetric solid phase 
assay based on indigo formation. 
Library Total colonies screened Number of blue colonies [%] 
CDO F278DBC 108 100 93 
CDO I288BBT 100 88  88 
CDO I336BBT 154 132 86 
CDO F378DBC 90 9[a] 10 
[a] All sequenced blue colonies represented CDO wild type as DBC also encodes for 
phenylalanine. 
B A 
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Characterization of CDO mutants 
In order to characterize the generated mutant libraries of CDO, the effect of introduced mutations on 
product formation and selectivity for alkenes 1, 3, 4, 5, 6 and 7 was tested and the examined 
variants were compared to CDO wild type. Among the tested mutants, CDO F278A, F278C and 
I336V displayed altered selectivities and product formations for olefins 1, 3, 4 and 5 (Table 20). 
 
Table 20: Product formations as well as regio- and stereoselectivities for CDO wt and selected CDO variants. 
Olefin CDO wt CDO F278A CDO F278C CDO I336V 
 Product formation [%][a] 
1 71 ± 6 > 99 57 ± 0.3 45 ± 3 
3 36 ± 4 11 ± 0.2 28 ± 6 10 ± 2 
4[e] 80 ± 7 22 ± 4 18 ± 6 17 ± 0.3 
5 29 ± 6 < 1 14 ± 2 13 ± 1 
6 - - - - 
 Stereoselectivity ee [%][b] 
1 43 ± 3 (R-1a) 84 ± 3 (R-1a) 70 ± 4 (R-1a) n.d. 
3 74 ± 0.5 (R-3a) 56 ± 0.4 (R-3a) 71 ± 0.4 (R-3a) 73 ± 1 (R-3a) 
4 38 ± 1 (1S,2R-4b) 12 ± 0.4 (1S,2R-4b) 8 ± 4 (1S,2R-4b) 33 ± 2 (1S,2R-4b) 
5 
78 (n.d., 5b) 
> 95 (R-5c) 
47 (n.d., 5d) 
n.d. n.d. n.d. 
6 - - - - 
 Product distribution [%][c] 
1 0.3:99.7 (1a:1b) 19:81 (1a:1b) 18:82 (1a:1b) 10:90 (1a:1b) 
3[d] 80:20 (3a:3b) 78:22 (3a:3b) 79:21 (3a:3b) 78:22 (3a:3b) 
4[e] 64:36 (4a:4b) 50:50 (4a:4b) 54:46 (4a:4b) 58:42 (4a:4b) 
5 
48:18:18:17 
(5a:5b:5c:5d) 
n.d. 
59:14:8:19 
(5a:5b:5c:5d) 
52:19:10:19 
(5a:5b:5c:5d) 
6 - - - - 
[a] Product formations were determined by GC-FID analysis after 24 h using standard curves of the 
respective products. [b] Enantiomeric excess values were determined by HPLC analysis using a chiral 
stationary phase. [c] Product distributions were determined by GC-FID analysis. [d] Cyclohexanone 
formation resulting from isomerization of 3a was added to the total amount of 3a. [e] Traces of 1-indanol 
were detected (1-2%) resulting from the RO-catalyzed oxidation of 1-indane present in small amounts in 4. 
To determine standard deviations for the CDO variants, triplicates from one expression batch were used. 
-: not detected. n.d.: not determined.  
With alkene 1, regioselectivities for products 1a and 1b were slightly altered for each of the three 
mutants with a larger fraction of 1a being formed compared to the wild type enzyme. Yet, the ratio 
of 1a:1b did not exceed 19:81 as obtained for the CDO variant F278A (Table 20), indicating that 
introduced mutations did not have a pronounced effect on regioselectivity for 1. In contrast, mutants 
CDO F278A and CDO F278C showed a strong increase in stereoselectivities for 1a yielding 
maximum ee values of 84% (R)-1a for CDO F278A, the variant also giving the highest product 
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formation (> 99%). For oxidation of alkenes 3–5, all examined CDO variants showed decreased 
conversions and/ or stereoselectivities compared to CDO wild type (Table 20). For substrate 3, 
stereoselectivities dropped especially after the replacement of wild type amino acid residues with 
small side chain sizes as observed for CDO F278A (56% ee for (R)-3a compared to 74% ee) while 
for diol 4b, the decrease of ee values was most pronounced with mutants CDO F278A and 
CDO F278C (Table 20). Yet, absolute configurations of oxidized products did not change compared 
to the wild type enzyme. Additionally, CDO variants showed slight alterations in regioselectivity for 
substrates 4 and 5 while ratios of 3a and 3b were not influenced (Table 20). In contrast to the CDO 
variant M232A, none of the mutations enabled the oxidation of terpene 6. 
Whereas variants CDO F278A, CDO 278C and CDO I336V showed the most significant alterations 
in selectivity for alkenes 1, 3, 4 and 5, a strong shift in regioselectivity for substrate (S)-7 was 
observed with mutant CDO I288V. Compared to CDO wild type, the main product in the 
biotransformation of (R)-7 remained unchanged and the allylic alcohol 7b was formed with good 
regio- (> 90%, Figure 19A) and stereoselectivity (> 95% de for 1R,5S-7b). Yet, for the opposite 
substrate enantiomer (S)-7, CDO I288V gave 44% isopiperitenol 7c and 34% 1-methyl-4-
(prop-1-en-2-yl) cyclohex-2-enol 7d while 7b was only obtained with 22% (Figure 19). Allylic 
alcohols 7b and 7c were isolated from large scale biotransformations for structure determination by 
NMR analysis. Product 7d was identified by comparison with the authentic standard and might 
result from dehydration of limonene-1,2-diol. Indeed, traces of cis-limonene-1,2-diol were obtained 
during the CDO I288V-catalyzed oxidation of (S)-7. Whether compound 7d, however, resulted from 
dehydration of the diol and whether this reaction might be spontaneous or enzyme-catalyzed was 
not determined. Even though obtained as product mixture, the stereoselectivities for 7b, 7c and 7d 
were excellent with de values ≥ 95%.  
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Figure 19: (A) GC chromatogram of the CDO I288V-catalyzed biotransformation of (R)-7 (pink) and (S)-7 
(black). *: In biotransformations of (S)-7, (1R,5S)-7b results from oxidation of (R)-7 contaminants that are 
present in (S)-7 as determined by chiral GC analysis. (B) Product distribution for the oxidation of (S)-7 by CDO 
I288V. The product ratio only includes the main products 7b, 7c and 7d and several minor potential oxidation 
products detected in GC-FID analysis that could not be clearly identified due to low amounts were excluded. 
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3.4. Semi-preparative biotransformations with CDO M232A as catalyst 
To proof the applicability of ROs for organic synthesis, semi-preparative scale biotransformations of 
selected substrates were performed with the CDO variant M232A. The mutant was chosen as 
catalyst due to its improved characteristics compared to the wild type enzymes and other CDO 
variants. For oxyfunctionalization, compounds 6 and (R)-7 were selected considering the good 
regio- and stereoselectivities obtained for these terpenes. On the one hand, shake flask 
experiments with 70 mg substrate were performed using resting cells supplemented with glucose 
for in situ cofactor regeneration. Further up-scaling to 4 L was tested with growing cells in a 
fed-batch process using a stirred tank bioreactor. 
 
3.4.1. Biotransformations with resting cells in 70 mg scale 
Semi-preparative scale biotransformations of substrates 6 and (R)-7 were performed in 70 mg scale 
with resting cells expressing CDO M232A. For up-scaling of oxyfunctionalizations, a reaction set-up 
comparable to analytical scale biotransformations was used. Since a sufficient headspace volume 
proved to be critical for effective substrate oxidation, a ratio of 20:1 between headspace and the 
reaction mixture was maintained which was also applied for analytical scale oxidations. 
Without further optimization of the reaction set-up, (1S,2S,3R,5S)-(+)-6a and (1R,5S)-(+)-7b were 
isolated and purified by flash column chromatography in 33% and 38% yield, respectively (35% and 
87% conversion). For 7b, the decay in isolated yield from 87% product formation to 38% was 
presumably caused by product loss during extraction and flash column chromatography. On the one 
hand, in preparative biotransformations, downstream processing of 7b was found to be difficult as 
phase separation during extraction was not as easily achieved as in analytical biotransformations. 
In addition, some fractions of the flash column purification had to be discarded as they contained 
the allylic alcohol 7a that could not be completely separated, thereby leading to a further reduced 
overall yield. Yet, the good regio- and stereoselectivities obtained for products 6a and 7b in 
analytical scale biotransformations were maintained during up-scaling to 70 mg substrate. 
 
3.4.2. Biotransformation of (R)-limonene with growing cells in a bioreactor (4 L) 
For further up-scaling, hydroxylation of (R)-7 was performed on 4 L scale in a stirred tank 
bioreactor. To circumvent harvesting of cells and storage of the biocatalyst, the reaction was 
performed with growing cells having high metabolic activity for cofactor regeneration.186 The 
biotransformation immediately proceeded protein expression by direct addition of the substrate to 
the fermentation broth. Compound (R)-7 was chosen as substrate for scale-up since its 
oxyfunctionalization by CDO M232A had already been successfully tested in shake flask 
experiments with 70 mg substrate. Furthermore, its low toxicity in combination with a flash point of 
50°C made terpene (R)-7 suitable for experiments performed in a bioreactor. Representing the 
lowest point at which a compound can vaporize to form an ignitable mixture in air, the flash point of 
a substrate during biotransformation in a stirred tank reactor should be significantly higher than the 
reaction temperature to avoid the risk of explosion. As the biotransformation was performed at 
30°C, terpene 6 as well as alkenes 1 and 2 also showing good regio- and stereoselectivities in CDO 
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M232A-catalyzed oxidations, were excluded for scale-up due to their low flash points (1: 32°C, 
2: 21°C and 6: 33°C).f 
Applying a protocol adapted by Yildirim et al.,154 the fermentation process was divided into three 
parts (Figure 20). In order to generate cell mass, cells were grown in batch culture over night 
(~12 h) to obtain about 30 g cww L-1. Subsequently, fed-batch fermentation was started with a 
constant feed of glycerol. After induction of protein expression for 2 h, the biotransformation was 
initiated by addition of (R)-7. Due to the reported antimicrobial effect of (R)-7 on growing E. coli 
cells,156 the substrate was added repeatedly during the biotransformation, not exceeding a final 
concentration of 5 mM. However, due to its high volatility, (R)-7 was stripped off the reactor and had 
to be added frequently (8 x 5 mM) to obtain a constant product formation. 
 
 
 
Figure 20: Simplified scheme of the biotransformation process, adapted from Bühler et al..186 The batch 
fermentation over night was subsequently followed by a fed-batch cultivation. After induction of protein 
expression, the biotransformation was started by the repeated addition of substrate. 
 
Figure 21: Biotransformation of (R)-limonene (R)-7 with growing E. coli JM109 cells expressing CDO M232A 
in a stirred tank bioreactor on 4 L scale. After batch fermentation to generate cell mass, fed-batch fermentation 
was started (-3 h) and protein expression was induced for 2 h (-2 h - 0 h, Induction). The dashed line indicates 
the start of the biotransformation by addition of (R)-7 (0 h). Substrate was added repeatedly (8 x 5 mM) during 
the course of the biotransformation. IS: internal standard. 
 
                                                     
f Flash points of the respective compounds were derived from the supplier. 
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After 10 h biotransformation, 0.4 g L-1 isolated product yield were obtained, giving (1R,5S)-(+)-7b 
with an excellent stereoselectivity of 96% de. 0.4 g L-1 7b corresponds to a product yield coefficient 
(YP/S) of only 7% which was partly caused by the volatility of the substrate. Since furthermore, a 
antimicrobial effect of the product 7b on growing E. coli cells has been reported187 and the 
concentration of 7b did not exceed a certain threshold in the biotransformation (Figure 21), its 
microbial toxicity was tested for the specific reaction conditions (Figure 22). (1R,5S)-(+)-7b isolated 
from the fermentation broth was added in varying concentrations (0 mM, 1 mM, 5 mM and 10 mM) 
to shake flasks inoculated with E. coli JM109 cells harboring the plasmid for CDO M232A 
expression. Starting with an optical density (OD600) of 0.05, cell growth was monitored over 24 h at 
30°C. The growth rate of cells incubated with 1 mM of 7b did not differ significantly from that of cells 
grown without 7b as a control and both cultures reached an OD600 of around 15 after 24 h. 
However, at concentrations of 5 mM and 10 mM 7b, cells did not show growth within 24 h. 
Therefore, a limitation of product formation during the biotransformation might be caused by the 
toxicity of 7b on growing E. coli cells. 
 
 
Figure 22: Microbial toxicity of (1R,5S)-(+)-carveol 7b on growing E. coli JM109 cells. To determine a toxic 
effect, cell growth was monitored over 24 h by determining the optical density (OD) of the culture when grown 
in the presence of different concentrations of (1R,5S)-(+)-7b (0 mM, 1 mM, 5 mM and 10 mM). 
Next to product toxicity and substrate volatility, also the formation of acetate by E. coli can diminish 
product yields and detrimental effects on cell growth have been reported for concentrations as low 
as 0.5 g L-1.188 Therefore, acetate levels were monitored by HPLC analysis during the fed-batch 
fermentation. Acetate formation increased after the start of the glycerol feed but remained constant 
at 0.4 g L-1 when protein expression was induced (Figure 23). Yet, 8 h after the biotransformation 
was initiated, acetate concentrations started to rise again, yielding acetate levels of 0.9 g L-1 at the 
end of the process (10 h). 
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Figure 23: Acetate formation during the fed-batch process with E. coli JM109 expressing CDO M232A and a 
constant glycerol feed over 13 h. After starting the fed-batch process, protein expression was induced for 2 h 
(-2 h–0 h). At 0 h, the biotransformation was initiated by the addition of (R)-limonene (R)-7, indicated by the 
dashed line. 
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4. DISCUSSION 
4.1. Oxyfunctionalization of alkene substrates by RO wild type enzymes 
Based on their activity towards unnatural substrates, three ROs were selected and characterized for 
the oxyfunctionalization of a set of structurally diverse olefins. Instead of purified enzyme, reactions 
were performed with whole cells due to the reported instability of isolated ROs172,173 as well as to 
provide an efficient in situ cofactor regeneration system by the addition of glucose. Examining the 
selected substrate panel with NDO, BDO and CDO, stereoselectivities and product formations were 
found to be strongly dependent on the RO as well as the alkene substrate. In order to evaluate the 
RO-catalyzed oxidation of different alkene types, the olefins comprised four of the six alkenes (mono-, 
gem-di-, cis-di- and tri-substituted alkenes). A preference of RO-catalyzed dihydroxylation has been 
reported by Boyd and coworkers in the order mono-substituted alkene > cis-di-substituted alkene > 
gem-di-substituted alkene > tri-substituted alkene > trans-di-substituted > tetra-substituted alkene.74,75 
However, with the diverse substrate panel in this study, such general conclusions could be drawn 
neither with BDO, CDO nor NDO and next to the specific enzyme, also the overall substrate structure 
as well as the electronic properties of the C=C double bond played an important role for alkene 
preference. Furthermore, for several of the examined olefin substrates, monohydroxylation in allylic 
position competed with dihydroxylation of the alkene bond. 
As described by Boyd et al., the RO-catalyzed dihydroxylation preferentially occurs at mono-
substituted C=C double bonds.74,75 Yet, even though both compounds contained a mono-substituted 
alkene bond, styrene 1 was converted with high product formations by all enzymes whereas 
conversions dropped for vinylcyclohexane 2, indicating that the substrate preference is not solely 
determined by the alkene type. On the one hand, the alkene bond of olefin 1 is conjugated in contrast 
to the unconjugated system of 2. Consistent with obtained conversions for compound 2, such 
unconjugated olefins have already been described to be poor substrates for RO-catalyzed 
dihydroxylations.75 Furthermore, alkene 1 has a planar structure due to its aromatic substituent 
whereas for 2, the cyclic six-membered ring is supposed to have a chair-like conformation, hence 
deviating much more from the planar structure of the natural aromatic compounds than 1 (Figure 24). 
 
                               
Figure 24: 3D-Structures of compounds 1 and 2 generated with Chem3D Pro. In contrast to 1 having a planar 
aromatic moiety, the cyclohexane ring of 2 adopts an out of plane configuration. 
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Like compound 2, the cyclic olefin cyclohexene 3 also possesses an unconjugated yet cis-di-
substituted C=C double bond. Even though CDO and NDO showed conversions < 40% with 3 as 
substrate, BDO yielded 59% product formation. Solely relating to activities obtained for the mono-
substituted alkene 1, these results would be in accordance with literature, reporting that mono-
substituted olefins are preferred over cis-di-substituted alkenes.74,75 Yet, with BDO, conversion of the 
mono-substituted alkene 2 was < 1%, indicating that the shape of the active site binding pocket in 
combination with the spatial structure of the substrate plays a major role for alkene preference. 
Furthermore, the conjugated cis-di-substituted alkene indene 4 was well accepted by the three 
enzymes and product formations between 80% and > 99% were comparable to conversions obtained 
for substrate 1 but much higher than for compounds 2 and 3. Like olefins 2 and 3, also the five-
membered ring of 4 had a twist about the plane compared to aromatic systems. Nevertheless, besides 
the arene-substituted alkene 1, compound 4 was the best converted substrate in the panel. Even 
though allylic monohydroxylation competed with dihydroxylation of the C=C double bond, diol 
formation with substrate 4 was at least with NDO and BDO still higher than for 2. These results 
suggest that a conjugated C=C double bond in combination with an aromatic moiety to give the 
substrate a more planar character is promoting alkene oxyfunctionalization by ROs.  
Due to their structural diversity, it was hard to link the olefins of the substrate panel with respect to a 
preference for a distinct alkene type. For this purpose, polyene myrcene 5 combining a mono-, gem-di- 
as well as tri-substituted C=C double bond in one molecule was a good model substrate. With NDO, 
the sequence mono-substituted alkene > gem-di-substituted alkene > tri-substituted alkene postulated 
by Boyd and coworkers could be observed during oxyfunctionalization with a slight preference for the 
mono-substituted over the gem-di-substituted C=C double bond (44:41) whereas dihydroxylation of 
the tri-substituted alkene bond was clearly disfavored (3%). Yet, the formation of different products 
was also dependent on the orientation and positioning of 5 in the active site of the three enzymes. 
With CDO, the allylic alcohol (Z)-5a was preferred over dihydroxylation and diols 5b-5d were formed in 
rather equal ratios even though the terminal mono-substituted and the gem-di-substituted C=C double 
bonds are conjugated and sterically better accessible than the tri-substituted isolated alkene bond 
giving 5c. In this enzyme, the shape of the substrate binding pocket might favor orientation of the 
methyl groups close to the catalytic iron center and thus also show enhanced dihydroxylation of the 
adjacent tri-substituted alkene bond compared to NDO. 
Even though closely related with regard to their overall sequence similarity, such differences in product 
ratios for BDO, CDO and NDO could be observed for most of the substrates. As already mentioned, 
the formation of different products indicated diverse binding modes in the active sites of the enzymes 
due to differently shaped substrate binding pockets (Figure 25). Since the examined olefins lack any 
oxyfunctionalities, their orientation in the substrate binding pocket is coordinated by hydrophobic 
interactions and the steric constraints that are specified by the active site topology. Whereas the 
conversion of their natural arene substrates (benzene, cumene and naphthalene) exclusively yielded 
the corresponding arene-1,2-dihydrodiols,189–191 dihydroxylation competed with alcohol formation 
during oxyfunctionalization of olefins giving varying ratios of mono- and dihydroxylated products. 
Consistent with previous reports from literature, monohydroxylation reactions were observed to be 
dependent on both the aliphatic compound as well as the allylic position73 and monohydroxylated 
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products were obtained for substrates 3, 4, 5 and limonene 7. Monohydroxylation presumably occurs 
when the activated allylic carbon center is oriented close to O2 bound to the catalytic iron and has 
been suggested to proceed via a radical reaction mechanism.106 While one oxygen atom is inserted 
during the reaction to yield the alcohol, the second oxygen atom might be reduced to water as 
observed for monooxygenases like P450 enzymes192 albeit this has to be elucidated. In contrast to 
P450 monooxygenases, the oxyfunctionalization of unactivated sp3 carbon centers was not observed 
and no example for such a reaction has been described in literature to be catalyzed by ROs.  
 
                 
Figure 25: Shapes of the substrate binding pockets of CDO (grey, left, PDB code: 1WQL)170 and NDO (green, 
right, PDB code: 1O7N)101. The catalytic iron and bound oxygen are shown as orange and red spheres. 
Also with regard to their stereoselectivities, the three ROs showed interesting differences and opposite 
enantiomers were obtained for the CDO-catalyzed oxyfunctionalization of 4 compared to NDO and 
BDO. As mirror-image enzymes for the formation of both product enantiomers are rare in nature, 
enantiocomplementary biocatalysts performing the same reaction with opposite stereoselectivities are 
highly interesting. Yet, examples for an enzymatic access to both enantiomers are limited and for ROs, 
only few reactions have been described, all including NDO and TDO as enantiocomplementary 
catalysts.75,175,193,194 Even though the two enzymes share the same protein fold, exchanged locations 
of their binding sites due to eight amino acids differing in the enzymes’ active sites caused the 
dihydroxylation of 1,2-dihydroxynaphthalene, different aryl alkyl sulfides, indan-2-ol and 4 with 
opposite stereoselectivities.75,94 While for the dihydroxylation of 4 the (1S,2R)-enantiomer of diol 4b 
was obtained, the absolute configuration of the allylic alcohol 4a was dependent on the TDO enzyme. 
Accordingly, TDO from P. putida UV4 gave the opposite enantiomer ((R)-4a) compared to NDO 
whereas TDO from P. putida 39/Dg yielded (S)-4a, too.90,92,195 Like TDO from the UV4 strain, also CDO 
showed the opposite enantiopreference for both 4a and 4b compared to NDO and BDO. Its reversed 
enantioselectivity presumably results from different substrate orientations in the active site due to a 
varying topology of the substrate binding pocket. Thus, in the three enzymes, the active sites are 
functionally mirror images of one another so that during catalysis of the same reaction, opposite faces 
of the substrate are exposed to the catalytic iron center resulting in opposite stereoselectivities 
                                                     
g P. putida 39/D is a mutant of P. putida F1 lacking cis-dihydrodiol dehydrogenase activity.65 
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(Scheme 18).94 Interestingly, the α-subunits of BDO and TDO from P. putida F1 containing the active 
site only differ in 33 amino acid residues153 even though the two ROs are enantiocomplementary 
biocatalysts for the formation of 4b. Similarly, also CDO and BDO share 78% and 63% overall 
sequence similarity and identity, respectively, while opposite absolute configurations were obtained, 
indicating that the stereoselectivity of 4 is determined by a small number of amino acid residues in the 
substrate binding pocket. 
 
 
Scheme 18: Enantiocomplementary dihydroxylation of indene 4 by NDO, BDO and CDO yielding diol 4b with 
opposite absolute configurations, modified after Mugford et al..94 
With the exception of 4, the same absolute configurations were obtained for all other tested substrates 
in RO-catalyzed biotransformations. In general, with NDO stereoselectivities were considerably higher 
for most products (1a, 2a, 4a, 4b, 5b and 5d) compared to BDO and CDO. Only for alcohol 3a, BDO 
and CDO showed better ee values what might be attributed to the small size of substrate 3. With the 
bulky methionine side chain at position 232 and 220, the cyclic olefin 3 could be more tightly bound in 
one distinct orientation to the iron center in the pockets of both enzymes.  
Interestingly, the best stereoselectivities were obtained for linear alkenes which have been described 
in literature as challenging substrates for RO-catalyzed oxyfunctionalizations,74,75 yielding good to 
excellent ee values for the dihydroxylation of compounds 2 and 5 (> 95%). In contrast to NDO, CDO 
gave products 5b and 5d with lower ratios and ee values of 78% and 47% while stereoselectivities for 
5c were excellent (> 95%). Yet, even the moderate ee values for diols 5b and 5d were still higher than 
stereoselectivities reported for shorter acyclic dienes like isoprene, piperylene and 1,3-butadiene with 
ee values not exceeding 45% in whole cell biotransformations using BDO, NDO or TDO.74 
Regarding the substrate scope, BDO displayed the most limited spectrum for the selected alkene 
panel. In contrast to NDO or CDO, it did not tolerate several compounds with out of plane 
configurations or diverse substituents like alkenes 2, 5, 7 and 3-chlorostyrene 13 (≤ 5% product 
formation) being better accepted by the other RO enzymes. Its more restricted substrate specificity 
might result from the fact that BDO was evolved for the small compound benzene while cumene and 
naphthalene are more bulky due to the isopropyl moiety or second phenyl ring. Yet, like BDO, also 
NDO and CDO did not accept (+)-α-pinene 6 and (+)-valencene 8 which represent sterically 
demanding compounds due to their various methyl substituents and out of plane configurations. 
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4.2. Influence of different active site residues on the RO-catalyzed alkene oxidation 
In contrast to their natural aromatic substrates, the applicability of NDO, CDO and BDO for the 
oxyfunctionalization of olefins was limited by their poor stereoselectivities and product formations for 
several of the tested compounds. To overcome these limitations and improve RO enzymes for the 
conversion of aliphatic substrates, mutations in the binding pockets of the three ROs were introduced. 
Residue M232 in CDO as well as the corresponding positions in NDO and BDO were selected based 
on a phylogenetic comparison with other members of the RO family. Furthermore, positions F278, 
I288, I336 and F378 in CDO were mutated using different codon degeneracies (DBC: F, C, I, T, S, V, 
A, G and BBT: F, S, C, L, P, R, V, A, G). With the exception of F378 being highly conserved, all 
targeted positions had an average to high mutability according to HotSpot Wizard, a web server 
calculating the mutability of a distinct residue from its conservation level.184 In general, less conserved 
amino acids are naturally more tolerant to a wider range of substitutions and were thus chosen for 
mutagenesis.196 Yet, some positions attributing to enzyme specificity might be conserved to maintain a 
particular selectivity196 and since the corresponding residue in NDO (F352) has been reported to have 
a significant influence on stereo- and regioselectivity for aromatic compounds, position F378 in CDO 
was selected for mutagenesis.124,125 However, as predicted by HotSpot Wizard, with variants of the 
F378DBC mutant library, no activity towards indole was observed in the colorimetric solid phase 
screening and in line with the assay, clones without color formation that were examined with the 
substrate panel did not show oxidation activity.  
In contrast, most mutants from the libraries based on positions M232, F278, I288 and I336 maintained 
their activity according to the indole assay (CDO F278DBC, I288BBT and I336BBT) or the substrate 
screening (CDO M232NDT: F, L, I, V, Y, H, N, D, C, S and G), indicating that these positions are 
rather robust for the introduction of other amino acids. This tolerance might be attributed to the low 
conservation level found for the targeted residues, a feature maybe connected to the diverse substrate 
scope of ROs. Amino acid side chains predicted to interact with the accepted compounds have been 
reported to be quite variable in dioxygenases whose primary substrates include aromatic 
hydrocarbons, chlorinated aromatics, amino- and nitroaromatic compounds as well as aromatic 
acids.125 These results in combination with previous data suggest that a wide range of amino acid 
residues can be tolerated near the active site of ROs, having significant effects on the 
oxyfunctionalization of a variety of compounds125 as also detected for the examined substrate panel 
with variants from the generated libraries. 
Furthermore, the influence of targeted amino acid residues on selectivities and product formations 
confirm reports from literature describing that the most effective mutations can be found within 15 Å of 
a key catalytic atom. All positions that were chosen for mutagenesis are located within a distance of 
12 Å of the non-heme iron center as variations of amino acid residues within this distance are more 
likely to result in an altered substrate specificity or stereoselectivity.123 In addition, positions F278, 
I288, I336 and F378 are concentrated at the C-terminal portion of the α-subunit in CDO which 
comprises the residues affecting substrate specificity in the toluene/biphenyl RO subfamily64,197 while 
M232 is located closer to the active site iron ligands.182 
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Mutagenesis of M232 in CDO and its corresponding positions in BDO and NDO 
Among the five selected positions in CDO, variation of residue M232 had the most significant effects 
on selectivity and activity. M232 is one of 14 amino acid side chains constituting the substrate binding 
pocket and contributes to the more hydrophobic inner surface of CDO compared to NDO.170 The 
exchange of M232 in CDO by alanine as found in NDO resulted in a variant with improved selectivities 
and product formations for several alkene substrates. One of the most significant changes in regio- as 
well as stereoselectivity was observed for substrate 1. The single targeted point mutation induced a 
shift in regioselectivity, yielding alkene-1,2-diol 1a as main product with enhanced stereoselectivities. 
By varying the size of the amino acid side chain, regio- and stereoselectivities could be further 
modulated and variants of the NDT mutant library showed in general higher stereoselectivities and 
ratios of alkene-1,2-diol 1a when substituted with smaller residues.  
The altered regioselectivity in combination with an increased ee value for 1a was also obtained for 
BDO M220A. Yet, in contrast to CDO and BDO variants, the reciprocal exchange of alanine by 
methionine at the corresponding position 206 in NDO did not result in the formation of the arene-1,2-
dihydrodiol. Due to the introduction of the bulky methionine side chain in the substrate binding pocket, 
however, the activity of NDO mutant A206M dropped significantly. The decrease in conversion might 
be caused by the diminished active site volume and the replacement of methionine by the smaller 
isoleucine indeed increased product formations, yet without having an influence on regioselectivity. 
Similar results have been obtained for the reciprocal exchange of amino acid residues in the active 
site of closely related P450 monooxygenases to alter the substrate orientation. By phylogenetic 
comparison, Schalk and Croteau identified a single point mutation that was sufficient to completely 
switch the regioselectivity for one of the two enzymes.198 As observed for CDO and NDO, the amino 
acid substitution did only work in one direction whereas introduction of the larger amino acid residue 
gave an enzyme inactive for the tested substrate due to compromised binding affinity and a binding 
orientation that was likely to prevent catalysis.198  
Besides an increased stereoselectivity for 1a, enhanced ee values with variant CDO M232A were also 
obtained for products giving better stereoselectivities with NDO than CDO wild type. Stereoselectivities 
increased to > 95% ee for diols 2a and 5b and also for the oxyfunctionalized products of 4, the optical 
purity was enhanced albeit ee values for the diol did not reach stereoselectivities obtained with NDO. 
Yet, it should be highlighted that the absolute configuration of both 4a and 4b was reversed compared 
to CDO wild type, giving the same absolute configuration as NDO. The switch in stereoselectivity 
presumably results from different substrate orientations due to an altered active site topology as the 
amino acid side chain at position 232 forms part of the substrate binding pocket (Figure 26, as no 
crystal structure of the CDO variant M232A was available, a homology model was created based on 
CDO wild type). By introducing a single point mutation, enantiocomplementary enzymes for the 
oxidation of 4 were generated, enabling the attack of dioxygen from opposite faces of the substrate. In 
the NDT mutant library, opposite stereoselectivities could be further modulated by altering the steric 
demand of the amino acid side chain at position 232. Smaller side chain sizes (V, C, S, G) increased 
the ee values for (S)-4a and resulted in an enantiopreference for (1R,2S)-4b while more bulky 
residues (F, L, I) yielded the (1S,2R)-enantiomer. An induced switch in stereoselectivity has been 
already reported for the conversion of aromatic compounds by engineered variants of NDO and 
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nitrobenzene dioxygenase. Compared to the wild type enzymes, NDO F352V and nitrobenzene 
dioxygenase variant V207A formed the opposite enantiomers for biphenyl cis-3,4-dihydrodiol or 
different thioanisole derivatives.124,142 Similar to CDO M232A, in both mutants the original amino acid 
was substituted with a smaller residue, presumably allowing for opposite substrate orientations to the 
non-heme iron center in the active sites of the enzymes. 
 
        
 
Figure 26: Active site model of CDO M232A (grey) in comparison with CDO wild type (yellow). The homology 
model of the CDO variant M232A was created based on the CDO crystal structure (PDB code: 1WQL)170 using 
SWISS-MODEL.183 The structures of CDO and CDO M232A were aligned in the PyMOL molecular graphics 
system, version 1.2r1 Schrödinger, LLC. The methionine residue at position 232 is shown as yellow sticks. The 
catalytic iron center is shown as orange spheres while bound O2 is shown as red spheres. 
Even though CDO M232A displayed enhanced stereoselectivities for most of the tested olefins, a 
decrease in ee values was obtained for substrates giving lower stereoselectivities with NDO compared 
to CDO. The drop in ee for the allylic alcohol 3a was presumably caused by the enlarged substrate 
binding pocket which might allow binding of the small cyclic alkene 3 in more than one defined 
orientation and was also observed with BDO M220A. 
On the other hand, the increase in size of the substrate binding pocket enabled productive binding of 
the sterically demanding terpene 6 in the active site of CDO M232A. In CDO wild type, 
accommodation of the substrate might be hindered due to the clash with the bulky methionine residue 
at position 232. Albeit in NDO, an alanine residue is already present at the corresponding position, 
other amino acid side chains obviously prevented oxidation of 6 in the enzyme active site. NDO has 
been described to have a rather flat substrate binding pocket formed by the hydrophobic residues 
L227, F224 and L253 which can accommodate planar aromatic systems but might impede the binding 
of substrates with spatial three-dimensional structures.199 As indicated by docking analysis, also in 
BDO M220A, productive binding of 6 in the catalytic site might be prevented due to steric constraints 
caused by amino acid residues lining the entrance tunnel or the substrate binding pocket. In contrast, 
CDO M232A catalyzed the formation of (1S,2S,3R,5S)-6a with a high de > 95%. The same 
diastereomer was also obtained in the OsO4-catalyzed dihydroxylation of 6 yielding stereoselectivities 
> 95% de even in the absence of a chiral ligand.163,200 For both the chemical as well as the biocatalyst, 
the spatial structure of the substrate might prevent an attack from the opposite side of the molecule, 
thus forming only one of the two possible diastereomers due to steric hindrance.  
Besides oxyfunctionalization of terpene 6, enhanced product formations with CDO M232A were also 
observed for other substrates. The higher conversions with this CDO variant might be either caused by 
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higher expression levels, increased stability or enhanced catalytic efficiency. However, due to their 
cofactor-dependency and multicomponent nature, ROs were only applied in whole cell systems and no 
kcat/ KM values were determined in order to compare the catalytic efficiency of wild type enzymes and 
variants thereof.  
Considering the strong effect on selectivity and product formation not only for CDO but also for BDO, 
position 232 (numbering refers to CDO) was examined in the context of a broader sequence space. In 
cooperation with Dr. Constantin Vogel from the bioinformatics group of the Institute of Technical 
Biochemistry, the amino acid distribution at this position as well as the surrounding residues were 
compared within about 18,000 sequences. According to their global sequence homology, these 
putative dioxygenases can be grouped into two superfamilies (orange and blue, Figure 27A). The 
mutated residues in CDO and BDO were found to be located at a variable position (underlined) at the 
end of a highly conserved motif (N-W-K-x(3)-[ED]-[NQ]-x(3)-[DE]-x-Y-H) which proved to be specific 
for the superfamily comprising BDO, NDO and CDO (orange, Figure 27A). At this position, alanine 
was the most frequent amino acid (28%) followed by proline (20%) and glycine (16%, Figure 27B). Its 
high frequency at position 232 in natural RO variants within the specific superfamily might be one 
reason why alanine is that well tolerated in CDO. 
 
                          
Figure 27: Bioinformatic analysis of the sequence space surrounding position 232 (numbering refers to CDO). 
(A) 18,006 Dioxygenase sequences were grouped according to their global sequence homology into different 
homologous families (squares) and two superfamilies (orange and blue). Homologous families displaying more 
than 40% global sequence similarity are connected by grey lines. Homologous families with available structural 
information are marked in red. The picture was provided by Dr. Constantin Vogel. (B) Amino acid distribution at 
position 232 within the specific RO superfamily (orange). 
Being located at a variable position in a highly conserved motif, residue 232 might also have an 
influence on selectivity and/ or product formation in other RO enzymes belonging to the same 
superfamily. Next to CDO and BDO as shown in this study, an effect on selectivity has been 
demonstrated for both TDO and NDO. The single amino acid exchange M220A at the corresponding 
position resulted in a TDO variant with activity towards 1,2,4,5-tetrachlorobenzene, a substrate that 
could not be converted by the wild type enzyme125 while mutations of A206 in NDO have been 
reported to show an significant effect on product formations as well as selectivities for several aromatic 
compounds.125 
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Mutagenesis of positions F278, I288, I336 and F378 in CDO 
In contrast to position M232 that was identified by comparison with another member of the RO family, 
positions F278, I288, I336 and F378 were selected according to their distance from the catalytic iron 
(within 12 Å) and their conservation level. To facilitate the identification of active variants within the 
focused mutant libraries, an initial colorimetric solid phase assay based on indigo formation was 
applied for screening. This assay has been already described in literature to be suitable for the 
identification of active clones that did not lose the ability to dihydroxylate indole as a first step towards 
variants with altered features for the substrate of interest.109,124,185 Yet, even though indole is 
structurally similar to compound 4 from the selected substrate panel, it differs greatly from the other 
olefins that were investigated. Even though colonies that did not show color formation were screened 
against the alkene panel without detecting activity, a screening assay which employs a different 
compound than the substrate of interest might nevertheless lead to false negative results. Other 
assays described for the screening of oxygenases libraries like colorimetric assays based on NADH 
depletion139 were however excluded as especially with unnatural substrates, uncoupling has been 
reported.201 Thus, such an assay would not only select variants with improved activity towards a 
distinct substrate but also for increased uncoupling rates. On the other hand, the adrenaline assay for 
the detection of the diol products did not proof to be suitable as it is sensitive to glucose or glycerol 
which was used in whole cell biotransformations for in situ cofactor regeneration.202 Despite its 
disadvantages, the colorimetric solid phase indole assay was found to be applicable for screening of 
active mutants, being a first indicator which variants had maintained their structural integrity.  
As determined with HotSpot Wizard, positions F278, I288, I336 and F378 possess different degrees of 
conservation. Herein, the conservation level of the residues correlated with the number of colored 
colonies found in the indole assay. For the DBC library at the highly conserved position F378, the 
small degree of blue colonies observed during screening (10%) indicated that its tolerance for 
introduced mutations was rather low. Unlike for CDO, the corresponding position F352 in NDO has 
been shown to have an effect on both regio- and stereoselectivity for conversion of the aromatic 
compounds biphenyl and phenanthrene when substituted with other amino acids.124 
In contrast to position F378, residues F278, I288 and I336 were categorized as average to highly 
mutable due to their low conservation level. This result was confirmed by the indole assay, indicating 
active enzyme variants at least for the oxyfunctionalization of indole and > 80% of the screened 
colonies in these libraries displayed blue color formation. For the selected substrate panel, mutations 
at position 278, 288 and 336 were furthermore shown to influence selectivities and product formations. 
In contrast to CDO M232A, only slight changes in regioselectivity could be observed for the 
oxyfunctionalization of alkene 1 with the examined variants CDO F278A, CDO F278C and 
CDO I336V. Even though mutants CDO F278A and CDO F278C gave an about 2-fold higher ratio of 
1a than CDO I336V, amounts of the alkene-1,2-diol did not exceed 19%. Yet, CDO variants based on 
position F278 resulted in a strong increase in stereoselectivity from 43% up to 84% ee for (R)-1a. 
Accordingly, stereoselectivities for diol 4b were affected significantly for mutants CDO F278A and 
CDO F278C, yet, the introduced mutations caused a decrease in ee values from 38% to 12% and 8%, 
respectively, while the absolute configuration of the products was maintained. 
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The large influence on stereoselectivity of position 278 for the oxyfunctionalization of 1 and 4 might be 
caused by its close proximity to residue M232 with both residues being located on one side of the 
catalytic iron center (Figure 17). Furthermore, F278 is located in a loop opening a channel to the active 
site while forming part of the inner surface of the catalytic pocket.170 Also residue I288, displaying the 
most interesting changes in regioselectivity of all examined active variants from the mutant libraries 
(CDO F278A, CDO F278C, CDO I336V and CDO I288V) forms part of this loop.170 During 
oxyfunctionalization of (S)-7, monohydroxylation still only occurred in allylic position and no oxidation 
of unactivated C-H bonds was observed. Yet, instead of 7b as main product, 7c and 7d were formed 
with ratios of 44% and 34%. In contrast to product 7c obtained by allylic monohydroxylation at C-3 of 
the substrate, the tertiary alcohol 7d might be a result of the dehydration of limonene-1,2-diol but no 
controls have been performed yet to verify this hypothesis. For the opposite substrate enantiomer 
(R)-7, the change in regioselectivity was not as pronounced as for (S)-7 and only traces of 7c could be 
detected during the CDO I288V-catalyzed biotransformation with 7b as main product (> 90%). Besides 
altering the regioselectivity for the oxyfunctionalization of (S)-7, position I288 has been already shown 
to influence substrate specificity in natural occurring cumene-type dioxygenase variants from arene-
contaminated soil samples.197 In combination with residue L321, isoleucine at position 288 enabled 
degradation of toluene and benzene while the substrate scope of variants containing a methionine at 
both positions was narrowed and toluene was not accepted anymore.197 
 
4.3. Semi-preparative biotransformations with CDO M232A 
As ROs are complex cofactor-dependent multicomponent enzymes, the up-scaling of analytical 
biotransformations was performed with whole cell biocatalysts for efficient in-situ cofactor regeneration 
and increased oxygenase stability. In two different reaction scales, CDO M232A-catalyzed oxidations 
were performed with 0.25 g mL-1 (cww) resting cells in shake flask experiments (70 mg of substrates 6 
and (R)-7, respectively) as well as with growing cells in a bioreactor (4 L scale with (R)-7). Both 
approaches were compared and advantages as well as disadvantages in the application of resting and 
growing cells for the oxyfunctionalization of terpene (R)-7 were elucidated. 
With 250 g L-1, the cww in shake flasks experiments was about 5-fold higher than the cell amount in 
biotransformations of (R)-7 performed with growing cells (between 47 g L-1 and 59 g L-1 cww). 
Compared to resting cells giving 27 mg isolated product yield after 24 h (in a total reaction volume of 
55 mL), the biotransformation on 4 L scale yielded lower isolated titers of 0.4 g L-1 7b after 10 h. 
However, considering the significantly lower amount of cells, a higher average specific yield 
(7.5 mg product g-1 cww versus 1.9 mg product g-1 cww) could be obtained with metabolically active 
cells.  
Despite the higher specific yields, the use of growing cells has disadvantages (Figure 28) and during 
oxyfunctionalizations, substrate and product toxicity can diminish isolated yields. For E. coli JM109 
used as expression host, both (R)-7 and 7b proved to be toxic for growing cells. Due to its reported 
antimicrobial effect,156 terpene (R)-7 was added repeatedly in the biotransformation on 4 L scale to 
maintain concentrations below a toxic level. Whereas detrimental concentrations of the substrate could 
be avoided, the antimicrobial effect of 7b that accumulated during the reaction might have reduced the 
final product titers obtained in the process. As shown in shake flask experiments with growing E. coli 
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JM109 cells, (1R,5S)-7b inhibited cell growth under the specific reaction conditions and after passing a 
certain threshold in the bioreactor, product formation might be limited by its toxic microbial effect. 
Besides product toxicity, also substrate volatility severely hampered obtained product yields as during 
the process, 7 was stripped off the reactor due to air sparging, leading to an overall isolated yield of 
only 7%. These major constraints of the process, substrate and product toxicity as well as substrate 
volatility might be overcome by process design. The use of a second liquid phase could not only 
prevent air stripping of the substrate but also function as a reservoir for antimicrobial compounds like 7 
and hence avoid the need of repeated manual addition without inhibiting bacterial cell growth. 
Therefore, such two-phase systems are frequently employed for the biotransformation of 
hydrocarbons which often are not only toxic or inhibitory to the biocatalyst but also poorly water 
soluble.186 Next to the reduction of substrate loss and toxicity, a second organic phase can also be 
useful for in situ product removal (as well as the use of membrane reactors or solid phase extraction), 
minimizing the antimicrobial effect of the product to obtain high and stable productivities during cell 
growth and therewith higher product yields.154 In such two-phase systems with whole cell RO 
catalysts, the biocatalyst has been reported to have a greater tolerance to the biotransformation 
conditions than resting cells when the biotransformation immediately proceeded the fermentation by 
direct addition of the organic phase to the fermentation broth.203 
 
 
Figure 28: Limitations in in vivo biotransformations of (R)-7 during fed-batch cultivation of E. coli cells in a 
bioreactor. Figure adapted from Malca.204 
Due to the above mentioned advantages, oxygenase-based bioprocesses are often carried out in 
biphasic media.205 Yet, in such systems, mass transfer of the poorly water soluble hydrocarbon 
substrate from the organic phase to the biocatalyst is critical and there have been reports in literature 
when the substrate was trapped in the organic phase and no longer available for the 
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biotransformation.206 This problem was observed by Wriessnegger and coworkers for conversion of 
the sesquiterpene (+)-valencene with Pichia pastoris. To eliminate the loss of substrate, in situ 
production of (+)-valencene with valencene synthase was performed by metabolic engineering instead 
of external substrate addition.206 As additional alternative, Lynch and coworkers reduced the high loss 
of substrate during whole cell biotransformations in a bioreactor by replacing air sparging with 
membrane oxygenation.207 
Another limitation observed during the process was the formation of acetate which can retard growth 
and inhibit formation of recombinant protein.188 Even though glycerol was added as C-source being 
superior for reduced acetate formation and increased yields of recombinant protein compared to 
glucose,188 acetate concentrations of 0.9 g L-1 were observed at the end of the biotransformation. As 
detrimental acetate levels have been reported to be as low as 0.5 g L-1,188 a more advanced feeding 
strategy might be employed to reduce acetate formation and hence enhance product yields. Coupling 
the feed to dissolved oxygen (DO) levels or a specific growth rate that is maintained below a critical 
threshold can avoid acetate formation and increase the cell amount. Furthermore, growth rate and 
acetate formation are strain dependent and also strains with genetic modifications for reduced acetate 
levels are available.188 
Compared to RO-catalyzed biotransformations performed in bioreactors on a larger scale, obtained 
space-time yields for the CDO M232A-mediated oxyfunctionalization of terpene (R)-7 are in the range 
of other processes with unnatural alkene substrates. Even though reports from literature mainly cover 
aromatic substrates, several examples are known for the biotransformation of compound 4.9,208 For 
these processes, average space-time yields of 32-50 mg L-1 h-1 have been reported employing 
different biocatalysts which mainly include TDO (Table 21). With around 40 mg L-1 h-1, the space-time 
yield for oxidation of (R)-7 is comparable to the processes for conversion of 4. Yet, these 
biotransformations were performed on a considerably larger scale (15-70 L) and with longer reaction 
times (Table 21). When compared to up-scaled biotransformations with ROs involving their natural 
substrates, activities towards aromatics are often considerably higher than for non-physiological 
compounds (e.g. up to 400 mg L-1 h-1 for toluene or naphthalene dependent on the production strain 
and process conditions).154  
 
Table 21: RO-catalyzed biotransformations of olefins in a bioreactor adapted from Yildirim et al..154  
RO Production strain Substrate 
Space-time  
yield [g L-1 h-1] 
Scale 
[L] 
Time [h] Reference 
CDO M232A 
E. coli JM109 
(pIP107D_M232A) 
(R)-7 0.04 4 10 This study 
TDO P. putida 4 0.044 70[a] 8 9 
-[b] Rhodococcus sp. B264-1 4 0.032 23[a] 150 9 
TDO E. coli D160-1 4 0.05 15 24 208 
TDO[a] E. coli D160-1 4 0.042 23[a] 24 9 
[a] total reactor volume, [b] not mentioned. 
Ranging between 32-50 mg L-1 h-1, average space-time yields obtained in these processes are still 
below values that would be industrially feasible. Depending on the product, requirements for industrial 
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oxidation processes include productivities between 10 and 60 g L-1 d-1, high biocatalyst stability, high 
yields (60-80%), product concentrations of 10-100 g L-1 and simple product recovery.186 One main 
problem for the up-scaling of biotransformations include the reduced specific activities of whole cell 
biocatalysts which are frequently lower under process conditions in bioreactors than in shake flasks.154 
Due to their multicomponent nature, oxygenases are often instable or inactivated during the 
bioconversion process.205 Furthermore, these enzymes have in general low catalytic efficiencies 
compared with e.g. hydrolases and maximum activities in in vivo biotransformations over 10-15 h 
normally do not exceed 50 U g-1 cdw. Other limiting factors for activity include the transport of 
substrate and product between the apolar liquid or solid phase and the biocatalyst containing aqueous 
phase, substrate uptake and product export by whole cell biocatalysts, cofactor regeneration rates, 
uncoupling as well as oxygenase expression levels in native or heterologous hosts.205 As also 
observed for NDO, BDO and CDO, expression levels of ROs are usually low and an increase in 
protein concentration would be beneficial to obtain significantly higher whole cell oxygenase activities.  
 
4.4. RO-catalyzed alkene oxyfunctionalization versus Sharpless AD and Riley 
oxidation – Benefits and limitations 
4.4.1. Sharpless AD 
Due to the inherent disadvantages of heavy metal catalysts, the aim of this project was to provide a 
sustainable biocatalytic alternative to the oxyfunctionalization of alkenes by chemical means. For the 
AD of olefins, the osmium(VIII)-oxide-catalyzed variant developed by Sharpless and coworkers is still 
the method of choice due to its broad substrate scope and the good to excellent stereoselectivities 
that are obtained for five of the six alkene types (mono-, gem-di-, trans-di-, tri- and tetra-substituted 
alkenes).7 Yet, with regard to atom economy, toxicity, side-product formation and catalyst 
stoichiometry, an enzymatic route would be advantageous. 
To be able to compare the RO-mediated dihydroxylation of olefins against Sharpless AD, the selected 
substrate panel comprised mono- (1, 2, 5), gem-di- (5, 7), cis-di- (3, 4) and tri-substituted alkenes 
(5, 6, 7). While the examined wild type enzymes still showed major disadvantages compared to the 
osmium(VIII)-oxide-catalyzed AD, enzyme engineering improved the performance regarding both 
product formation and selectivity of ROs with ee values that were comparable to Sharpless AD for 
several of the tested olefins (Table 22). Furthermore, next to the selective dihydroxylation of alkene 
C=C double bonds, also aromatic systems can be regioselectively targeted with RO enzymes and 
even though the stereoselectivities for product 1b were not determined, data from literature suggest 
that such arene-1,2-dihydrodiols are normally formed with excellent ee values > 98%.20,64 In contrast 
to the AD of alkenes, this reaction is not known to possess a chemical equivalent, further highlighting 
the potential of ROs for asymmetric synthesis.51 
From the selected alkene panel, in particular compounds 5 and 6 proved to be interesting substrates 
for the RO-catalyzed dihydroxylation. Herein, terpene 6 was a challenging substrate not only for 
Sharpless AD under standard reaction conditions.163 Also for wild type ROs, the spatial structure of 6 
with various methyl groups in combination with the sterically hindered tri-substituted C=C double bond 
presumably makes this olefin hard to accommodate in a substrate binding pocket evolved for planar 
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aromatic compounds. Nevertheless, enlarging the size of the active site in CDO M232A enabled 
productive binding of 6. With both the biocatalytic as well as the osmium(VIII)-oxide-catalyzed AD, the 
(1S,2S,3R,5S)-(+)-isomer was obtained with excellent stereoselectivities. As with osmium(VIII)-oxide, 
no chiral ligands were required to induce the high stereoselectivities,163,200 the steric hindrance of the 
substrate might favor attack from only one side, promoting the high de values obtained with chemical 
as well as biocatalytic means. For polyene 5, the regioselectivity of Sharpless AD is determined both 
by electronic and steric effects. Herein, electronic factors greatly influence the regioselectivity and the 
osmylation of unsymmetrical polyenes preferentially occurs at the most electron-rich double bond.7,209 
Due to the +I-effect, the tri-substituted C=C double bond of 5 was attacked and diol 5b was the only 
product obtained. In contrast, in RO-catalyzed biotransformations, all alkene bonds of the substrate 
could be targeted yielding excellent stereoselectivities > 95% with the different enzymes (Table 22). 
Yet, regioselectivities were rather poor and will have to be improved as product mixtures were 
obtained. The low regioselectivities, partially caused by the RO-catalyzed formation of allylic alcohols, 
was one of the major disadvantages when comparing the biocatalytic and Sharpless AD. Yet, as 
shown for the dihydroxylation of 1, regioselectivities can be improved by enzyme engineering as they 
are dependent on the positioning and orientation of the substrate in the active site of the enzyme. In 
contrast, regioselectivities for the Sharpless AD are not only dependent on steric effects but also 
greatly rely on the electronic properties of the substrate. Due to its electrophilic nature, osmium(VIII)-
oxide will preferentially attack the most electron rich double bond when applied under heterogeneous 
conditions with potassium ferricyanide as oxidant.7 
 
Table 22: Stereoselectivities obtained by Sharpless AD employing the most suitable chiral ligands compared to 
best stereoselectivities determined with examined ROs.  
Product 
Stereoselectivities ee or de [%] 
RO-catalyzed AD Sharpless AD 
1a 95 (R) 99 (R)176 
2a > 98 (R)  96 (R)176,177 
4b 
76 (1R,2S) 
57 (1S,2R) 
63 (1R,2S)177 
34 (1S,2R)23 
5b[a] > 95 (n.d.) - 
5c > 95 (R) > 95[b] 
5d[a] > 95 (n.d.) - 
6a > 95 (1S,2S,3R,5S) > 95 (1S,2S,3R,5S)[b]  
[a]KMnO4-mediated dihydroxylation gives the racemic mixture and thus, 
absolute configurations could not be determined. [b] this study. 
-: the product was not formed in the OsO4-catalyzed AD under standard 
conditions. 
Whereas cis-di-substituted alkenes can be oxidized with low to moderate stereoselectivities by 
Sharpless AD even when employing the best suitable chiral ligands,24,177 examples have been 
reported in literature for the RO-catalyzed dihydroxylation of these alkenes with excellent 
stereoselectivities (e.g. methylindene or cyclohexadiene).75 However, the cis-di-substituted alkene 4 
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was a challenging substrate for RO-catalyzed biotransformations and highest stereoselectivities for 4b 
were obtained with NDO giving 76% ee. Despite these moderate ee values, the RO-catalyzed 
oxidation of 4 proved to be interesting as both enantiomers could be targeted, normally representing a 
weakness of biocatalysis in asymmetric synthesis.52 Like AD-mix α or β which can be employed 
depending on the desired enantiomer, ROs and generated variants thereof gave comparable 
selectivities to Sharpless AD for both enantiomers (Table 22).  
Considering that Sharpless AD has been continuously improved for decades with regard to its ligands, 
oxidants and process conditions,4,7,210 with further engineering it might also be possible to turn ROs 
into more efficient catalyst for the AD of olefins. Even though in this project, only a limited number of 
seven alkenes was examined, the selected compounds included structurally highly diverse olefins with 
different alkene types. For this panel, it was demonstrated that the introduction of a single point 
mutation proved to be sufficient to transform wild type ROs into efficient catalysts with enhanced 
stereoselectivities and product formations. Furthermore, the feasibility of engineered RO variants for 
semi-preparative biotransformations could be shown. Especially the up-scaling of the Sharpless AD is 
difficult regarding the formation of undesired waste products. Even though both AD-mixes contain 
osmium(VIII)-oxide in its less volatile form as potassium salt, potassium ferricyanide employed as 
oxidant for catalyst regeneration is also a highly toxic waste product in the process.11 
 
4.4.2. Riley oxidation 
Besides the AD of C=C double bonds, the oxidation of allylic carbon centers is catalyzed during the 
RO-mediated oxyfunctionalization of alkenes. This reaction is of interest as the allylic hydroxylation of 
C-H bonds can chemically still only be reliably achieved by stoichiometric amounts of SeO2.211 Next to 
its toxicity, SeO2-mediated reactions show poor regioselectivity for substrates with multiple allylic 
positions displaying similar electronic properties. Therefore, the regiospecific introduction of hydroxyl 
groups into 7 by chemical means has proven difficult due to the similarity of the allylic methylene (C-3 
and C-6) and methyl groups (C-7 and C-10), yielding a product mixture of limonene-4-ol, trans- and 
cis-carveol, perillyl alcohol and limonene-10-ol.212 In contrast, the RO-catalyzed allylic hydroxylation of 
(R)-7 occurred with good regioselectivity and excellent stereoselectivity at C-6 of the substrate.  
 
 
Scheme 19: Allylic hydroxylation of aliphatic substrates either catalyzed by SeO2 (Riley oxidation) or by ROs. 
Employing less challenging substrates than terpene 7, the SeO2-mediated allylic oxidation showed 
improved regioselectivities and oxidation of olefin 5 gave exclusively the (E)-isomer of alcohol 5a as 
generally described for tri-substituted alkenes.213 In contrast, the biocatalytic oxidation yielded the 
(Z)-isomer, a compound naturally present in thyme oil.161 
However, due to competing diol formation for several of the examined substrates, ROs still display 
disadvantages concerning the allylic oxidation of alkenes. While most of the research concerning 
these enzymes has focused on the AD of substrates, the exact mechanism as well as factors 
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controlling monohydroxylation versus dihydroxylation still have to be elucidated. Except for the 
oxyfunctionalization of (R)-7 yielding 7b with good regioselectivity, the allylic oxidation by ROs needs 
to be further improved to avoid the formation of product mixtures. Yet, with further enzyme engineering 
to control the regioselectivity of the reaction, ROs might have the potential to also become a 
sustainable alternative to Riley oxidation. 
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5. CONCLUSIONS AND OUTLOOK 
Despite their broad substrate scope, most of the research concerning RO-catalyzed 
oxyfunctionalizations has focused on the dihydroxylation of aromatic compounds and limited data is 
available for the oxidation of unnatural substrates by this class of enzymes. Thus, in the present work, 
the applicability of ROs for the oxidation of a broad range of structurally diverse olefins was 
demonstrated. Their large hydrophobic substrate binding pocket enables these enzymes to convert a 
variety of alkenes, lacking the planar structure of the aromatic compounds that are naturally oxidized. 
This active site feature might account for the versatility of ROs with respect to substrate specificity but 
also catalyzed reactions. Different substrate positioning in the active site with either the C=C double 
bond or the allylic/ benzylic carbon of the substrate oriented close to the non-heme iron center 
presumably results in the formation of diverse reaction products. 
The low stereoselectivities and conversion rates displayed by the wild type enzymes could be 
overcome by the introduction of a single targeted point mutation that was identified based on 
sequence and structural comparisons with a member of the RO family. The generated BDO and CDO 
variants displayed remarkable changes in regio- and stereoselectivities for different aliphatic 
compounds. Especially the CDO variant M232A resulted in excellent ee values ≥ 95% for linear 
alkenes, which have been reported to be challenging substrates for RO-catalyzed 
oxyfunctionalizations.74,75 Site-saturation mutagenesis of position 232 in CDO using the NDT codon 
degeneracy revealed a correlation between the steric demand of the introduced amino acid residue 
and its influence on regio- and/ or stereoselectivity for the tested olefin substrates. For indene 
biooxidation, enantiocomplementary enzymes were generated by the single point mutation, 
overcoming the weakness of biocatalysts that lack the presence of mirror-image enzymes for the 
formation of either enantiomer of a product.94 These data support the importance of position M232 for 
the engineering of ROs, a fact that is further highlighted by its location at a variable position 
(underlined) in the conserved motif N-W-K-x(3)-[ED]-[NQ]-x(3)-[DE]-x-Y-H which is specific for this RO 
superfamily. 
Biocatalysts that accept a wide range of substrates to regioselectively form optically pure products are 
of particular interest for synthetic organic chemistry.144 Yet, for compounds like cyclohexene, myrcene 
or indene, the regio- as well as stereoselectivities obtained with RO enzymes are still a subject for 
further improvements and additional positions for mutagenesis should be identified to increase the 
selectivity for the oxidation of alkenes. One starting point towards more selective ROs might be the 
mutation of the remaining variable residues found in the conserved motif. Since these positions differ 
within the specific RO superfamily, they might contribute to diverse selectivities or activities. Using an 
alanine scanning approach, their influence on enzyme properties can be determined. In addition, the 
combinatorial active-site saturation test (CAST)214 could be performed to examine additive or 
synergistic effects, neighboring positions of M232 might have on enzyme properties in order to 
generate variants with increased regioselectivity for the above mentioned substrates. Modification of 
the active site topology to allow the binding of these compounds in only one defined orientation would 
give the desired products with high regio- and stereospecificities. Furthermore, mono- and 
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dihydroxylation of substrates might be controlled by creating variants that only catalyze one reaction 
type, yielding either the allylic alcohol or the diol.  
Next to enzyme engineering, mono- versus dihydroxylation might also be guided by substrate design. 
Interestingly, for the conjugated olefin 1,3-cyclohexadiene, no competing allylic monohydroxylation has 
been described for biotransformations with NDO.75 This result is in contrast to the NDO-mediated 
oxidation of cyclohexene that was tested in this work and yields both the diol as well as the allylic 
alcohol, indicating that the type of catalyzed reaction might be influenced by the substrate structure. 
Due to their versatile reaction spectrum and broad substrate scope, ROs have often been described 
as the non-heme iron analogues to cytochrome P450 monooxygenases.215 Even though several of the 
different reaction types including sulfoxidations, dealkylations, epoxidations and allylic hydroxylations 
are catalyzed by both enzyme classes, other reactions performed by P450 monooxygenases cannot 
be targeted with ROs to date (Figure 29).93,216,217 By substrate screening with different ROs in 
combination with enzyme engineering or directed evolution, RO enzymes catalyzing novel types of 
reactions like the oxidation of unactivated C-H bonds might be generated. 
 
 
Figure 29: Reaction types catalyzed by P450 monooxygenases and ROs.83,93,216,217 While the reaction spectrum 
of both enzyme classes partly overlaps, other reaction types are only catalyzed by either P450 monooxygenases 
or ROs. 
Besides their broad substrate and reaction scope, another feature shared by ROs and P450 
monooxygenases is the uncoupling of NAD(P)H consumption and substrate oxidation in the presence 
of compounds lacking a productive binding mode in the active site.192,201 Next to H2O2 formation which 
can inactivate the enzyme, uncoupling also leads to a loss of reducing equivalents from the host cell 
and an increased oxygen demand as well as a lowered specific activity with regard to product 
formation.205 For the oxyfunctionalization of the alkene substrate panel examined in this study, the 
extent of H2O2 production was not determined. However, as uncoupling has been described to 
constitute ~40-50% of the total O2 consumption for benzene oxidation with NDO,201 it might also occur 
for the reactions performed within this study. Whereas for ROs no data is available from literature, the 
reduction of uncoupling due to inappropriate positioning of the substrate in the enzyme active site by 
protein engineering or directed evolution has been reported for P450 monooxygenases.205 This 
approach might also be applicable to ROs, diminishing potential H2O2 formation during the 
biotransformation of olefin substrates and hence increase product formation. 
Another strategy to enhance product formation having been described for P450 monooxygenases is 
the generation of functional fusion proteins between the redox partners and the oxygenase. Linking 
the single components for more efficient electron transport or higher expression levels due to a better 
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coordination of transcription and translation has been successfully applied, resulting in an increased 
substrate oxidation.218 Also for CDO, a covalent linkage of the reductase and ferredoxin on the gene 
level proved to be successful and enzyme activity could be reconstituted with the fused redox partners 
(data not shown). Thus, linkage of the redox construct with the terminal oxygenase component might 
be performed and compared with the physiological three component system.  
In general, the choice of the redox partners (physiological or artificial) and their fusion to the 
oxygenase component has been assumed not to affect the type and selectivity of reactions catalyzed 
by P450 monooxygenases. Yet, the group of Li recently reported different reaction types dependent if 
the P450 enzyme was linked with its surrogate redox partner or present as free component.216 This 
example highlights the potential role of redox partner protein-protein-interactions in modulating the 
catalytic activity of P450 monooxygenases216 and might also be applicable to other oxygenase 
multicomponent enzymes like ROs. 
Next to biotransformations in analytical scale, the preparative oxidation of (+)-α-pinene and 
(R)-limonene with isolated product yields in mg and g scale was successfully performed. These results 
indicate that ROs can provide a biocatalytic access to both the asymmetric cis-dihydroxylation and the 
regio- and stereoselective allylic monohydroxylation of various alkenes, targeting also products that 
are difficult to access by Sharpless AD or Riley oxidation. Several of the biotransformation products 
generated in this study are interesting building blocks for organic synthesis or might be applied in the 
flavor and fragrance industry, including carveol, the biooxidation products of myrcene as well as 
pinanediol.161,163,178 
Besides cis-diols and allylic alcohols, the formation of additional building blocks might be targeted by 
the integration of ROs into enzyme cascades (Scheme 20). Starting from alkenes, the combination of 
ROs with ADHs to selectively obtain the corresponding hydroxy ketones from cis-diols would be one 
possibility. These oxidations might be further coupled with ω-transaminases (ω-TAs) to yield optically 
pure amino alcohols in a process similar to the work described by Kroutil and coworkers.219  
 
 
Scheme 20: Enzymatic cascade involving ROs, ADHs and ω-TAs for the generation of amino alcohols starting 
from alkenes. PLP: pyridoxal-5’-phosphate, PMP: pyridoxamine-5‘-phosphate. 
Even though still not always competitive with respect to selectivity and product formation, with further 
optimization, engineered ROs can provide an enzymatic approach to valuable building blocks for the 
chemical and pharmaceutical industry. Therefore, these enzymes offer a sustainable alternative to 
existing chemical routes as targeted by CHEM21.  
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7. SUPPLEMENTARY 
7.1. Plasmids 
Table S23: Plasmid constructs encoding for different ROs and variants thereof used in this work. 
Name Gene insert ITB No. 
pDTG141 NDO operon: oxygenase, ferredoxin and reductase pITB1009 
pDTG141_A206M NDO operon with oxygenase variant A206M  - 
pDTG141_A206I NDO operon with oxygenase variant A206I pITB1010 
pJRM501 BDO operon: oxygenase, ferredoxin and reductase pITB1014 
pJRM501_M220A BDO operon with oxygenase variant M220A pITB1015 
pIP107D CDO operon: oxygenase, ferredoxin and reductase pITB1011 
pIP107D_M232A CDO operon with oxygenase variant M232A pITB1012 
pIP107D_M232G CDO operon with oxygenase variant M232G pITB1253 
pIP107D_M232F CDO operon with oxygenase variant M232F pITB1254 
pIP107D_M232L CDO operon with oxygenase variant M232L pITB1255 
pIP107D_M232I CDO operon with oxygenase variant M232I pITB1256 
pIP107D_M232V CDO operon with oxygenase variant M232V pITB1257 
pIP107D_M232Y CDO operon with oxygenase variant M232Y pITB1258 
pIP107D_M232H CDO operon with oxygenase variant M232H pITB1259 
pIP107D_M232N CDO operon with oxygenase variant M232N pITB1260 
pIP107D_M232D CDO operon with oxygenase variant M232D pITB1261 
pIP107D_M232C CDO operon with oxygenase variant M232C pITB1262 
pIP107D_M232S CDO operon with oxygenase variant M232S pITB1263 
pIP107D_F278A CDO operon with oxygenase variant F278A - 
pIP107D_F278C CDO operon with oxygenase variant F278C - 
pIP107D_I288V CDO operon with oxygenase variant F288V - 
pIP107D_I288P CDO operon with oxygenase variant I288P - 
pIP107D_I336V CDO operon with oxygenase variant I336V - 
pIP107D_F378S CDO operon with oxygenase variant F378S - 
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7.2. Sequencing primers  
Table S24: Primers used for sequencing of RO genes in the plasmid constructs. As RO operons were large in 
size, several primers had to be used for complete sequencing of the gene insert. fwd: forward primer, 
rev: reverse primer. 
Primer name Sequence 
pIP107D lacP_fwd 5’-GGCTTTACACTTTATGCTTCCG-3’ 
pIP107D 1_fwd 5’-GTGACAAAAAAGAGGGTGACTG-3’ 
pIP107D 2_fwd 5’-GGTCTTTCATCGTAGTGGATGC-3’ 
pIP107D 3_fwd 5’-CAGAAATGCCCGTCAGTCTTG-3’ 
pIP107D 4_fwd 5’-GCCAATCTCCTCGGGACTTTGC-3’ 
pIP107D 5_fwd 5’-GCATTTTCCGAGTGCGTAC-3’ 
pIP107D 6_fwd 5’-GCCTACGACCGACTGCTATTAG-3’ 
pIP107D 7_fwd 5’-CCATGTTAGGCAAGTCTATCCC-3’ 
pIP107D 8_rev 5’-GCTTTGACGTATGCGGTGTG-3’ 
pDTG141 T7P_fwd 5’-TAATACGACTCACTATAGGG-3’ 
pDTG141 1_fwd 5’-GCCGACGAAATTGTCACTCAC-3’ 
pDTG141 2_fwd 5’-GCGATGGTTGAAGCGTTG-3’ 
pDTG141 3_fwd 5’-GGTAAGTGAATCTGGTCTGAGC-3’ 
pDTG141 4_fwd 5’-GCAAATGACCTCCAAATACGG-3’ 
pDTG141 5_fwd 5’-CTC CAA CTGGGCTGAGTTC-3’ 
pDTG141 6_fwd 5’-AAGCATTGGTAACTGTCAGACC-3’ 
pJRM501 pKK223-3_fwd 5’-CGACATCATAAC GGTTCTGGC-3’ 
pJRM501 1_fwd 5’-GAAGACCAGTGAGATAGAAACG-3’ 
pJRM501 2_fwd 5’-GGAAATTCGCAGCAGAGCAG-3’ 
pJRM501 3_fwd 5’-GCTGAAAATGATGACCTCACC-3’ 
pJRM501 4_fwd 5’-CGCAATCGCTTGGAAAGACAAC-3’ 
pJRM501 5_fwd 5’-CTTCCCTATGACCGACCATCC-3’ 
pJRM501 6_fwd 5’-GTTTGGAATGTGATCGTGGTG-3’ 
pJRM501 7_fwd 5’-CAGAAAAGCTGGCAGATGTGTC-3’ 
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7.3. Genes 
NDO gene cluster (nahAa  nahAb  nahAc  nahAd) 
NCBI reference sequence:NC_004999.1 
 
ATGGAACTCCTCATACAACCGAACAATCGCATAATTCCCTTCAGTGCCGGTGCCAACCTTCTGGAAGTGCTTC
GCGAGAACGGTGTAGCTATTTCCTACAGTTGCTTGTCTGGGCGTTGCGGAACCTGTCGCTGCCGGGTTATAG
ATGGCAGTGTCATTGATTCTGGGGCGGAAAATGGGCAATCAAACCTCACCGACAAGCAGTATGTGCTCGCCT
GTCAGTCAGTACTCACTGGCAATTGCGCTATCGAAGTCCCAGAAGCCGACGAAATTGTCACTCACCCGGCGC
GAATCATCAAGGGCACAGTGGTCGCAGTCGAGTCGCCCACTCACGATATCCGTCGCTTACGCGTACGCCTC
TCCAAGCCCTTCGAGTTCTCACCCGGACAGTACGCGACACTGCAGTTCAGCCCTGAGCATGCGCGTCCGTA
TTCAATGGCAGGTTTGCCAGATGACCAAGAAATGGAGTTCCACATACGCAAGGTGCCGGGTGGGCGCGTCA
CGGAGTATGTTTTCGAACACGTCCGCGAAGGTACAAGCATCAAGTTGAGCGGGCCTCTTGGTACGGCTTATC
TACGTCAGAAGCACACCGGACCGATGCTGTGTGTAGGTGGCGGGACCGGACTCGCACCGGTGCTGTCGATT
GTTCGCGGCGCGCTGAAGTCGGGTATGACGAACCCCATCCTCCTTTATTTCGGGGTGCGCAGTCAGCAAGA
CCTCTACGACGCAGAGCGATTGCACAAACTCGCCGCTGACCACCCTCAACTGACCGTACACACGGTGATTG
CAACGGGCCCGATTAATGAGGGTCAGCGAGCCGGCCTAATTACCGATGTGATCGAAAAAGACATCCTTTCGC
TGGCTGGGTGGAGGGCCTACCTGTGCGGCGCACCAGCGATGGTTGAAGCGTTGTGCACCGTCACCAAGCA
TCTTGGAATATCACCCGAACATATTTATGCCGATGCCTTCTATCCCGGTGGGATCTGAATAGTTCCCGGCCAT
GCACCTCTGTCCATCGAGAATTCATCAGGAAGACATTCAAATGAACGTAAACAATAAGGGCAGCGTCTGTATT
TGCGGCAGCGAAATGCTCCCTAAATTCCTCATTTACCCCATCTGAGGATTGCTTTATGACAGTAAAGTGGATT
GAAGCAGTCGCTCTTTCTGACATCCTTGAAGGTGACGTCCTCGGCGTGACTGTCGAGGGCAAGGAGCTGGC
GCTGTATGAAGTTGAAGGCGAAATCTACGCTACCGACAACCTGTGCACGCATGGTTCCGCCCGCATGAGTG
ATGGTTATCTCGAGGGTAGAGAAATCGAATGCCCCTTGCATCAAGGTCGGTTTGACGTTTGCACAGGCAAAG
CCCTGTGCGCACCCGTGACACAGAACATCAAAACATATCCAGTCAAGATTGAGAACCTGCGCGTAATGATTG
ATTTGAGCTAAGAATTTTAACAGGAGGCACCCCGGGCCCTAGAGCGTAATCACCCCCATTCCATCTTTTTTAG
GTGAAAACATGAATTACAATAATAAAATCTTGGTAAGTGAATCTGGTCTGAGCCAAAAGCACCTGATTCATGG
CGATGAAGAACTTTTCCAACATGAACTGAAAACCATTTTTGCGCGGAACTGGCTTTTTCTCACTCATGATAGC
CTGATTCCTGCCCCCGGCGACTATGTTACCGCAAAAATGGGGATTGACGAGGTCATCGTCTCCCGGCAGAA
CGACGGTTCGATTCGTGCTTTTCTGAACGTTTGCCGGCATCGTGGCAAGACGCTGGTGAGCGTGGAAGCCG
GCAATGCCAAAGGTTTTGTTTGCAGCTATCACGGCTGGGGCTTCGGCTCCAACGGTGAACTGCAGAGCGTT
CCATTTGAAAAAGATCTGTACGGCGAGTCGCTCAATAAAAAATGTCTGGGGTTGAAAGAAGTCGCTCGCGTG
GAGAGCTTCCATGGCTTCATCTACGGTTGCTTCGACCAGGAGGCCCCTCCTCTTATGGACTATCTGGGTGAC
GCTGCTTGGTACCTGGAACCTATGTTCAAGCATTCCGGCGGTTTAGAACTGGTCGGTCCTCCAGGCAAGGTT
GTGATCAAGGCCAACTGGAAGGCACCCGCGGAAAACTTTGTGGGAGATGCATACCACGTGGGTTGGACGCA
CGCGTCTTCGCTTCGCTCGGGGGAGTCTATCTTCTCGTCGCTCGCTGGCAATGCGGCGCTACCACCTGAAG
GCGCAGGCTTGCAAATGACCTCCAAATACGGCAGCGGCATGGGTGTGTTGTGGGACGGATATTCAGGTGTG
CATAGCGCAGACTTGGTTCCGGAATTGATGGCATTCGGAGGCGCAAAGCAGGAAAGGCTGAACAAAGAAAT
TGGCGATGTTCGCGCTCGGATTTATCGCAGCCACCTCAACTGCACCGTTTTCCCGAACAACAGCATGCTGAC
CTGCTCGGGTGTTTTCAAAGTATGGAACCCGATCGACGCAAACACCACCGAGGTCTGGACCTACGCCATTGT
CGAAAAAGACATGCCTGAGGATCTCAAGCGCCGCTTGGCCGACTCTGTTCAGCGAACGTTCGGGCCTGCTG
GCTTCTGGGAAAGCGACGACAATGACAATATGGAAACAGCTTCGCAAAACGGCAAGAAATATCAATCAAGAG
ATAGTGATCTGCTTTCAAACCTTGGTTTCGGTGAGGACGTATACGGCGACGCGGTCTATCCAGGCGTCGTCG
GCAAATCGGCGATCGGCGAGACCAGTTATCGTGGTTTCTACCGGGCTTACCAGGCACACGTCAGCAGCTCC
AACTGGGCTGAGTTCGAGCATGCCTCTAGTACTTGGCATACTGAACTTACGAAGACTACTGATCGCTAACAG
ACGAGTCGACCATGATGATCAATATTCAAGAAGACAAGCTGGTTTCCGCCCACGACGCCGAAGAGATTCTTC
GTTTCTTCAATTGCCACGACTCTGCTTTGCAACAAGAAGCCACTACGCTGCTGACCCAGGAAGCGCATTTGTT
GGACATTCAGGCTTACCGTGCTTGGTTAGAGCACTGCGTGGGGTCAGAGGTGCAATATCAGGTCATTTCACG
CGAACTGCGCGCAGCTTCAGAGCGTCGTTATAAGCTCAATGAAGCCATGAACGTTTACAACGAAAATTTTCA
GCAACTGAAAGTTCGAGTTGAGCATCAACTGGATCCGCAAAACTGGGGCAACAGCCCGAAGCTGCGCTTTA
CTCGCTTTATCACCAACGTCCAGGCCGCAATGGACGTAAATGACAAAGAGCTACTTCACATCCGCTCCAACG
TCATTCTGCACCGGGCACGACGTGGCAATCAGGTCGATGTCTTCTACGCCGCCCGGGAAGATAAATGGAAA
SUPPLEMENTARY 
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CGTGGCGAAGGTGGAGTACGAAAATTGGTCCAGCGATTCGTCGATTACCCAGAGCGCATACTTCAGACGCA
CAATCTGATGGTCTTTCTGTGA 
 
CDO gene cluster (cumA1  cumA2  cumA3  cumA4) 
GenBank: D37828.1 
 
ATGAGTTCAATAATAAATAAAGAAGTGCAGGAAGCCCCTTTGAAATGGGTGAAAAACTGGTCTGACGAGGAG
ATTAAAGCGCTCGTTGATGAGGAAAAGGGGTTGCTTGATCCACGTATTTTCTCTGATCAGGATTTGTATGAGA
TCGAGCTTGAGAGGGTGTTTGCTCGATCCTGGCTGCTGCTTGGGCACGAGGGGCACATTCCCAAAGCCGGG
GATTATCTGACCACCTACATGGGTGAAGACCCAGTAATTGTAGTGAGGCAGAAAGACCGGAGCATTAAAGTC
TTTTTAAACCAATGTCGGCATCGCGGTATGCGTATTGAGCGATCGGATTTTGGCAACGCAAAGTCATTTACCT
GCACTTATCACGGGTGGGCCTATGACACCGCCGGTAATCTGGTCAATGTACCCTACGAGAAAGAGGCTTTTT
GTGACAAAAAAGAGGGTGACTGCGGGTTCGACAAGGCCGACTGGGGGCCGCTGCAAGCGCGGGTGGATAC
TTACAAGGGGCTGATTTTTGCCAACTGGGATACCGAAGCCCCTGATTTGAAGACCTATCTGAGCGATGCAAC
ACCCTATATGGACGTGATGCTCGATCGGACCGAGGCAGTTACTCAGGTCATCACCGGTATGCAAAAGACGGT
AATCCCCTGTAACTGGAAATTCGCCGCCGAGCAATTCTGTAGCGATATGTACCATGCGGGAACGATGGCGCA
TCTTTCAGGTGTATTGTCCAGCCTCCCGCCTGAAATGGATTTGTCCCAAGTAAAGTTACCGTCAAGTGGGAAT
CAGTTCCGGGCTAAGTGGGGTGGACATGGGACCGGCTGGTTCAATGACGATTTCGCACTTCTGCAAGCCAT
CATGGGTCCTAAGGTTGTCGATTACTGGACCAAAGGTCCAGCTGCTGAGCGTGCAAAAGAGCGTCTGGGTA
AAGTTCTTCCGGCTGATCGCATGGTTGCTCAGCATATGACCATTTTTCCGACATGCTCATTTCTTCCTGGCAT
CAATACAGTCCGTACTTGGCACCCACGTGGCCCTAATGAGATCGAAGTTTGGTCTTTCATCGTAGTGGATGC
TGATGCACCTGAAGATATCAAGGAAGAATATCGTCGGAAAAACATCTTCACCTTCAATCAAGGGGGAACCTAC
GAGCAGGACGATGGCGAAAACTGGGTGGAGGTTCAGCGGGGATTGCGCGGCTACAAGGCTAGAAGTAGAC
CTCTTTGTGCCCAGATGGGGGCGGGTGTGCCAAACAAGAACAACCCGGAGTTTCCTGGAAAGACCAGCTAC
GTTTATAGCGAAGAAGCTGCGCGAGGGTTCTACCACCACTGGAGCCGCATGATGTCCGAGCCGAGTTGGGA
CACGCTAAAGTCTTGAGCAGATAAAGTGACCGAAAAAAGCAATCACTTTCATCGGGTTTCTACCGTGGTAGAC
AAGGGTTTAGCCTGTTTTTTGGTTGCTGGAAGTGCCTAAGTGAATTGATTAACTTGGGTAAACCCCTGGCTTT
GTCGGGGGTATTTACTCGGGTGCATTCCAAAATGTACAGCTGTGCGTTTGGTGATAATCGTCATGCTATGGA
TTTGCTATTTGCATGAGCCGAGTGCAGGTCGCCCAACATATATACAGGAAACTAATTATGACATCCGCTGATT
TGACAAAACCCATCGAGTGGCCAGAAATGCCCGTCAGTCTTGAATTGCAAAATGCCGTTGAGCAATTCTACTA
TCGCGAAGCACAGTTGCTTGATTATCAAAACTATGAGGCCTGGCTGGCTTTACTGACCCAAGACATCCAATAT
TGGATGCCAATTCGTACTACTCATACATCCCGGAATAAGGCGATGGAGTACGTGCCCCCCGGCGGTAATGC
CCATTTTGACGAGACGTATGAGAGCATGCGTGCGCGCATTCGGGCGAGGGTTTCGGGGCTTAACTGGACTG
AAGATCCACCGTCGCGCAGCCGGCACATTGTAAGCAACGTTATCGTCCGCGAAACTGAGAGTGCTGGTACTT
TGGAAGTTAGTTCTGCGTTCCTTTGTTACCGTAATCGATTGGAGCGTATGACGGACATCTATGTCGGTGAGC
GTCGAGATATTTTGCTCCGTGTAAGTGACGGGCTGGGATTCAAAATTGCCAAGCGAACGATCTTGCTCGACC
AGAGCACGATTACAGCGAATAATCTCAGCCAGTTTTTCTAACTAGGGAATGCTGGCCACTTACCCTATACCCA
GCCTATTCATGAGAGCGGCCTGAAAATGAAGAGGAGCTACCCGATAGCTACGCAAACTAATCGCGCTCGCC
CTTTCCTGATCGCGATCGGTATCTTTTACTTGGCCAATCTCCTCGGGACTTTGCATTTCAGCAGCCTGCGGCT
GTTCGGCATGATGTATTCGGGTGTGGATTTGCAGGTCGGCGCTCCGGTATTCACCCTGCTGCAGGATGCCT
GGGCCGTAGTCGGGCTGCAGCTGGGGGGCACTGGGCTGGTTGCGTTGTGGGGCGCACGTCAGCCCGTGC
GCTTCATGGCGGTTGTCCCCGTGGTCATCGTCACGGAAGTGCTCGACGGTATCTGGGACTTGTACAGCATC
GTTTGGAGTCACGAAGCCATGTGGTTCGGGCTCCTGACGTTCGCCATCCACGTGGTGTGGATCGTCTGGGG
GTTACAGGTATGGCGCGTGTCGTCTCGCCGGTCATCTGGCTTAACCGTCCCAACCTCCTGAATCTGTGGGC
CTGAATTGAACTCTGTCATTTCCCATGCGCGTCGACGTTATCCGGCCGCTTGCGCCAAGCTGGCTGCCGGAT
TTAATGAGTAGTTAAAGTTAGCTATAGAAACTCTGAAAAAGGCTTGACCTCATGAGATATCCAGTCTGCAGTC
CGCGTGGTTACTGGCGTGCATTTTCCGAGTGCGTACTTTTTCAGACCAACTCTATAATAAGAGACAAAAAAGA
ATGACTTTTTCCAAAGTTTGTGAAGTATCTGATGTGCCCGTCGGTGACGCCTTGCAGGTTGAAAGTAAGGGC
GAAGCCGTCGCGATTTTCAACGTCGATGGAGAGTTGTTCGCAACACAGGACCGTTGCACTCATGGTGACTG
GTCCTTGTCCGAAGGCGGCTACCTAGAGGGTGACATTGTCGAATGCTCGCTGCACATGGGTAGGTTCTGTG
TCCGCACGGGCAAGGTAAAAGCAGCACCGCCCTGTGAGCCGCTGAAGATATATCCGATTCGAATAGATGGC
AGCGATGTGTTCGTAGACTTTGATGCCGGGTATCTAGCGCCATGATTAAATCAATCGTCATTATTGGTGCTGG
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CTTGGCTGGCGCAACTGCCACTCGCTATCTTCGCGCCCAAGGATATCAGGGAAAGATCCATCTGGTCGGGG
AGGAGTTGCATGTGGCTTACGATCGCCCCTCCTTATCCAAGGACACCCTGTCAGGAAAAGTGGTCGAACCAC
CCGCAATCCTGGATCCTTGTTGGTATGCATCGGCCGATATAGATCTCCATTTAGGTGTACGCGTGACCGGTA
TTGATGTGGTAAACCACCAGGTACTTTTCGAATCCGGTGACATTCTAGCCTACGACCGACTGCTATTAGCCAC
CGGCGCTCGCGCGCGGCGTATGGCTATTACGGGAAGCGAGTTGGCCGGCATTCACACCTTGCGTGACCGC
GCCGACAGCCAGGCGCTGAGGCAGGCGCTTGAGCCGGGCCAGTCTCTGGTAATTGTCGGCGGTGGCCTGA
TCGGTTGCGAAGTGGCGACCACTGCTATTAATGCCGGTGCCCACGTCACTGTTCTGGAGGCCGGGGACGAA
CTGCTGTTGCGAGTGCTAGGCCGATCAACCGGGGCCTGGTGTCGCAACGAGTTGGAGCGTTTGGGTGTCC
GGGTTGAACTGAACGCACAGGCAGCGCATTTCGAGGGCGAGGGACACGTGCATGCCGTCGTTTGTGCCGAT
GGACGTCGGATAGCAGCTGGCACAGTTTTGGTGAGCATCGGTGCAGAACCAGCCGACGAACTGGCACGTG
CGGCCGGTATCGCATGTGAGCGCGGCGTGGTAGTTGACGCTACGGGTGCAAGCTCATGTCCTGCAGTATTC
GCGGCAGGTGACGTAGCAGCCTGGCCCCTGAGGTCCGGTGAACTGCGCTCGCTGGAGACCTACCTGAACA
GCCACATGCAGGCTGAAACTGCCGCCGCGGCCATGTTAGGCAAGTCTATCCCGGCTCTTCAGGTGCCAACC
TCTTGGACGGAGATTGCAGGGCATCGGATACAGATGGTTGGCGACATCGAAGGCCCCGGAGAAGTTGTCTT
GCGCGGTAACGTCGAGAATGGTCAGCCGCTGGTGCAGTTCAGGGTTCTTGATGGTCGCGTTGAAGCCGCAA
CGGCTATCAATGCCCCGGAAGATTTTCCCGTTGCAACCCGATTGGTGGCTGACCACATTCCTGTATCGGCCA
CAAAATTGCAGGACGCTAGCTCTAACTTGCGGGATTTTATGAAAGCTAAAGCTGAGCGATGCGAGTGA 
 
BDO gene cluster (bedC1  bedC2  bedB  bedA) 
GenBank: AF148496.1 
 
ATGAATCAGACAGAAACAACACCTATTAGAGTGCGCAAAAATTGGAAGACCAGTGAGATAGAAACGCTCTTTG
ATGAGCAAGCTGGACGTATCGATCCGCGCATTTATACCGATGAGGATCTGTACCAACTCGAACTAGAACGTG
TATTTGCTCGGTCATGGCTCCTATTGGGGCATGAAACTCACATTCGTAAACCAGGTGATTATTTCACGACCTA
TATGGGTGAAGATCCTGTCGTGGTCGTAAGACAGAAGGATGCCAGTATCGCTGTGTTCCTGAACCAGTGCCG
CCATCGTGGTATGCGTATCTGTCGTTCGGATGCTGGAAACGCGAAGGCATTTACTTGTAGTTACCATGGGTG
GGCTTACGATACTGCTGGCAATCTTATTAATGTGCCTTACGAGGCCGAATCCTTCGCCTGCTTAGACAAGAA
GGAATGGAGTCCACTGAAGGCTCGAGTGGAAACCTACAAAGGTCTGATTTTTGCCAACTGGGATGAAAACGC
CATAGACCTTGATACATATCTCGGCGAGGCGAAGTTCTACATGGACCACATGCTCGACCGTACTGAGGCAGG
CACTGAGGTGATTCCAGGTATACAGAAGTGGGTTATTCCCTGTAACTGGAAATTCGCAGCAGAGCAGTTTTG
TAGTGACATGTACCATGCCGGGACTACAGCACATTTATCTGGAATCATTGCTGGTCTGCCAGAAGATCTTGA
GTTGGCTGATCTTGCACCGCCGAAATTTGGCAAGCAGTACCGTGCATCATGGGGTGGGCATGGCAGTGGCT
TCTATATTGGCGACCCCAACATGATGCTTGCCATGATGGGGCCGAAGGTCACCAGCTACTTGACCGAAGGC
CCCGCGGCGGAAAAGGCGGCCGAGCGTCTGGGTAGTATAGAGCGCGGCACGAAAATCATGCTTGAGCACA
TGACTGTCTTTCCTACGTGTTCCTTCCTCCCAGGTGTCAATACGATCCGAACATGGCATCCACGCGGGCCGA
ACGAGGTTGAAGTGTGGGCATTTACAGTCGTCGATGCTGATGCTCCAGATGATATTAAGGAAGAGTTTCGTC
GTCAGACACTACGTACCTTCTCTGCCGGTGGTGTATTCGAGCAGGATGACGGCGAGAACTGGGTTGAAATC
CAGCATATTCTGCGAGGTCATAAGGCACGTAGCCGTCCATTCAATGCTGAGATGAGTATGGGGCAAACCGTT
GATAACGATCCAATTTACCCTGGTCGTATATCTAACAACGTGTATAGCGAAGAAGCTGCTCGTGGACTATATG
CACATTGGCTGAAAATGATGACCTCACCAGACTGGGAAGCATTAAAGGCGACGCGTTAAACCTAACGACAGC
TAGCGCCACATCGTGGTGCCAGTTAGAAGCCGCATTTGATTCATAACCAAATTGGATGCGGTGGACTATCCA
TTTGAAATCTACACGGAATGATTACGATTCCAAAAAGGAGTGACCATGATTGATTCAGTCAACAGAGCTGACC
TCTTTCTTCGCAAACCTGCACCGGTAGCACTTGAACTGCAAAATGAAATTGAGCAGTTCTACTATTGGGAAGC
TAAGCTTCTCAATGATCGCCGCTTTGATGAATGGTTCGCACTACTTGCCAAAGACATTCACTACTTCATGCCT
ATCCGCACCACACGAATCATGCGTGATTCACGCCTTGAATATTCGGGCTTGCGAGACTATGCACATTTTGATG
ATGACGCCACAATGATGAAAGGACGTTTGCGTAAGATTACTTCTGACGTAAGTTGGTCCGAGAATCCTGCGT
CAAGAACACGACATATTGTGAGCAATGTGATGATCATTCCCACAGAAGTAGAAGGAGAATACGAAATCTCCA
GTACCTTCATCGTGTACCGCAATCGCTTGGAAAGACAACTTGATATCTTTGCTGGAGAGCGTCGCGACAGAT
TGCGTCGTAACAAGGGTGAAGCTGGATTCGAGATAGTCAATCGGACAATCCTGATCGACCAAAGCACCATCC
TAGCCAATAACCTCAGTTTCTTCTTCTAGGAGATGTCATGACTTGGACATATATACTGCGGCAAAGTGATTTG
CCACCTGGTGAAATGCAACGCTATGAAGGTGGATCAGAACCAGTGATGGTCTGTAACGTCGATGGTGAGTTT
TTCGCAGTTCAGGATACCTGCACGCATGGAGACTGGGCATTATCAGAGGGATACCTTGATGGTGATGTCGTC
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GAATGTACGTTGCATTTTGGGAAGTTCTGTGTGCGAACTGGGAAAGTGAAAGCGTTGCCTGCTTGTAAACCT
ATCAAAGTATACCCTATCAAGATAGAAGGTGATGAGGTACACGTTGATCTTGACAATGGGGAGCTAAAGTGAT
GGCTAATCATGTTGCAATCATCGGTAATGGCGTAGCTGGGTTCACCACCGCGCAAGCCCTTCGTGCCGAAG
GTTATGAAGGACGAATCTCACTGATTGGGGAAGAACAGCATCTTCCCTATGACCGACCATCCTTGTCTAAGG
CCGTCCTTGATGGAAGCTTTGAGCAGCCACCTAGACTGGCCGAGGCAGATTGGTACAGTGAAGCCAGCATC
GAGATGCTGACTGGCTCAGAAGTTACTGACCTAGATACACAGAAAAAAATGATCAGTTTGAATGATGGCAGC
ACGATTTCTGCTGATGCTATCGTTATTGCAACTGGAAGTCGAGCACGGATGTTGTCTTTACCCGGCAGTCAAT
TGCCTGGTGTCGTGACATTACGCACTTATGGTGATGTGCAGTTATTACGTGATAGCTGGACACCCAATACTC
GGTTGCTCATTGTAGGCGGTGGGTTGATTGGTTGTGAGGTAGCAACAACGGCTCGCAAGCTTGGTCTTTCTG
TCACGATCCTTGAAGCTGGTGATGAACTGTTGGTTCGTGTTCTTGGACGACGTATCGGTGCTTGGCTACGTG
GTTTGTTAACTGAACAGGGTGTGCAGGTAGAACTAAAAACTGGAGTTTCAGGTTTTTCAGGCGAAGGTCAGC
TTGAAAAAGTGATGGTGAATGATGGGCGTAGCTTTATTGCTGATAACGCACTTATCTGCGTAGGGGCAGATC
CTGCAGATCAACTCGCACGTCAAGCCGGTTTGGAATGTGATCGTGGTGTCGTTGTTGATCATAGAGGTGCGA
CATCTGCTAAAGGCATATTCGCGGTCGGGGATGTAGCCACTTGGCCACTTCATTCAGGCGGAAAGCGCTCG
CTTGAAACCTATATGAATGCTCAGCGCCAAGCCACAGCAGTTGCCAAAGCCATTCTAGGAAAAGAAGTATCA
GCACCGCAATTGCCAGTGTCATGGACGGAGATTGCCGGGCATCGAATGCAAATGGCTGGTGATATCGAAGG
ACCGGGTGAATATGTTTTGCGCGGAACCTTAGGCATTGGCTCTGCTTTATTGTTCCGTCTGCTAGATGGACG
GATTCAAGCGGTTGTAGCGGTTGATGCACCTCGTGATTTCGCACTCGCAAATCGATTAGTGGAAGCTCAAGT
CATAATTGAGCCAGAAAAGCTGGCAGATGTGTCAAATAATATGCGCGATATTGTTCGTGCGAATGAAGGGAA
TCAAAAATGA 
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7.4. Sequence alignments 
CustalW2 multiple sequence alignment220 
 
BDO             MN-----QTETTPIRVRKNWKTSEIETLFDEQAGRIDPRIYTDEDLYQLELERVFARSWL 55 
TDO             MN-----QTDTSPIRLRRSWNTSEIEALFDEHAGRIDPRIYTDEDLYQLELERVFARSWL 55 
CDO             MSSIINKEVQEAPLKWVKNWSDEEIKALVDEEKGLLDPRIFSDQDLYEIELERVFARSWL 60 
NDO             -----------------MNYNN---KILVSESGLSQKHLIHGDEELFQHELKTIFARNWL 40 
                                  .:.    : *..*     .  *. *::*:: **: :***.** 
 
BDO             LLGHETHIRKPGDYFTTYMGEDPVVVVRQKDASIAVFLNQCRHRGMRICRSDAGNAKAFT 115 
TDO             LLGHETQIRKPGDYITTYMGEDPVVVVRQKDASIAVFLNQCRHRGMRICRADAGNAKAFT 115 
CDO             LLGHEGHIPKAGDYLTTYMGEDPVIVVRQKDRSIKVFLNQCRHRGMRIERSDFGNAKSFT 120 
NDO             FLTHDSLIPAPGDYVTAKMGIDEVIVSRQNDGSIRAFLNVCRHRGKTLVSVEAGNAKGFV 100 
                :* *:  *  .***.*: ** * *:* **:* ** .*** *****  :   : ****.*. 
 
BDO             CSYHGWAYDTAGNLINVPYEAESFA-------CLDKKEWSP-LKARVETYKGLIFANWDE 167 
TDO             CSYHGWAYDTAGNLVNVPYEAESFA-------CLNKKEWSP-LKARVETYKGLIFANWDE 167 
CDO             CTYHGWAYDTAGNLVNVPYEKEAFCDKKEGDCGFDKADWGP-LQARVDTYKGLIFANWDT 179 
NDO             CSYHGWGFGSNGELQSVPFEKDLYG------ESLNKKCLGLKEVARVESFHGFIYGCFDQ 154 
                *:****.:.: *:* .**:* : :         ::*   .    ***::::*:*:. :*  
 
BDO             NAIDLDTYLGEAKFYMDHMLDRTEAGTEVIPGIQKWVIPCNWKFAAEQFCSDMYHAGTTA 227 
TDO             NAVDLDTYLGEAKFYMDHMLDRTEAGTEAIPGVQKWVIPCNWKFAAEQFCSDMYHAGTTS 227 
CDO             EAPDLKTYLSDATPYMDVMLDRTEAVTQVITGMQKTVIPCNWKFAAEQFCSDMYHAGTMA 239 
NDO             EAPPLMDYLGDAAWYLEPMFKHSGG-LELVGPPGKVVIKANWKAPAENFVGDAYHVG-WT 212 
                :*  *  **.:*  *:: *:.:: .  : :    * ** .*** .**:* .* **.*  : 
 
BDO             HLSGIIAG---LPEDLELADLAPPKFGKQYRASWGGHGSGFYIGDPNMMLAMMGPKVTSY 284 
TDO             HLSGILAG---LPEDLEMADLAPPTVGKQYRASWGGHGSGFYVGDPNLMLAIMGPKVTSY 284 
CDO             HLSGVLSS---LPPEMDLSQVKLPSSGNQFRAKWGGHGTGWFNDDFALLQAIMGPKVVDY 296 
NDO             HASSLRSGESIFSSLAGNAALPPEGAGLQMTSKYGSGMGVLWDGYSGVHSADLVPELMAF 272 
                * *.: :.   :.     : :     * *  :.:*.     : .   :  * : *::  : 
 
BDO             LTEGPAAEKAAERLGSIERGTKIMLEHMTVFPTCSFLPGVNTIRTWHPRGPNEVEVWAFT 344 
TDO             WTEGPASEKAAERLGSVERGSKLMVEHMTVFPTCSFLPGINTVRTWHPRGPNEVEVWAFT 344 
CDO             WTKGPAAERAKERLGKVLPADRMVAQHMTIFPTCSFLPGINTVRTWHPRGPNEIEVWSFI 356 
NDO             G--GAKQERLNKEIGDVRARIYRSHLNCTVFPNNSMLTCSGVFKVWNPIDANTTEVWTYA 330 
                   *.  *:  :.:*.:         : *:**. *:*.  ...:.*:* ..*  ***::  
 
BDO             VVDADAPDDIKEEFRRQTLRTFSAGGVFEQDDGENWVEIQHILRGHKARSRPFNAEMSMG 404 
TDO             VVDADAPDDIKEEFRRQTLRTFSAGGVFEQDDGENWVEIQHILRGHKARSRPFNAEMSMD 404 
CDO             VVDADAPEDIKEEYRRKNIFTFNQGGTYEQDDGENWVEVQRGLRGYKARSRPLCAQMGAG 416 
NDO             IVEKDMPEDLKRRLADSVQRTFGPAGFWESDDNDNMETASQNGKKYQSRDSDLLSNLGFG 390 
                :*: * *:*:*..   .   **. .* :*.**.:*    .:  : :::*.  : :::. . 
 
BDO             QTVDNDPIYPGRISNNVYSEEAARGLYAHWLKMMTSPDWEALKATR------------- 450 
TDO             QTVDNDPVYPGRISNNVYSEEAARGLYAHWLRMMTSPDWDALKATR------------- 450 
CDO             VPNKNNPEFPGKTS-YVYSEEAARGFYHHWSRMMSEPSWDTLKS--------------- 459 
NDO             EDVYGDAVYPGVVGKSAIGETSYRGFYRAYQAHVSSSNWAEFEHASSTWHTELTKTTDR 449 
                    .:. :**  .  . .* : **:*  :   ::...*  ::                 
 
 
 
 
 
 
Figure S30: Multiple sequence alignment of BDO (P. putida ML2), CDO (P. fluorescens IP01), NDO 
(Pseudomonas sp. NCIB 9816-4) and TDO (P. putida F1) α-subunit amino acid sequences performed with 
ClustalW2. Amino acid residues that correspond to position 232 in CDO are highlighted in yellow. 
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EMBOSS Needle global sequence alignments221 of CDO, BDO and NDO oxygenase α-subunits 
 
Alignment CDO and NDO alpha subunit 
 
#======================================= 
# 
# Aligned_sequences: 2 
# 1: 1WQLA (CDO) 
# 2: 1O7MA (NDO) 
# Matrix: EBLOSUM62 
# Gap_penalty: 10.0 
# Extend_penalty: 0.5 
# 
# Length: 500 
# Identity:     155/500 (31.0%) 
# Similarity:   231/500 (46.2%) 
# Gaps:          92/500 (18.4%) 
# Score: 632.5 
#  
#======================================= 
 
1WQLA              1 MSSIINKEVQEAPLKWVKNWSDEEIKALVDEEKGLLDPR-IFSDQDLYEI     49 
                                      .|:::   |.|| .|.||.... |..|::|::. 
1O7MA              1 -----------------MNYNN---KILV-SESGLSQKHLIHGDEELFQH     29 
 
1WQLA             50 ELERVFARSWLLLGHEGHIPKAGDYLTTYMGEDPVIVVRQKDRSIKVFLN     99 
                     ||:.:|||:||.|.|:..||..|||:|..||.|.|||.||.|.||:.||| 
1O7MA             30 ELKTIFARNWLFLTHDSLIPAPGDYVTAKMGIDEVIVSRQNDGSIRAFLN     79 
 
1WQLA            100 QCRHRGMRIERSDFGNAKSFTCTYHGWAYDTAGNLVNVPYEKEAFCDKKE    149 
                     .|||||..:...:.||||.|.|:||||.:.:.|.|.:||:||:.:.:... 
1O7MA             80 VCRHRGKTLVSVEAGNAKGFVCSYHGWGFGSNGELQSVPFEKDLYGESLN    129 
 
1WQLA            150 GDC-GFDKADWGPLQARVDTYKGLIFANWDTEAPDLKTYLSDATPYMDVM    198 
                     ..| |..:.      |||:::.|.|:..:|.|||.|..||.||..|::.| 
1O7MA            130 KKCLGLKEV------ARVESFHGFIYGCFDQEAPPLMDYLGDAAWYLEPM    173 
 
1WQLA            199 LDRTEAVTQVITGMQKTVIPCNWKFAAEQFCSDMYHAGTMAHLSGVLS--    246 
                     ...:..: :::....|.||..|||..||.|..|.||.| ..|.|.:.|   
1O7MA            174 FKHSGGL-ELVGPPGKVVIKANWKAPAENFVGDAYHVG-WTHASSLRSGE    221 
 
1WQLA            247 ----------SLPPEMDLSQVKLPSSGNQFRAKWG-GHGTGWFNDDFA-L    284 
                               :||||         .:|.|..:|:| |.|..|  |.:: : 
1O7MA            222 SIFSSLAGNAALPPE---------GAGLQMTSKYGSGMGVLW--DGYSGV    260 
 
1WQLA            285 LQAIMGPKVVDYWTKGPAAERAKERLGKVLPADRMVAQHM--TIFPTCSF    332 
                     ..|.:.|:::.:  .|...||..:.:|.|  ..|:...|:  |:||..|. 
1O7MA            261 HSADLVPELMAF--GGAKQERLNKEIGDV--RARIYRSHLNCTVFPNNSM    306 
 
1WQLA            333 LPGINTVRTWHPRGPNEIEVWSFIVVDADAPEDIKEEYRRKNIFTFNQGG    382 
                     |......:.|:|...|..|||::.:|:.|.|||:|.........||...| 
1O7MA            307 LTCSGVFKVWNPIDANTTEVWTYAIVEKDMPEDLKRRLADSVQRTFGPAG    356 
 
1WQLA            383 TYEQDDGENWVEVQRGLRGYKARSRPLCAQMGAGVPNKNNPEFP------    426 
                     .:|.||.:|.....:..:.|::|...|.:.:|.|.....:..:|       
1O7MA            357 FWESDDNDNMETASQNGKKYQSRDSDLLSNLGFGEDVYGDAVYPGVVGKS    406 
 
1WQLA            427 --GKTSYVYSEEAARGFYHHWSRMMSEPSWDTLKS---------------    459 
                       |:|||       ||||..:...:|..:|...:.                
1O7MA            407 AIGETSY-------RGFYRAYQAHVSSSNWAEFEHASSTWHTELTKTTDR    449 
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Alignment CDO and BDO alpha subunit 
 
#======================================= 
# 
# Aligned_sequences: 2 
# 1: 1WQLA (CDO) 
# 2: BEDC1_PSEPU (BDO) 
# Matrix: EBLOSUM62 
# Gap_penalty: 10.0 
# Extend_penalty: 0.5 
# 
# Length: 462 
# Identity:     294/462 (63.6%) 
# Similarity:   360/462 (77.9%) 
# Gaps:          15/462 ( 3.2%) 
# Score: 1639.5 
#  
# 
#======================================= 
 
1WQLA              1 MSSIINKEVQEAPLKWVKNWSDEEIKALVDEEKGLLDPRIFSDQDLYEIE     50 
                          ..:.:..|::..|||...||:.|.||:.|.:||||::|:|||::| 
BEDC1_PSEPU        1 -----MNQTETTPIRVRKNWKTSEIETLFDEQAGRIDPRIYTDEDLYQLE     45 
 
1WQLA             51 LERVFARSWLLLGHEGHIPKAGDYLTTYMGEDPVIVVRQKDRSIKVFLNQ    100 
                     |||||||||||||||.||.|.|||.|||||||||:||||||.||.||||| 
BEDC1_PSEPU       46 LERVFARSWLLLGHETHIRKPGDYFTTYMGEDPVVVVRQKDASIAVFLNQ     95 
 
1WQLA            101 CRHRGMRIERSDFGNAKSFTCTYHGWAYDTAGNLVNVPYEKEAFCDKKEG    150 
                     ||||||||.|||.||||:|||:||||||||||||:|||||.|:|.      
BEDC1_PSEPU       96 CRHRGMRICRSDAGNAKAFTCSYHGWAYDTAGNLINVPYEAESFA-----    140 
 
1WQLA            151 DCGFDKADWGPLQARVDTYKGLIFANWDTEAPDLKTYLSDATPYMDVMLD    200 
                      | .||.:|.||:|||:|||||||||||..|.||.|||.:|..|||.||| 
BEDC1_PSEPU      141 -C-LDKKEWSPLKARVETYKGLIFANWDENAIDLDTYLGEAKFYMDHMLD    188 
 
1WQLA            201 RTEAVTQVITGMQKTVIPCNWKFAAEQFCSDMYHAGTMAHLSGVLSSLPP    250 
                     ||||.|:||.|:||.||||||||||||||||||||||.|||||:::.||. 
BEDC1_PSEPU      189 RTEAGTEVIPGIQKWVIPCNWKFAAEQFCSDMYHAGTTAHLSGIIAGLPE    238 
 
1WQLA            251 EMDLSQVKLPSSGNQFRAKWGGHGTGWFNDDFALLQAIMGPKVVDYWTKG    300 
                     :::|:.:..|..|.|:||.|||||:|::..|..::.|:|||||..|.|:| 
BEDC1_PSEPU      239 DLELADLAPPKFGKQYRASWGGHGSGFYIGDPNMMLAMMGPKVTSYLTEG    288 
 
1WQLA            301 PAAERAKERLGKVLPADRMVAQHMTIFPTCSFLPGINTVRTWHPRGPNEI    350 
                     ||||:|.||||.:....:::.:|||:|||||||||:||:||||||||||: 
BEDC1_PSEPU      289 PAAEKAAERLGSIERGTKIMLEHMTVFPTCSFLPGVNTIRTWHPRGPNEV    338 
 
1WQLA            351 EVWSFIVVDADAPEDIKEEYRRKNIFTFNQGGTYEQDDGENWVEVQRGLR    400 
                     |||:|.|||||||:|||||:||:.:.||:.||.:||||||||||:|..|| 
BEDC1_PSEPU      339 EVWAFTVVDADAPDDIKEEFRRQTLRTFSAGGVFEQDDGENWVEIQHILR    388 
 
1WQLA            401 GYKARSRPLCAQMGAGVPNKNNPEFPGKTS-YVYSEEAARGFYHHWSRMM    449 
                     |:||||||..|:|..|....|:|.:||:.| .|||||||||.|.||.:|| 
BEDC1_PSEPU      389 GHKARSRPFNAEMSMGQTVDNDPIYPGRISNNVYSEEAARGLYAHWLKMM    438 
 
1WQLA            450 SEPSWDTLKS--    459 
                     :.|.|:.||:   
BEDC1_PSEPU      439 TSPDWEALKATR    450 
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Alignment NDO and BDO alpha subunit 
 
#======================================= 
# 
# Aligned_sequences: 2 
# 1: 1O7MA (NDO) 
# 2: BEDC1_PSEPU (BDO) 
# Matrix: EBLOSUM62 
# Gap_penalty: 10.0 
# Extend_penalty: 0.5 
# 
# Length: 486 
# Identity:     157/486 (32.3%) 
# Similarity:   225/486 (46.3%) 
# Gaps:          73/486 (15.0%) 
# Score: 652.5 
#  
# 
#======================================= 
 
1O7MA              1 ------------MNYNN---KILVSESGLSQKHLIHGDEELFQHELKTIF     35 
                                 .|:..   :.|..|........|:.||:|:|.||:.:| 
BEDC1_PSEPU        1 MNQTETTPIRVRKNWKTSEIETLFDEQAGRIDPRIYTDEDLYQLELERVF     50 
 
1O7MA             36 ARNWLFLTHDSLIPAPGDYVTAKMGIDEVIVSRQNDGSIRAFLNVCRHRG     85 
                     ||:||.|.|::.|..||||.|..||.|.|:|.||.|.||..|||.||||| 
BEDC1_PSEPU       51 ARSWLLLGHETHIRKPGDYFTTYMGEDPVVVVRQKDASIAVFLNQCRHRG    100 
 
1O7MA             86 KTLVSVEAGNAKGFVCSYHGWGFGSNGELQSVPFEKDLYGESLNKKCLGL    135 
                     ..:...:|||||.|.||||||.:.:.|.|.:||:|.:.:.      ||.. 
BEDC1_PSEPU      101 MRICRSDAGNAKAFTCSYHGWAYDTAGNLINVPYEAESFA------CLDK    144 
 
1O7MA            136 KE----VARVESFHGFIYGCFDQEAPPLMDYLGDAAWYLEPMF-KHSGGL    180 
                     ||    .||||::.|.|:..:|:.|..|..|||:|.:|::.|. :...|. 
BEDC1_PSEPU      145 KEWSPLKARVETYKGLIFANWDENAIDLDTYLGEAKFYMDHMLDRTEAGT    194 
 
1O7MA            181 ELVGPPG--KVVIKANWKAPAENFVGDAYHVGWT-HASSLRSGESIFSSL    227 
                     |::  ||  |.||..|||..||.|..|.||.|.| |.|.:.:|......| 
BEDC1_PSEPU      195 EVI--PGIQKWVIPCNWKFAAEQFCSDMYHAGTTAHLSGIIAGLPEDLEL    242 
 
1O7MA            228 AGNAALPPEGAGLQMTSKYGSGMGVLWDGY-SGVHSADLVPELM-AFGGA    275 
                     |..|  ||         |:|......|.|: ||.:..|  |.:| |..|. 
BEDC1_PSEPU      243 ADLA--PP---------KFGKQYRASWGGHGSGFYIGD--PNMMLAMMGP    279 
 
1O7MA            276 K----------QERLNKEIGDVR--ARIYRSHLNCTVFPNNSMLTCSGVF    313 
                     |          .|:..:.:|.:.  .:|...|:  ||||..|.|...... 
BEDC1_PSEPU      280 KVTSYLTEGPAAEKAAERLGSIERGTKIMLEHM--TVFPTCSFLPGVNTI    327 
 
1O7MA            314 KVWNPIDANTTEVWTYAIVEKDMPEDLKRRLADSVQRTFGPAGFWESDDN    363 
                     :.|:|...|..|||.:.:|:.|.|:|:|........|||...|.:|.||. 
BEDC1_PSEPU      328 RTWHPRGPNEVEVWAFTVVDADAPDDIKEEFRRQTLRTFSAGGVFEQDDG    377 
 
1O7MA            364 DNMETASQNGKKYQSRDSDLLSNLGFGEDVYGDAVYPGVVGKSAIGETSY    413 
                     :|........:.:::|.....:.:..|:.|..|.:|||.:..:...|.:. 
BEDC1_PSEPU      378 ENWVEIQHILRGHKARSRPFNAEMSMGQTVDNDPIYPGRISNNVYSEEAA    427 
 
1O7MA            414 RGFYRAYQAHVSSSNWAEFEHASSTWHTELTKTTDR    449 
                     ||.|..:...::|.:|...:...              
BEDC1_PSEPU      428 RGLYAHWLKMMTSPDWEALKATR-------------    450 
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7.5. Stereoselectivities 
1-Phenyl-1,2-ethanediol (1a) 
 
 
Figure S31: Product distribution (bars) for the RO-catalyzed conversion of styrene 1 yielding alkene-1,2-diol 1a 
(black) and arene-1,2-dihydrodiol 1b (grey) as well as stereoselectivities for 1a (squares) with the variants of the 
NDT mutant library as well as CDO wild type and CDO M232A. 
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1-Phenyl-1,2-ethanediol (1a) 
  
  
  
Figure S32: Chiral GC-FID analysis of 1-phenyl-1,2-ethanediol 1a enantiomers of the commercially available 
standard (A) or from RO-catalyzed conversion of styrene 1 (B-F). A: rac-1a (black, Fluka), (R)-1a (blue, Sigma-
Aldrich, 99% optical purity), (S)-1a (pink, Sigma-Aldrich, 99% optical purity). B: CDO M232A, C: CDO, D: NDO, E: 
BDO, F: BDO M220A (B-F shown in pink compared to rac-1a in black). 
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Figure S33: Chiral HPLC analysis of 1-phenyl-1,2-ethanediol 1a enantiomers of the commercially available 
standard rac-1a (Fluka, upper panel) or from RO-catalyzed conversion of styrene 1 (A-I, lower panel). A: CDO 
M232A, B: CDO M232G, C: CDO M232S, D: CDO M232C, E: CDO M232V, F: CDO M232I, G: CDO M232L, 
H: CDO M232F, I: CDO M232H. 
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1-Cyclohexylethane-1,2-diol (2a) 
  
   
Figure S34: Chiral GC-FID analysis of 1-cyclohexylethane-1,2-diol 2a enantiomers of the synthesized standard 
(A) or from RO-catalyzed conversion of vinylcyclohexane 2 (B-D). A: (R)-2a (black), (S)-2a (pink). B: CDO 
M232A, C: CDO, D: NDO (B-D shown in pink compared to rac-2a in black). 
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2-Cyclohexenol (3a) 
   
  
Figure S35: Chiral GC-FID analysis of 2-cyclohexenol 3a enantiomers of the synthesized standard (A) or from 
RO-catalyzed conversion of cyclohexene 3 (B-F). A: rac-3a (black, Fluka), synthesized (R)-3a (pink, ee = 13%), 
B: CDO M232A, C: CDO, D: NDO, E: BDO, F: BDO M220A (B-F shown in pink compared to rac-3a in black). 
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1-Indenol (4a) 
1-Indenol enantiomers were identified based on comparison with data known from literature for the 
NDO-catalyzed conversion of indene 4 yielding (S)-indenol.92 
 
  
   
  
Figure S36: Chiral GC-FID analysis of 1-indenol 4a enantiomers from RO-catalyzed conversion of indene 4 
(A-F). A: NDO (black), B: CDO M232A, C: CDO, D: BDO, E: BDO M220A (B-E shown in pink compared to NDO 
in black). 
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NDO + indene 
NDO + indene NDO + indene 
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A B C 
D E F 
NDO + indene 
NDO + indene NDO + indene NDO + indene 
G H I 
SUPPLEMENTARY 
136 
   
Figure S37: Chiral HPLC analysis of 1-indenol 4a enantiomers from RO-catalyzed conversion of indene 4 (A-J). 
1-Indenol 4a formation of NDO (upper panel), A: CDO M232A, B: CDO M232S, C: CDO M232G, D: CDO M232C, 
E: CDO M232V, F: CDO M232I, G: CDO M232F, H: CDO M232L, I: CDO, J: CDO M232H (lower panel). 
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cis-1,2-Indandiol (4b) 
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Figure S38: Chiral HPLC analysis of cis-1,2-indandiol 4b enantiomers synthesized with AD-mix β (ee = 46% for 
(1R,2S)-4b; upper panel) and of the RO-catalyzed conversion of indene 4 (A-L, lower panel). A: CDO M232A, 
B: CDO, C: NDO, D: BDO, E: BDO M220A, F: CDO M232S, G: CDO M232G, H: CDO M232C, I: CDO M232V, 
J: CDO M232F, K: CDO M232I, L: CDO M232L. 
 
 
 
2-Methyl-6-methyleneocta-2,7-dien-1-ol (5a) 
The product 2-methyl-6-methyleneocta-2,7-dien-1-ol (5a) of the CDO M232A-catalyzed 
biotransformation of myrcene 5 could be identified as (Z)-isomer by comparison of its 1H NMR 
spectrum with the synthesized standard (E)-2-methyl-6-methyleneocta-2,7-dien-1-ol and the different 
retention times of both compounds in GC-analysis albeit their MS fragmentation patterns are identical. 
 
 
 
Figure S39: GC-MS analysis of (Z)- and (E)-2-methyl-6-methyleneocta-2,7-dien-1-ol 5a on a achiral DB-5 
column. RO-catalyzed biotransformation of myrcene 5 to yield (Z)-5a is shown in black, (E)-5a obtained from 
synthesis with SeO2 and myrcene is shown in pink. 
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3,10-dihydro myrcene (5b) 
      
     
Figure S40: Chiral GC-FID analysis of 3,10-dihydroxy myrcene 5b enantiomers synthesized with potassium 
permanganate (A) or from RO-catalyzed conversion of myrcene 5 (B-D). B: CDO M232A, C: CDO, D: NDO. As 
dihydroxylation with potassium permanganate was not stereoselective, absolute configurations could not be 
determined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B C D 
SUPPLEMENTARY 
140 
2-Methyl-6-methyleneoct-7-ene-2,3-diol (5c) 
 
                  
 
                      
 
Figure S41: Chiral GC-FID analysis of 2-methyl-6-methyleneoct-7-ene-2,3-diol 5c enantiomers synthesized with 
AD-mix α (A) and β (B) or from RO-catalyzed conversion of myrcene 5 (C+D). C: CDO M232A, D: CDO. 
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1,2-dihydro myrcene (5d) 
 
 
 
                  
 
 
Figure S42: Chiral GC-FID analysis of 1,2-dihydro myrcene 5d enantiomers synthesized with potassium 
permanganate (A) or from RO-catalyzed conversion of myrcene 5 (B+C). B: CDO, C: NDO. As dihydroxylation 
with potassium permanganate was not stereoselective, absolute configurations could not be determined. 
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Pinanediol (6a) 
As potential products during the CDO M232A-catalyzed biotransformation of (+)-α-pinene 6, 
(1S,2S,3R,5S)-(+)- and (1R,2S,3R,5S)-(+)-pinanediol 6a could be formed. However, racemic 
synthesis of (1S,2S,3R,5S)-(+)- and (1R,2S,3R,5S)-(+)-pinanediol diastereomers was not possible by 
osmylation and only the (1S,2S,3R,5S)-(+)-isomer could be obtained. Thus, a chiral GC method was 
developed using the commercially available (1S,2S,3R,5S)-(+)- and (1R,2R,3S,5R)-(-)-pinanediol 
enantiomers. As this method allows the separation of enantiomers, diastereomer separation should 
also be possible. As during chiral GC-analysis, only the (1S,2S,3R,5S)-(+)-isomer could be detected in 
biotransformations using CDO M232A, in addition, a 1H NMR and a 1H 1H COSY analysis of the 
product was performed. According to coupling constants at 3.99 ppm (1 H, dd, J1 = 9.36 Hz, 
J2 = 5.20 Hz), no detectable amounts of (1R,2S,3R,5S)-(+)-pinanediol were present (de > 95%). 
 
 
 
  
Figure S43: Chiral GC-FID analysis of pinanediol 6a enantiomers of the commercially available standard (A) or 
from CDO M232A-catalyzed conversion of (+)-α-pinene 6 (B). A: rac-6a (black), (1S,2S,3R,5S)-(+)-6a (pink, 
Sigma-Aldrich), (1R,2R,3S,5R)-(-)-6a (blue, Sigma-Aldrich). B: CDO M323A (pink) compared to rac-6a (black). 
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Carveol (7b) 
(R)-(+)-limonene (R)-7 (Sigma-Aldrich) was available with an ee of 99%. (1R,5R)-(-)-7b and 
(1S,5R)-(-)-7b that were formed in traces as a result of (S)-(-)-7 hydroxylation were not considered for 
determination of de values. 
 
 
 
Figure S44: Chiral GC-FID analysis of carveol 7b isomers of the synthesized standards (A) or from RO-catalyzed 
conversion of (R)-limonene (R)-7 (B+C). A: Black: racemic mixture of (-)-carveol isomers (Sigma-Aldrich), 
(1R,5R)-(-)-7b (pink), (1S,5S)-(+)-7b (blue), (1R,5S)-(+)-7b (brown) from biotransformations using CDO M232A 
and (R)-7b. B: CDO M232A, C: CDO (B+C shown in pink compared to (1S,5S)-(+)-7b in black).  
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Limonene (7) 
 
  
Figure S45: GC-FID analysis of the chiral separation of limonene enantiomers. Black: (R)-(+)-limonene (Sigma-
Aldrich), pink: (S)-(-)-limonene (Alfa Aesar). ee (S)-(-)-limonene = 68%, ee (R)-(+)-limonene = 99% 
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7.6. Conservation level of positions F278, I288, I336 and F378 in CDO 
The conservation level of residues F278, I288, I336 and F378 (numbering refers to CDO) chosen for 
site-saturation mutagenesis and the amino acid distribution at the respective position was determined 
by HotSpot Wizard.184 
 
                  
  
Figure S46: Conservation level and amino acid distributions at positions F278, I288, I336 and F378 (numbering 
refers to CDO) as determined by HotSpot Wizard.184 
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7.7. NMR spectra 
1H NMR 1-cyclohexylethane-1,2-diol (2a, CDO M232A)  
 
 
Figure S47: 1H NMR of 1-cyclohexylethane-1,2-diol in CDCl3 isolated from the CDO M232A-catalyzed 
biotransformation of vinylcyclohexane. 
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13C NMR 1-cyclohexylethane-1,2-diol (2a, CDO M232A) 
 
 
Figure S48: 13C NMR of 1-cyclohexylethane-1,2-diol in CDCl3 isolated from the CDO M232A-catalyzed 
biotransformation of vinylcyclohexane. 
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1H NMR 1-cyclohexylethane-1,2-diol (2a, AD-mix α) 
 
 
Figure S49: 1H NMR of 1-cyclohexylethane-1,2-diol in CDCl3 isolated from the AD of vinylcyclohexane using 
AD-mix α. 
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13C NMR 1-cyclohexylethane-1,2-diol (2a, AD-mix α) 
 
 
Figure S50: 13C NMR of 1-cyclohexylethane-1,2-diol in CDCl3 isolated from the AD of vinylcyclohexane using 
AD-mix α. 
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1H NMR 1-cyclohexylethane-1,2-diol (2a, AD-mix β) 
 
 
Figure S51: 1H NMR of 1-cyclohexylethane-1,2-diol in CDCl3 isolated from the AD of vinylcyclohexane using 
AD-mix β. 
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13C NMR 1-cyclohexylethane-1,2-diol (2a, AD-mix β) 
 
 
Figure S52: 13C NMR of 1-cyclohexylethane-1,2-diol in CDCl3 isolated from the AD of vinylcyclohexane using 
AD-mix β. 
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HSQC 1-cyclohexylethane-1,2-diol (2a, AD-mix β) 
 
Figure S53: HSQC of 1-cyclohexylethane-1,2-diol in CDCl3 isolated from the AD of vinylcyclohexane using 
AD mix β. 
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1H NMR (R)-(+)-2-cyclohexenol ((R)-3a) 
 
 
Figure S54: 1H NMR of (R)-(+)-2-cyclohexenol in CDCl3 isolated from the synthesis with LiAlH4 and 
cyclohexenone.  
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13C NMR (R)-(+)-2-cyclohexenol ((R)-3a) 
 
 
Figure S55: 13C NMR of (R)-(+)-2-cyclohexenol in CDCl3 isolated from the synthesis with LiAlH4 and 
cyclohexenone.  
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1H NMR 1-indenol (4a, CDO) 
 
 
Figure S56: 1H NMR of 1-indenol in CDCl3 isolated from the CDO-catalyzed biotransformation of indene.  
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13C NMR 1-indenol (4a, CDO) 
 
 
Figure S57: 13C NMR of 1-indenol in CDCl3 isolated from the CDO-catalyzed biotransformation of indene.  
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1H NMR cis-1,2-indandiol (4b, CDO) 
 
 
Figure S58: 1H NMR of cis-1,2-indandiol in CDCl3 isolated from the CDO-catalyzed biotransformation of indene.  
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13C NMR cis-1,2-indandiol (4b, CDO) 
 
 
Figure S59: 13C NMR of cis-1,2-indandiol in CDCl3 isolated from the CDO-catalyzed biotransformation of indene.  
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1H NMR cis-1,2-indandiol (4b, AD-mix β) 
 
 
Figure S60: 1H NMR of cis-1,2-indandiol in CDCl3 isolated from the AD of indene using AD-mix β. 
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13C NMR cis-1,2-indandiol (4b, AD-mix β) 
 
 
Figure S61: 13C NMR of cis-1,2-indandiol in CDCl3 isolated from the AD of indene using AD-mix β. 
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1H NMR (Z)-2-methyl-6-methyleneocta-2,7-dien-1-ol ((Z)-5a) 
 
 
Figure S62: 1H NMR of (Z)-2-methyl-6-methyleneocta-2,7-dien-1-ol in CDCl3 isolated from the CDO M232A-
catalyzed biotransformation of myrcene. 
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13C NMR (Z)-2-methyl-6-methyleneocta-2,7-dien-1-ol ((Z)-5a) 
 
 
Figure S63: 13C NMR of (Z)-2-methyl-6-methyleneocta-2,7-dien-1-ol in CDCl3 isolated from the CDO M232A-
catalyzed biotransformation of myrcene. 
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HSQC (Z)-2-methyl-6-methyleneocta-2,7-dien-1-ol ((Z)-5a) 
 
 
Figure S64: HSQC of (Z)-2-methyl-6-methyleneocta-2,7-dien-1-ol in CDCl3 isolated from the CDO M232A-
catalyzed biotransformation of myrcene. 
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1H NMR (E)-2-methyl-6-methyleneocta-2,7-dien-1-ol ((E)-5a) 
 
 
Figure S65: 1H NMR of (E)-2-methyl-6-methyleneocta-2,7-dien-1-ol in CDCl3 isolated from the synthesis with 
myrcene and SeO2. 
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13C NMR (E)-2-methyl-6-methyleneocta-2,7-dien-1-ol ((E)-5a) 
 
 
Figure S66: 13C NMR of (E)-2-methyl-6-methyleneocta-2,7-dien-1-ol in CDCl3 isolated from the synthesis with 
myrcene and SeO2. 
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HSQC (E)-2-methyl-6-methyleneocta-2,7-dien-1-ol ((E)-5a) 
 
Figure S67: HSQC of (E)-2-methyl-6-methyleneocta-2,7-dien-1-ol in CDCl3 isolated from the synthesis with 
myrcene and SeO2. 
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HMBC (E)-2-methyl-6-methyleneocta-2,7-dien-1-ol ((E)-5a) 
 
Figure S68: HMBC of (E)-2-methyl-6-methyleneocta-2,7-dien-1-ol in CDCl3 isolated from the synthesis with 
myrcene and SeO2. 
 
 
 
 
 
SUPPLEMENTARY 
168 
1H NMR 2-methyl-6-methyleneoct-7-ene-2,3-diol (5c, CDO M232A) 
 
 
Figure S69: 1H NMR of 2-methyl-6-methyleneoct-7-ene-2,3-diol in CDCl3 isolated from the CDO M232A-
catalyzed biotransformation of myrcene. 
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13C NMR 2-methyl-6-methyleneoct-7-ene-2,3-diol (5c, CDO M232A) 
 
 
Figure S70: 13C NMR of 2-methyl-6-methyleneoct-7-ene-2,3-diol in CDCl3 isolated from the CDO M232A-
catalyzed biotransformation of myrcene. 
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1H NMR 2-methyl-6-methyleneoct-7-ene-2,3-diol (5c, AD-mix β) 
 
 
Figure S71: 1H NMR of 2-methyl-6-methyleneoct-7-ene-2,3-diol in CDCl3 isolated from the AD of myrcene using 
AD-mix β. 
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13C NMR 2-methyl-6-methyleneoct-7-ene-2,3-diol (5c, AD-mix β) 
 
 
Figure S72: 13C NMR of 2-methyl-6-methyleneoct-7-ene-2,3-diol in CDCl3 isolated from the AD of myrcene using 
AD-mix β. 
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1H NMR 3,10-dihydro myrcene (5b) 
 
 
Figure S73: 1H NMR of 3,10-dihydro myrcene in CDCl3 isolated from the synthesis with myrcene and KMnO4. 
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13C NMR 3,10-dihydro myrcene (5b) 
 
 
Figure S74: 13C NMR of 3,10-dihydro myrcene in CDCl3 isolated from the synthesis with myrcene and KMnO4. 
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HSQC 3,10-dihydro myrcene (5b) 
 
Figure S75: HSQC of 3,10-dihydro myrcene in CDCl3 isolated from the synthesis with myrcene and KMnO4. 
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1H NMR 1,2-dihydro myrcene (5d) 
 
 
Figure S76: 1H NMR of 1,2-dihydro myrcene in CDCl3 isolated from the synthesis with myrcene and KMnO4. 
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13C NMR 1,2-dihydro myrcene (5d) 
 
 
Figure S77: 13C NMR of 1,2-dihydro myrcene in CDCl3 isolated from the synthesis with myrcene and KMnO4. 
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HSQC 1,2-dihydro myrcene (5d) 
 
Figure S78: HSQC of 1,2-dihydro myrcene in CDCl3 isolated from the synthesis with myrcene and KMnO4. 
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1H NMR 2-methyl-6-methylene-octa-1,7-dien-3-ol (CDO M232A) 
 
 
Figure S79: 1H NMR of 2-methyl-6-methylene-octa-1,7-dien-3-ol in CDCl3 isolated from the CDO M232A-
catalyzed biotransformation of myrcene. 
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13C NMR 2-methyl-6-methylene-octa-1,7-dien-3-ol (CDO M232A) 
 
 
Figure S80: 13C NMR of 2-methyl-6-methylene-octa-1,7-dien-3-ol in CDCl3 isolated from the CDO M232A-
catalyzed biotransformation of myrcene. 
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HSQC 2-methyl-6-methylene-octa-1,7-dien-3-ol (CDO M232A) 
 
Figure S81: HSQC of 2-methyl-6-methylene-octa-1,7-dien-3-ol in CDCl3 isolated from the CDO M232A-catalyzed 
biotransformation of myrcene. 
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1H NMR pinanediol (6a, CDO M232A) 
 
 
Figure S82: 1H NMR of pinanediol in CDCl3 isolated from the CDO M232A-catalyzed biotransformation of 
(+)-α-pinene.  
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13C NMR pinanediol (6a, CDO M232A) 
 
 
Figure S83: 13C NMR of pinanediol in CDCl3 isolated from the CDO M232A-catalyzed biotransformation of 
(+)-α-pinene.  
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1H 1H COSY pinanediol (6a, CDO M232A) 
 
Figure S84: 1H 1H COSY of pinanediol in CDCl3 isolated from the CDO M232A-catalyzed biotransformation of 
(+)-α-pinene.  
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1H NMR pinanediol (6a, OsO4) 
 
 
Figure S85: 1H NMR of pinanediol in CDCl3 isolated from the synthesis with OsO4 and (+)-α-pinene. 
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13C NMR pinanediol (6a, OsO4) 
 
 
Figure S86: 13C NMR of pinanediol in CDCl3 isolated from the synthesis with OsO4 and (+)-α-pinene. 
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HSQC pinanediol (6a, OsO4) 
 
Figure S87: HSQC of pinanediol in CDCl3 isolated from the synthesis with OsO4 and (+)-α-pinene. 
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1H NMR (+)-mentha-1.8-dien-10-ol (7a) 
 
 
Figure S88: 1H NMR of (+)-mentha-1.8-dien-10-ol in CDCl3 isolated from the synthesis with SeO2 and 
(R)-limonene. 
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13C NMR (+)-mentha-1.8-dien-10-ol (7a) 
 
 
Figure S89: 13C NMR of (+)-mentha-1.8-dien-10-ol in CDCl3 isolated from the synthesis with SeO2 and 
(R)-limonene. 
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1H NMR carveol (7b, CDO M232A) 
 
 
Figure S90: 1H NMR of carveol in CDCl3 isolated from the CDO M232A-catalyzed biotransformation of 
(R)-limonene. 
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13C NMR carveol (7b, CDO M232A) 
 
 
Figure S91: 13C NMR of carveol in CDCl3 isolated from the CDO M232A-catalyzed biotransformation of 
(R)-limonene. 
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1H NMR (1S,5S)-carveol ((1S,5S)-7b, LiAlH4) 
 
 
Figure S92: 1H NMR of (1S,5S)-carveol in CDCl3 isolated from the synthesis with LiAlH4 and (S)-(+)-carvone. 
 
 
 
 
 
 
 
 
SUPPLEMENTARY 
192 
13C NMR (1S,5S)-carveol ((1S,5S)-7b, LiAlH4) 
 
 
Figure S93: 13C NMR of (1S,5S)-carveol in CDCl3 isolated from the synthesis with LiAlH4 and (S)-(+)-carvone. 
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1H NMR (1R,5R)-carveol ((1R,5R)-7b) 
 
 
Figure S94: 1H NMR of (1R,5R)-carveol in CDCl3 isolated from the synthesis with LiAlH4 and (R)-(-)-carvone. 
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13C NMR (1R,5R)-carveol ((1R,5R)-7b) 
 
Figure S95: 13C NMR of (1R,5R)-carveol in CDCl3 isolated from the synthesis with LiAlH4 and (R)-(-)-carvone. 
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1H NMR isopiperitenol (7c) 
 
Figure S96: 1H NMR of isopiperitenol in CDCl3 isolated from the CDO I288V-catalyzed biotransformation of 
(S)-limonene. 
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13C NMR isopiperitenol (7c) 
 
Figure S97: 13C NMR of isopiperitenol in CDCl3 isolated from the CDO I288V-catalyzed biotransformation of 
(S)-limonene. 
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HSQC isopiperitenol (7c) 
Figure S98: HSQC of isopiperitenol in CDCl3 isolated from the CDO I288V-catalyzed biotransformation of 
(S)-limonene. 
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HMBC isopiperitenol (7c) 
Figure S99: HMBC of isopiperitenol in CDCl3 isolated from the CDO I288V-catalyzed biotransformation of 
(S)-limonene. 
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COSY isopiperitenol (7c) 
Figure S100: COSY of isopiperitenol in CDCl3 isolated from the CDO I288V-catalyzed biotransformation of 
(S)-limonene. 
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